Requirements for Assembly and Release of Newcastle Disease Virus-Like Particles: A Dissertation by Pantua, Homer Dadios
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2006-10-26 
Requirements for Assembly and Release of Newcastle Disease 
Virus-Like Particles: A Dissertation 
Homer Dadios Pantua 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Amino Acids, Peptides, and Proteins Commons, Animal Experimentation and Research 
Commons, and the Viruses Commons 
Repository Citation 
Pantua HD. (2006). Requirements for Assembly and Release of Newcastle Disease Virus-Like Particles: A 
Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/yzfk-h573. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/242 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
REQUIREMENTS FOR ASSEMBLY AND RELEASE OF  
NEWCASTLE DISEASE VIRUS-LIKE PARTICLES 
 
 
 
A Dissertation Presented  
By 
Homer Dadios Pantua 
 
 
 
Submitted to the Faculty of the  
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
October 27, 2006 
 
Program in Immunology and Virology 
COPYRIGHT NOTICE 
 
 
Parts of this dissertation have appeared in separate publications: 
 
 
Pantua H.D., L.W. McGinnes, M. Peeples, H. Gottlinger and T.G. Morrison. 2006. 
Requirements for assembly and budding of Newcastle disease virus-like particles. 
Journal of Virology. 80:11062-11073. 
 
Pantua H.D., L.W. McGinnes and T.G. Morrison.  2005. Characterization of the 
alternate form of Newcastle disease virus fusion protein. Journal of  Virology. 79:11660-
11670. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii
REQUIREMENTS FOR ASSEMBLY AND RELEASE OF
NEWCASTLE DISEASE VIRUS-LIKE PARTICLES
A Dissertation Presented
Homer D. Pantua
Trudy Morrison , Ph.D., Thesis Advisor
Mark Peeples, Ph.D., Member of Committee
Paul Clapham , Ph.D., Member of Committee
Elizabeth Luna, Ph.D., Member of Committee
Raymond Welsh , Ph.D., Member of Committee
Timothy Kowalik, Ph.D., Chair of Committee
Anthony Carruthers, Ph.
Dean of the Graduate School of Biomedical Sciences
Program in Immunology and Virology
October 27, 2006
ACKNOWLEDGEMENTS 
 
 
 There were a lot of people who have been instrumental in making this work 
successful.  I would like to thank my mentor, Dr. Trudy Morrison for the guidance, and 
invaluable support and encouragement during my entire thesis work.  I also thank her for 
allowing me to freely drive my research project.  There can be no mentor as excellent as 
her.  I am also thankful to my thesis research committee members, Dr. Timothy Kowalik, 
Dr. Raymond Welsh, Dr. Elizabeth Luna for their excellent direction and guidance 
through the conduct of this thesis work.  I would also like to thank Dr. Mark Peeples and 
Dr. Paul Clapham for their helpful suggestions during my defense. 
I would also like to thank all the members of the Morrison laboratory.  Special 
thanks to Lori McGinnes for being my second mentor.  I credit her for guiding me on 
how to design and perform key experiments for my thesis.  I am also thankful to Surbhi 
and Jay for all their help and for being such wonderful co-workers.  I am also thankful to 
Suzanne, Kathy and Dr. Julie Reitter for teaching me a lot of the molecular biology 
techniques that I know.  I must thank Kathy, Suzanne, Julie and Lori again for bringing 
laughter and light in the laboratory. 
I am also thankful to Dr. Heinrich Gottlinger for generously sharing reagents.  
Without his help, the third chapter of this thesis would not be a success.  Again, I would 
like to thank Dr. Peeples for sharing his precious anti-M antibodies.  I would also like to 
thank Dr. Robert Woodland and Dr. Madelyn Schmidt for sharing reagents and helping 
us in setting up the future immunology experiments. 
 iv
I am thankful for the immeasurable support of my family. Mom and Brothers (and 
your families), your encouragement and prayers have been crucial to my success, through 
many years of education.  I am really blessed to have you as my family.  I would like to 
thank my friends here in the US (Maloy, Chelly, Arlene, Jenny, Julius, Maria, Brigge and 
Nini) for being a family away from home and for all your help.  I am also thankful to my 
friends from home (Bab and Elmer) for their support and encouragement throughout 
veterinary school and graduate school. 
Lastly, and most importantly, I thank my wife and my best friend for the strength 
and loving support that she has provided me through our 5 years of marriage and 5 years 
of graduate school. Gen, you have excelled far above my expectations.  You possess the 
patience, wisdom, understanding and great love that made us much stronger through the 
years.  Words are not enough to thank you.  I dedicate this work to you and our child 
TALA ISABEL. Thank you. 
I thank the ALMIGHTY for blessing me with all these wonderful people in my 
life, for the strength to overcome the trials and for all the abilities that He blessed me. 
 
 
 
 
 
 
 
 v
ABSTRACT 
 
 
 The final step of paramyxovirus infection requires the assembly of viral structural 
components at the plasma membrane of infected cells followed by budding of virions.  
While the matrix (M) protein of some paramyxoviruses has been suggested to play a 
central role in the assembly and release of virus particles, the specific viral and host 
protein requirements are still unclear.  Using Newcastle disease virus (NDV) as a 
prototype paramyxovirus, we explored the role of each of the NDV structural proteins in 
virion assembly and release.  For these studies, we established a virus-like particle (VLP) 
system for NDV.  The key viral proteins required for particle formation and the specific 
viral protein-protein interactions required for assembly and release of particles were 
explored in chapter 2.  First we found that co-expression of all four proteins resulted in 
the release of VLPs with densities and efficiencies of release (1.18 to 1.16 g/cm3 and 
83.8%±1.1, respectively) similar to that of authentic virions.  Expression of M protein 
alone, but not NP, F-K115Q or HN proteins individually, resulted in efficient VLP 
release.  No combination of proteins in the absence of M protein resulted in particle 
release.  Expression of any combination of proteins that included M protein yielded 
VLPs, although with different densities and efficiencies of release.   
To address the roles of NP, F and HN proteins in VLP assembly, the interactions 
of proteins in VLPs formed with different combinations of viral proteins were 
characterized by co-immunoprecipitation.  The co-localization of M protein with cell 
surface F and HN proteins in cells expressing all combinations of viral proteins was 
characterized.   Taken together, the results show that M protein is necessary and 
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sufficient for NDV budding.  Furthermore, they suggest that M protein – HN protein and 
M protein - NP interactions are responsible for incorporation of HN protein and NP 
proteins into VLPs and that F protein is incorporated indirectly due to interactions with 
NP and HN protein.   
 Since the vacuolar protein sorting (VPS) system is involved in the release of 
several enveloped RNA viruses, chapter 3 describes studies which explored the role of 
the VPS system on NDV particle release.  First, we characterized the effects of three 
dominant negative mutant proteins of the VPS pathway on particle release.  Expression of 
dominant negative mutants of CHMP3, Vps4 and AIP1 proteins inhibited M protein 
particle release as well as release of complete VLPs.  Mutation of a YANL sequence in 
the NDV M protein to AANA inhibited particle release while replacement of this 
sequence with either of the classical late domain motifs, PTAP or YPDL, completely 
restored particle release.  The host protein AIP1, which binds YXXL late domain 
sequences, is incorporated into M protein particles.  These results suggest that an intact 
VPS pathway is necessary for NDV VLP release and that the YANL sequence is an NDV 
M protein L domain. 
 The sequence and structure of the Newcastle disease virus (NDV) fusion (F) 
protein are consistent with its classification as a type 1 glycoprotein.  We have previously 
reported, however, that F protein can be detected in at least two topological forms with 
respect to membranes in both a cell-free protein synthesizing system containing 
membranes as well as infected COS-7 cells (J. Virol. 2004 77:1951).  One form is the 
classical type 1 glycoprotein while the other is a polytopic form in which approximately 
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200 amino acids of the amino terminal end as well as the cytoplasmic domain (CT) are 
translocated across membranes.  Furthermore, we detected CT sequences on surfaces of F 
protein expressing cells and antibodies specific for these sequences inhibited red blood 
cell fusion to HN and F protein expressing cells suggesting a role for surface expressed 
CT sequences in cell-cell fusion.  In chapter 4, we extended these findings and found that 
the alternate form of the F protein can also be detected in infected and transfected avian 
cells, the natural host cells of NDV.  Furthermore, the alternate form of F protein was 
also found in virions released from both infected COS-7 cells and avian cells by Western 
analysis.  Mass spectrometry confirmed its presence in virions released from avian cells.  
Two different polyclonal antibodies raised against sequences of the CT domain of the F 
protein slowed plaque formation in both avian and COS-7 cells. Antibody specific for the 
CT domain also inhibited single cycle infections as detected by immunofluorescence of 
viral proteins in infected cells.   The potential roles of this alternate form of the NDV F 
protein in infection are discussed. 
 Virus-like particles (VLPs) generated from different viruses have been shown to 
have potential as good vaccines.  Chapter 5 explored the potential of NDV VLPs as a 
vaccine for NDV or as a vaccine vector for human pathogens. Significant quantities of 
NDV VLPs can be produced from tissue culture cells.  These VLPs are as pure as virions 
prepared in eggs.  In addition, some rules for incorporation of viral proteins into VLPs 
were also explored.  We found that the cytoplasmic domain of the fusion (F) protein is 
necessary for its incorporation into VLPs.  We found that an HN protein with an HA tag 
at its carboxyl terminus was incorporated into VLPs.  We also found that the HN and F 
 viii
proteins of NDV, strain B1, can be incorporated into VLPs with M and NP of strain AV.  
The demonstration of specific domains required for protein incorporation into particles is 
important in using NDV VLPs as a vaccine vector for important human pathogens. 
 In conclusion, this dissertation presents results that show that the M protein plays 
a central role in NDV assembly and release, a finding that is consistent with findings with 
other paramyxoviruses.  More importantly, this work extends the current knowledge of 
paramyxovirus assembly and release by providing the first direct evidence of interactions 
between paramyxovirus proteins.  These interactions between viral proteins provide a 
rational basis for incorporation of viral proteins into particles.  This work also provides a 
clearer understanding of the role of the host vacuolar protein sorting machinery in NDV 
budding.  A clear understanding of virus assembly and budding process contributes to the 
design of strategies for therapeutic intervention and in the development of safer, more 
economical and effective vaccines. 
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CHAPTER I 
INTRODUCTION 
 
 
A.  General statement of topic 
Enveloped RNA viruses must cross the plasma membrane of the host cell twice 
during the virus life cycle.  The first is during virus entry and second is during particle 
egress.  The latter process involves several steps including assembly of viral components 
at the plasma membrane and the subsequent release of particles by budding.  The aim of 
this work is to understand the mechanisms of assembly and release of Newcastle disease 
virus (NDV) by using a virus-like particle (VLP) system.  Using this system, this thesis 
has defined the viral determinants and host cellular machinery that participate in particle 
assembly and budding. The results of this work are also important in designing and 
developing VLPs as a vaccine for Newcastle disease or as a vaccine vector for important 
human diseases. 
B.  Newcastle disease virus 
Newcastle disease virus (NDV) causes a highly contagious disease of many 
species of domestic and wild birds.  The disease was first reported in Java in 1926 and 
was brought to international attention in Newcastle on Tyne, England, in 1926 (reviewed 
in (Shope 1964; Alexander 2001)).  The disease is characterized by respiratory, digestive 
and neurological signs.  The severity of clinical signs ranges from inapparent infection to 
a rapidly fatal condition.  Different strains of virus are categorized based on their ability 
to cause nervous, respiratory, and visceral lesions, or death (Alexander 2001).  Virulence 
differentiations among strains are determined by standard pathotyping assays, which 
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utilize inoculation of embryonated eggs and live chickens.  NDVstrains are classified as 
velogenic (highly virulent), mesogenic (moderately virulent) and lentogenic (avirulent), 
depending on the severity of the disease they cause (Beard and Hanson 1984; Alexander 
2000).  The velogenic strain is further divided into two pathotypes, the viscerotrophic 
velogenic (VVNDV) and the neurotrophic velogenic (NVNDV), which cause acute lethal 
disease with visceral hemorrhage or neurological and respiratory signs, respectively.   
NDV has been noted in a great majority of the countries in the world, possibly 
due to the wide range of the reservoir host.  NDV is an economically important pathogen, 
since periodic outbreaks affect the poultry industry.  Recently, a VVNDV epidemic in the 
United States resulted in the destruction of about 4 million birds.  Because of its potential 
as an agent of agrobioterrorism, the United States government has classified virulent 
strains as select agents under the Patriot Act.   
Vaccination against NDV is part of standard poultry vaccination protocols.  The 
widely used NDV vaccines are the lentogenic, live attenuated B1 or La Sota strains.  
Although these strains do not have pathogenic effects on the birds, vaccination using 
these strains still produces mild respiratory and digestive disorders, which affect the 
general productivity of birds in the poultry industry.   
Classification and general properties of Newcastle disease virus 
Newcastle disease virus (NDV) is classified as the only member of Avulavirus 
genus within the subfamily Paramyxovirinae in the family Paramyxoviridae within the 
order Mononegavirales (Table 1.1).  This family of viruses also includes other important 
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human and animal pathogens that cause measles, mumps, respiratory diseases (e.g. 
respiratory syncytial virus and parainfluenza viruses), canine distemper, and encephalitis 
(e.g. Hendra and Nipah viruses) (Table 1.1).   
Virions range in size range from 150 to 300 nm in diameter.  Purified virion 
buoyant density is 1.18-1.20 g/cm3.  Particles are pleiomorphic but usually spherical in 
shape (Figure 1.2A).   They consist of a host derived lipid-containing envelope and a 
helical nucleocapsid (Lamb and Kolakofsky 2001).   
The negative stranded NDV genome is about 15,186 nucleotides and encodes 6 
genes, positioned 3’-NP-P-M-F-HN-L-5’, which are separated in the positive sense by 
short untranslated regions (UTRs) (Figure 1.1).  The six NDV genes encode structural 
proteins that are categorized into membrane and core components.  The membrane 
components consist of two transmembrane glycoproteins, the F and HN proteins, and the 
matrix (M) protein (Figure 1.2B).  The virus envelope encases the ribonucleoprotein 
(RNP) core, which is formed by the RNA genome associated with the nucleocapsid 
protein (NP) and the polymerase complex composed of phosphoprotein (P) and large (L) 
proteins (Figure 1.2B).  The inner surface of the virion is lined by the M protein which is 
thought to mediate interaction between the RNP complex and lipid-bilayer, as well as the 
cytoplasmic tails of the spike glycoproteins (Figure 1.2B) (Cathomen, Mrkic et al. 1998).   
Paramyxovirus replication 
 All steps of NDV replication take place in the cytoplasm of the infected host cell 
(Figure 1.3).  NDV infection of the host cell is initiated by first binding to the sialic-acid  
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Figure 1.1.  Linear genome diagram of NDV. Schematic shows NDV genes from 3’ to 
5’. NP, nucleocapsid protein; P, phosphoprotein; V and W, accessory proteins; M, 
matrix; F, fusion; HN, hemagglutinin-neuraminidase; L, large.  Vertical bars show 
intervening regions (some sequences are transcribed but not translated).   
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containing receptors in the plasma membrane.  Attachment of the HN protein to the 
receptor activates and leads to conformational changes in the F protein, which directs 
fusion of the viral membrane with the host cell plasma membrane at neutral pH (White 
1990).  For most paramyxoviruses, co-expression of the F and HN proteins from the same 
virus is necessary for efficient membrane fusion (reviewed in (White 1990; Lamb 1993; 
Morrison 2003)).  After fusion of the viral membrane and the host cell membrane, the 
viral nucleocapsid dissociates from the M protein by an unknown mechanism and is 
delivered into the cytoplasm of the cell.    The viral polymerase complex transcribes each 
gene in the RNA genome.  Following translation of the primary transcripts and 
accumulation of the viral proteins, antigenome synthesis commences.  The products of 
this synthesis are then used by the same polymerase complex to produce exact, 
complementary copies of full length, negative-sense genomes that will be packaged into 
virions (Lamb and Kolakofsky 2001). 
 The viral nucleocapsids are assembled in two steps; first, the newly synthesized 
NP associates with nascent genomic RNA to form the helical nucleocapsid structure, and 
second, the P-L polymerase complex associates with the nucleocapsid.  The well 
conserved N-terminal region of NP contains the RNA binding domain and the 
determinants for the NP-NP interaction that forms the helical structure (Curran, Homann 
et al. 1993; Bankamp, Horikami et al. 1996; Myers and Moyer 1997; Myers, Pieters et al. 
1997).  The C-terminal region of NP contains the domains that bind with the P protein 
(Buchholz, Retzler et al. 1994).  The C-terminal region is also responsible for its  
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Figure 1.2.  Morphology of Paramyxovirus particle. A, Electron micrograph of a 
typical paramyxovirus (Lamb, R.A. and D Kolakofsky (2001). Paramyxoviridae: The 
Viruses and Their Replication. Philadelphia, Lippincott Williams & Wilkins.) B,  
Schematic of a typical paramyxovirus showing the membrane components (F, HN, M 
proteins) and core components (RNA with NP, P, and L). 
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specific interaction with the M protein and is hypothesized to be necessary for the 
incorporation of nucleocapsid into virions (Coronel, Takimoto et al. 2001).   
The two newly synthesized HN and F glycoproteins are transported to the surface 
of infected cells.  Viral glycoproteins are synthesized in the endoplasmic reticulum and 
undergo a series of conformational maturation steps prior to transport through the 
secretory pathway (Lamb and Kolakofsky 2001).  NDV has two forms of F protein, the 
classical type I transmembrane glycoprotein and the partially translocated alternate form 
of F protein in which both the amino terminus and CT domain of the protein are 
translocated across the membrane (McGinnes, Reitter et al. 2003). 
 Paramyxovirus assembly takes place at the plasma membrane of infected cells 
(Lamb and Kolakofsky 2001).  All components of the virus, the nucleocapsid, M protein, 
and the envelope glycoproteins are transported to the plasma membrane and virions are 
assembled and particles are released by the process of budding.  NDV virion components 
are enriched in lipid rafts within the plasma membrane, and it has been suggested that 
these specific domains serve as sites of virus assembly and budding (Laliberte, McGinnes 
et al. 2006). 
C.  Mechanisms of enveloped RNA virus assembly and budding 
Many enveloped RNA virus particles are formed by a process that includes 
assembly of viral components at the plasma membrane of infected host cells and the 
subsequent release of particles by budding.  Buds emerge from sites on the plasma 
membrane where viral components have assembled and then pinch off, resulting in the  
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Figure 1.3.  Schematic of paramyxovirus replication. 1, Attachment of HN to receptor; 
2, Fusion of viral membrane with plasma membrane; 3, Delivery of RNA genome into 
the cytoplasm; 4, Transcription; 5, Translation; 6, Anti-genome synthesis and genome 
synthesis; 7, Transport of membrane components to the cell surface; 8, Assembly and 
budding of progeny virions. 
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release of particles.  A number of steps appear to be involved in the formation of the 
infectious virus particles, including the transport of viral glycoproteins to the cell surface, 
the transport of assembled RNPs and matrix proteins to the plasma membrane of the cell, 
interactions between viral proteins in the budding site, and interactions between viral 
components and host cell machinery that allow budding and release of particles. 
However, details of these processes in paramyxovirus infection are unclear.  Important 
questions that will be addressed in this thesis include the following:  
  (i) Which viral structural components actively contribute to the budding process? 
 (ii) What is the minimum viral component required for budding to occur? 
(iii) Do glycoproteins play an important role in virus budding? 
(iv) Does assembly require specific viral protein-protein interactions? 
(v)  Do paramyxoviruses recruit host machinery to assist in the budding process? 
(vi) Are these interactions with host proteins mediated by late domains? 
D.  Contributions of viral factors in enveloped RNA virus budding 
For some enveloped RNA viruses, the viral components that participate in virus 
assembly and budding have been well characterized.  The key role played by the viral 
matrix-like proteins in assembly of particles, as well as roles played by additional viral 
components such as the viral glycoproteins, are some of the important topics of 
discussion in this part of this dissertation.  In addition, interactions between viral 
components that are necessary for assembly of particles are also discussed.  
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Role of matrix protein 
In most enveloped RNA virus systems, it has been shown that the matrix-like 
proteins play an important role in assembly and budding.  Matrix-like proteins are 
situated in virions beneath the lipid envelope so that they have the potential to contact 
both the RNP core and envelope glycoprotein cytoplasmic tails.  Given this position, the 
matrix proteins are likely to play a central role in the organization of virus assembly 
perhaps by inducing ordered concentration of viral components at defined budding sites 
in the plasma membrane of infected cells.   
The importance of matrix-like proteins in assembly and budding of enveloped 
RNA viruses has been shown in experiments using temperature-sensitive viruses that 
have defective M genes, by direct manipulation of M genes in recombinant viruses by 
reverse genetics, and by reconstitution of budding directed by matrix proteins in 
transfected cells.  Evidence for the essential role of matrix-like proteins in enveloped 
RNA virus assembly is summarized below. 
A role of matrix-like proteins in virus budding was first demonstrated by use of 
temperature-sensitive (ts) mutants.  A variety of mutant vesicular stomatitis viruses 
(VSV) with ts mutations in their M genes have been characterized and found to be 
defective in assembly and budding of particles at restrictive temperature (Knipe, 
Baltimore et al. 1977).  In addition to inefficient release of virions, most of the particles 
released did not contain an RNA genome and the morphology of the particles was 
altered, being spherical or pleiomorphic instead of the normal bullet-shaped morphology 
(Lyles, McKenzie et al. 1996).  
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Another group found that ts mutations in the M gene of Sendai virus (SV) are 
defective in assembly and budding of particles at restrictive temperature (Yoshida, Nagai 
et al. 1979; Kondo, Yoshida et al. 1993).  Interestingly, massive over-expression of ts 
mutant M protein of SV restored normal release of particles suggesting that the budding 
defect is due to insufficient accumulation of M protein and not to a defect in function of 
the mutant M protein (Kondo, Yoshida et al. 1993).  This finding also suggests that SV 
budding may require a threshold level of M protein accumulation. 
Further studies which confirmed the key role played by matrix-like proteins in 
assembly and budding have utilized reverse genetics techniques, which allow the 
generation of recombinant enveloped negative-strand RNA viruses from plasmid DNA.  
Rabies virus (Cathomen, Mrkic et al. 1998; Mebatsion, Weiland et al. 1999), measles 
virus (MV) (Mebatsion, Weiland et al. 1999) and SV (Inoue, Tokusumi et al. 2003) 
generated to lack the entire M gene demonstrated impaired budding.  Moreover, MV 
containing mutant M protein derived from subacute sclerosing panencephalitis (SSPE) 
virus was also defective in release of particles (Patterson, Cornu et al. 2001).  These 
reports together with the ts mutant M protein results strongly support the idea that the M 
protein plays a central role in virus assembly and budding. 
The importance of matrix-like proteins for enveloped RNA virus budding has also 
been shown by reconstituting budding in cells that express matrix-like protein alone.  The 
usefulness of this approach was first demonstrated by generating virus-like particles from 
insect cells transduced with a recombinant baculovirus vector containing a  VSV M gene 
(Li, Luo et al. 1993).  Other important contributions in the field of enveloped RNA virus 
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assembly are studies on the retrovirus system.  Self-budding activity of Gag protein has 
been demonstrated in several different retroviruses (reviewed in (Morita and Sundquist 
2004)). 
The first direct evidence of budding mediated by paramyxovirus M protein was 
demonstrated by characterizing the M protein expressed from cDNA.  Similar to results 
obtained with the matrix-like proteins of retroviruses (Morita and Sundquist 2004), 
filoviruses (Jasenosky and Kawaoka 2004), rhabdoviruses (Jayakar, Jeetendra et al. 
2004), and influenza viruses (Barman, Adhikary et al. 2004), expression of human 
parainfluenza virus type 1 (hPIV1) M protein alone or the SV M protein alone resulted in 
the release of M protein containing particles (Coronel, Murti et al. 1999; Takimoto, Murti 
et al. 2001).  These results indicated that these M proteins contain all the functional 
elements necessary for formation and release of particles.  The VLPs released into the 
culture medium varied in size and were smaller than the regular virus particles.  The 
density of particles was less than that of virus particles released from infected cells, 
probably due to the lack of other structural proteins and the RNA genome.  
However, the role of the M protein in the budding of virus or VLPs seems to vary 
among paramyxoviruses.  In some cases, co-expression of M proteins along with 
additional viral components can substantially increase the efficiency of release of 
particles.  Unlike the expression of the M proteins of SV and hPIV1, expression of the 
simian virus 5 (SV5) M protein was not sufficient for particle release.  Although the M 
protein was necessary, expression of two other proteins (NP and either glycoprotein) 
along with M protein was required for release of SV5 virus like particles (VLPs) 
 14
(Schmitt, Leser et al. 2002).  Particle budding that is normally observed with SV M 
protein alone is also enhanced by co-expression of SV F protein (Takimoto, Murti et al. 
2001).  Thus, although M proteins of most paramyxoviruses are capable of directing 
budding of particles in the absence other viral components, in many cases, budding is 
enhanced by co-expression of multiple viral components.  The only data that implicates 
the NDV M protein in virus budding was a report that mutations in the M protein resulted 
in decreased F glycoprotein incorporation into virions (Peeples and Bratt 1984).  
However, there is no direct evidence that shows that the NDV M protein plays an 
important role in budding of particles.  
Role of glycoproteins in promoting efficient budding of enveloped RNA viruses 
Glycoproteins from different RNA viruses have been observed to play a role in 
the assembly and budding of particles.  The assembly and release of retroviral particles 
are mediated by Gag protein, though in some retroviral genera, the Env glycoproteins 
play a major role in directing Gag to the cell surface (Perez, Davis et al. 1987; Owens, 
Dubay et al. 1991; Yu, Yuan et al. 1993; Poumbourios, Wilson et al. 1997).  The 
glycoproteins of rhabdoviruses and filoviruses have also been demonstrated to have self-
budding activity as shown by budding of vesicles containing the rhabdovirus G protein 
from cells expressing the VSV or rabies virus G glycoproteins (Rolls, Webster et al. 
1994; Mebatsion, Konig et al. 1996).  Ebola virus GP expressed alone also induced 
release of particles with variable morphology (Volchkov, Volchkova et al. 1998; Noda, 
Sagara et al. 2002).  However, when GP was co-expressed with Ebola virus matrix 
protein, VP40, there was an enhancement in the release of particles with uniform 
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filamentous morphology (Noda, Sagara et al. 2002).  These findings in the rhabdovirus 
and filovirus systems demonstrated that glycoproteins play an important role in assembly 
and budding of these viruses particles.  While the orthomyxovirus influenza A matrix 
protein, M1, induces production of VLPs in the absence of other viral components, the 
efficiency of release is strongly increased by the neuraminidase (NA) protein. Co-
expression of influenza A structural proteins in the absence of NA protein resulted in the 
formation of VLPs that aggregated at the surfaces of cells (Gomez-Puertas, Mena et al. 
1999; Gomez-Puertas, Albo et al. 2000).  The enzymatic activity of NA prevents newly 
formed particles from aggregating at the surfaces of infected cells. 
 Paramyxoviruses encode two glycoproteins, the fusion protein and attachment 
protein.  Early studies have shown that the HN protein of SV is not necessary for the 
budding of virus particles (Portner, Marx et al. 1974; Stricker and Roux 1991).  Using the 
VLP system, the conclusion that the HN protein is not necessary for budding was further 
confirmed. Co-expression of SV proteins in the absence of HN protein resulted in 
efficient release of particles, suggesting that SV HN protein has no effect on VLP 
budding (Leyrer, Bitzer et al. 1998).  In contrast, budding of M protein containing 
particles was enhanced by co-expression of F protein, while co-expression of HN protein 
with M protein had no effect on budding efficiency (Takimoto, Murti et al. 2001).  These 
results suggested that the SV F protein but not the HN protein is important for efficient 
budding of particles.  Consistent with this view, the F protein was found to have self-
budding activity while HN protein was not observed to have this activity (Takimoto, 
Murti et al. 2001; Sugahara, Uchiyama et al. 2004).   
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The cytoplasmic domain of the F protein of paramyxoviruses has been shown to 
likely contain the domain required for efficient budding.  The cytoplasmic tails (CT) of 
SV and hPIV1 F protein share five consecutive amino acids (TYTLE).  Mutational 
analysis showed that these residues are important for particle formation (Takimoto, Murti 
et al. 2001).  Similar studies have been done with SV5, to define further the role of 
glycoproteins in paramyxovirus budding.  Budding of recombinant SV5 with truncated F 
or HN protein cytoplasmic tails were found to be inefficient (Schmitt, He et al. 1999; 
Schmitt, Leser et al. 2002).  It is still unclear which of the NDV glycoproteins are 
important for assembly and budding of virions.   
Interactions between components of enveloped RNA viruses during assembly 
For efficient assembly and budding of enveloped RNA viruses, two steps are 
essential.  First, all viral structural components must be transported to the site of 
assembly and budding.  Second, these components must interact with each other in an 
orderly manner to initiate the budding process that leads to the production of infectious 
progeny virus.  This process appears to be accomplished through a series of viral protein-
protein interactions, many of which involve the matrix protein.  The M protein potentially 
interacts with membranes, with glycoproteins likely via cytoplasmic tails and with RNPs 
in the cytoplasm of infected cells. 
Matrix-like proteins of VSV (Chong and Rose 1993; Chong and Rose 1994), 
Ebola virus (Jasenosky, Neumann et al. 2001), Marburg virus (Kolesnikova, Bugany et 
al. 2002), influenza virus (Kretzschmar, Bui et al. 1996), SV (Stricker, Mottet et al. 1994) 
and MV (Riedl, Moll et al. 2002) were shown to have intrinsic membrane-binding 
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properties.  Membrane association of NDV M protein was demonstrated by the  
reconstitution of matrix proteins and synthetic liposomes into vesicles (Faaberg and 
Peeples 1988). 
While paramyxovirus M proteins are clearly pivotal in the release of assembled 
virus, the interactions between M protein and other viral proteins required for the 
assembly of complete particles are less well defined.  Indeed, available information, 
based on properties of VLPs formed after co-expression of different viral proteins with M 
protein or on co-localization or co-fractionation of M protein with other viral proteins 
have often led to contradictory conclusions.  For example, some reports suggest that M 
protein binds to F protein while others suggest a specific interaction with the attachment  
protein (SV HN or RSV G) or both attachment and F proteins (Sanderson, Wu et al. 
1994; Ali and Nayak 2000; Ghildyal, Li et al. 2005).  It is also proposed by Schmitt et al 
that the cytoplasmic domain of F and HN proteins have redundant functions in mediating 
viral protein-protein interactions (Schmitt, He et al. 1999; Schmitt, Leser et al. 2002).  M 
protein is also proposed to interact with NP protein in some studies (Stricker, Mottet et al. 
1994). 
E.  Contributions of host factors in enveloped RNA virus budding 
Budding through the host cell plasma membrane is a crucial step in the life cycle 
of many viruses.  Recent studies of retroviruses and a number of other enveloped RNA 
viruses have now demonstrated that cellular proteins that are intimately involved in 
intracellular membrane trafficking and receptor relocalization play key roles in 
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facilitating the virus budding process (reviewed in (Bieniasz 2006)). Below is a brief 
review of the important role played by cellular proteins in virus budding. 
Role of the vacuolar protein sorting pathway in enveloped RNA virus budding 
The role of host cellular machinery in enveloped virus budding has been excellently 
demonstrated in the retrovirus system.  It has been shown that retroviruses  co-opt the 
cellular endosomal sorting machinery, vacuolar protein sorting (VPS) system, for use in 
virus egress.  The VPS machinery, first defined in yeast as class E Vps proteins, is 
normally used by cells to maintain surface transmembrane protein concentration and to 
deliver proteins targeted for degradation in the lysosomes (Babst 2005).  These functions 
are accomplished by the formation of multivesicular bodies (MVBs).  MVBs are 
structures formed from the invagination of the endosomal membrane into the endosomal 
lumen thus forming vesicles inside a vesicle (Figure 1.4) (Babst 2005; Bieniasz 2006).  
The formation of MVBs are coordinated mainly by  three endosomal sorting complexes 
required for transport (ESCRT I, II and III) first characterized in yeast (reviewed in 
(Babst 2005)) (Figure 1.5).  ESCRT I and ESCRT II both contain a subunit that binds to 
ubiquitin. ESCRT I recognizes the ubiquitinated protein cargos and recruits ESCRT II 
and ESCRT III that participate in protein sorting and vesicle formation (Figure 1.5A) 
(reviewed in (Pornillos, Garrus et al. 2002; Babst 2005)).  ESCRT II functions to recruit 
ESCRT III to the membrane.  The pathway also requires an ATPase, Vps4, which is 
responsible for the dissociation of the full ESCRT complex and subsequent recycling of 
its components (Babst, Sato et al. 1997; Babst, Wendland et al. 1998). 
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Figure 1.4.  Protein transport pathway in eukaryotic cells.  Endocytosed surface 
proteins from the secretory pathway are delivered into the endosomal system.  Cargo 
proteins destined for degradation in the lysosome are sorted into luminal vesicles of 
multivesicular bodies (MVBs). Mature MVBs fuse with the lysosome and deliver the 
MVB vesicles to the lysosomal lumen where the vesicles and cargo are degraded.  
(Adapted from published reports and Babst, M.B. et al. 2005. Traffic 6:2-9) 
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A key advance in understanding the budding process of enveloped RNA viruses 
came with the demonstration that retrovirus Gag proteins interact with components of the 
VPS machinery, presumably hijacking the system to direct virus release (Pornillos, 
Garrus et al. 2002; Martindale 2003; Morita and Sundquist 2004).  HIV-1 budding from 
infected human cells is modeled in analogy to vesicle formation in the yeast MVB 
(Pornillos, Garrus et al. 2002) (Figure 1.5B).  It is thought that the topology of vesicle 
formation is similar to virus particle budding in the sense that they are both directed away 
from the cytoplasm (Martindale 2003). It has been shown that that HIV-1 Gag interacts 
with the tumor susceptibility gene (TSG) 101 protein (Pornillos, Garrus et al. 2002), a 
subunit of ESCRT I, which suggests that ESCRT I participates in the virus budding 
process.  HIV-1 budding has also been shown to be blocked by dominant negative 
mutations that disrupt the activity of the CHMP3, a subunit of ESCRT III, as well as the 
ATPase, Vps4 (Garrus, von Schwedler et al. 2001; Strack, Calistri et al. 2003).  
Interestingly, other enveloped RNA viruses, most notably the filoviruses and 
rhabdoviruses, have evidently evolved a similar exit strategy by interaction of their 
matrix proteins with the endosomal sorting machinery (reviewed in (Jasenosky and 
Kawaoka 2004; Jayakar, Jeetendra et al. 2004; Schmitt and Lamb 2004; Hartlieb and 
Weissenhorn 2006)).  However, the role of the host VPS machinery in paramyxovirus 
budding is not well understood.   
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VPS Pathway 
Retrovirus Budding 
 
Figure 1.5.  Comparison of the model of vacuolar protein sorting pathway and HIV-
1 budding.  A, Multivesicular bodies formation showing ESCRT I, II and III and the 
ATPase, Vps4. B, Interplay between VPS molecules and Retrovirus Gag in the budding 
process. 
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Viral Late Domains 
The essential role of the matrix-like proteins in virus release is due in part to short 
motifs in the protein sequence, collectively termed as late (L) domains to reflect their 
function late in the budding process (reviewed in (Martin-Serrano, Zang et al. 2001; 
Strack, Calistri et al. 2002; Jasenosky and Kawaoka 2004; Morita and Sundquist 2004; 
Schmitt and Lamb 2004; Takimoto and Portner 2004; Patton, Morris et al. 2005; Bieniasz 
2006)).  L domains are highly conserved short peptide motifs that promote virus release 
by mediating  interactions with a member of the class E proteins, components critical for 
the formation of vesicles that inwardly bud into MVBs.  (Pornillos, Garrus et al. 2002; 
Freed 2003; Bieniasz 2006).  It is thought that matrix-like proteins with L domain motifs 
co-opt the host VPS pathway for use in virus budding (Freed 2002; Martindale 2003; 
Strack, Calistri et al. 2003; Morita and Sundquist 2004).  The first compelling evidence 
that a viral L domain functions in budding was shown with an HIV-1 mutant with a 
deletion in the p6 Gag. In this study, mutant HIV-1 failed to detach from the cell plasma 
membrane (Gottlinger, Dorfman et al. 1991). A highly conserved PTAP motif located 
near the N terminus was shown to play a crucial role in the budding activity of p6 
(Gottlinger, Dorfman et al. 1991).  This result was recapitulated in the Rous sarcoma 
virus.  Furthermore, it was shown that a highly conserved PPPY motif, which mapped in 
the p2b, plays an important role in virus particle production.  Three classes of motifs have 
since been identified to have L domain activity; PTAP, PPXY and YXXL.  In each case, 
the integrity of these motifs is essential for L domain function, suggesting that L domain 
serves to mediate interaction with host factors (Bieniasz 2006). 
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Figure 1.6.  Viral late domains in matrix-like proteins of different viruses.  L domain 
sequences in the matrix-like protein of different enveloped RNA viruses.  HIV-1, Human 
immunodeficiency virus type1; MLV, Moloney murine leukemia virus; RSV, Rous 
sarcoma virus; M-PMV, Mason-Pfizer monkey virus; EIAV, Equine infectious anemia 
virus; VSV, Vesicular stomatitis virus (Freed EO 2002 J. Virol. 76:4679-4687). 
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Subsequently, several L domain sequences have been identified in many different 
viruses (reviewed in (Freed 2004)). L domains in the VP40, the M protein of filoviruses, 
and rhabdoviruses M protein have been identified (Figure 1.6).  An L domain sequence, 
FPIV, in the SV5 M protein has also been defined (Schmitt, Leser et al. 2005).  However, 
this sequence cannot be sufficient for SV5 release since the M protein of this virus, when 
expressed alone, does not direct particle release.  Therefore, no classical L domain 
sequence has been identified in the M proteins of the paramyxoviruses. 
F.  Contents of dissertation 
The viral and host protein requirements for NDV assembly and budding remain to 
be determined.  Results in this thesis demonstrate the following: 
(i)  NDV VLPs are efficiently released from cells expressing the NP, M, F and     
     HN proteins; 
 (ii)  NDV M protein is required and sufficient for particle assembly and budding; 
(iii)  Co-expression of NDV M protein with at least two viral proteins is necessary  
       for efficient incorporation of other proteins into particles; 
(iv)  Specific viral protein-protein interactions are required for particle assembly; 
 (v)  Vacuolar protein sorting machinery is essential for particle budding; 
(vi)  YANL sequence in the NDV M protein has late domain function; 
          (vii)  The alternate form of F protein also exists in virus, suggesting a role in virus  
        assembly and budding; 
         (viii)  NDV VLPs have significant potential as a vaccine for Newcastle disease;  
        They may also provide framework for vaccines for other viruses. 
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Evidence supporting these conclusions are parts of a series of papers, two published, one 
submitted and one in preparation.  The Abstracts of each paper are shown below. 
Chapter 2: Requirements for assembly and release of Newcastle disease virus-like 
particles (Published in Journal of Virology November 2006 v80) 
Paramyxoviruses such as Newcastle disease virus (NDV) assemble in and bud 
from plasma membranes of infected cells.  To explore the role of each of the NDV 
structural proteins in virion assembly and release, virus-like particles (VLPs) released 
from avian cells expressing all possible combinations of the nucleoprotein (NP), 
membrane or matrix protein (M), an uncleaved fusion protein (F-K115Q), and 
hemagglutinin-neuraminidase (HN) protein were characterized for densities, protein 
content, and efficiencies of release.  Co-expression of all four proteins resulted in the 
release of VLPs with densities and efficiencies of release (1.18 to 1.16 g/cm3 and 
83.8%±1.1, respectively) similar to that of authentic virions.  Expression of M protein 
alone, but not NP, F-K115Q or HN proteins individually, resulted in efficient VLP 
release.  No combination of proteins in the absence of M protein resulted in particle 
release.  Expression of any combination of proteins that included M protein yielded 
VLPs, although with different densities and efficiencies of release.  To address the roles 
of NP, F and HN proteins in VLP assembly, the interactions of proteins in VLPs formed 
with different combinations of viral proteins were characterized by co-
immunoprecipitation.  The co-localization of M protein with cell surface F and HN 
proteins in cells expressing all combinations of viral proteins was characterized.   Taken 
together, the results show that M protein is necessary and sufficient for NDV budding.  
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Furthermore, they suggest that M-HN and M-NP interactions are responsible for 
incorporation of HN and NP proteins into VLPs and that F protein is incorporated 
indirectly due to interactions with NP and HN protein. 
Chapter 3:  Release of Newcastle disease virus-like particles requires the host VPS 
system (Submitted, Journal of Virology)  
 Newcastle disease virus-like particles (VLPs) are released from avian cells 
expressing the viral NP, F, HN, and M proteins and M protein is both necessary and 
sufficient for particle release (Pantua et al, J. of Virol 80: Nov). Here we show that VLPs 
were also released from HEK 293T cells expressing either M protein alone or in 
combination with NP, F and HN proteins.  Since the vacuolar protein sorting (VPS) 
system is involved in release of several enveloped RNA viruses, we explored the role of 
the VPS system on NDV particle release using three dominant negative mutant proteins 
of the VPS pathway.  Expression of dominant negative mutants of CHMP3, Vps4 and 
AIP1 proteins inhibited M protein particle release as well as release of complete VLPs.  
Mutation of a YANL sequence in the NDV M protein to AANA inhibited particle release 
while replacement of this sequence with either of the classical late domain motifs, PTAP 
or YPDL, completely restored particle release.  The host protein AIP1, which binds 
YXXL late domain sequences, is incorporated into M protein particles.  These results 
suggest that an intact VPS pathway is necessary for NDV VLP release, that the YANL 
sequence is an NDV M protein L domain, and that NDV may access the VPS system 
using the PTAP late domain. 
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Chapter 4:  Characterization of an alternate form of Newcastle disease virus fusion 
protein (Published in Journal of Virology, 2005 v79 pp.11660-11670) 
The sequence and structure of the Newcastle disease virus (NDV) fusion (F) 
protein are consistent with its classification as a type 1 glycoprotein.  We have previously 
reported, however, that F protein can be detected in at least two topological forms with 
respect to membranes in both a cell-free protein synthesizing system containing 
membranes as well as infected COS-7 cells (J. Virol. 2004 77:1951).  One form is the 
classical type 1 glycoprotein while the other is a polytopic form in which approximately 
200 amino acids of the amino terminal end as well as the cytoplasmic domain (CT) are 
translocated across membranes.  Furthermore, we detected CT sequences on surfaces of F 
protein expressing cells and antibodies specific for these sequences inhibited red blood 
cell fusion to HN and F protein expressing cells suggesting a role for surface expressed 
CT sequences in cell-cell fusion.  Extending these findings we have found that the 
alternate form of the F protein can also be detected in infected and transfected avian cells, 
the natural host cells of NDV.  Furthermore, the alternate form of F protein was also 
found in virions released from both infected COS-7 cells and avian cells by Western 
analysis.  Mass spectrometry confirmed its presence in virions released from avian cells.  
Two different polyclonal antibodies raised against sequences of the CT domain of the F 
protein slowed plaque formation in both avian and COS-7 cells. Antibody specific for the 
CT domain also inhibited single cycle infections as detected by immunofluorescence of 
viral proteins in infected cells.   The potential roles of this alternate form of the NDV F 
protein in infection are discussed. 
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Chapter 5: NDV virus-like particles as vaccine for Newcastle disease (In preparation) 
 Virus-like particles (VLPs) generated from different viruses have been shown to 
have potential as good vaccines.  Significant quantities of NDV VLPs can be produced 
from tissue culture cells.  These VLPs are as pure as virions prepared in eggs.  We also 
found that the cytoplasmic domain of the fusion (F) protein is necessary for its 
incorporation into VLPs.  We found that an HN protein with an HA tag at its carboxyl 
terminus was incorporated into VLPs.  We also found that the HN and F proteins of NDV 
strain B1 can be incorporated into VLPs with M and NP of strain AV.  The 
demonstration of specific domains required for incorporation into particles is important in 
using NDV VLPs as a vaccine vector for other important human pathogens. 
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CHAPTER II 
REQUIREMENTS FOR THE ASSEMBLY AND RELEASE  
OF NEWCASTLE DISEASE VIRUS-LIKE PARTICLES 
 
 
A.  Introduction 
Paramyxoviruses, such as Newcastle disease virus (NDV), assemble progeny 
virions at infected cell plasma membranes and release these particles by budding from 
cell surfaces (Lamb and Kolakofsky 2001).  Paramyxovirus assembly requires the 
packaging of genomic RNA with the nucleoprotein (NP) as well as phosphoprotein (P) 
and large (L) polymerase (Lamb and Kolakofsky 2001), components of the polymerase 
complex.  This ribonucleoprotein core is encased in a host-derived membrane modified 
by two transmembrane glycoproteins, the hemagglutinin-neuraminidase (HN) and the 
fusion (F) proteins, as well as the matrix or membrane (M) protein, which is associated 
with the inner surface of the viral membrane (Peeples 1991; Lamb and Kolakofsky 2001).  
The paramyxovirus protein-protein interactions required for particle assembly and the 
viral and cellular proteins necessary for particle release are not well defined. 
The matrix-like proteins of many enveloped RNA viruses play a pivotal role in 
virus assembly and release (Peeples 1991; Pornillos, Garrus et al. 2002; Freed 2003; 
Jasenosky and Kawaoka 2004; Jayakar, Jeetendra et al. 2004; Schmitt and Lamb 2004; 
Takimoto and Portner 2004).  These proteins are often sufficient for release of particles.  
For example, expression of the retroviral gag precursor protein, in the absence of other 
viral components, results in the assembly and release of gag virus-like particles (VLPs) 
(Delchambre, Gheysen et al. 1989; Gheysen, Jacobs et al. 1989; Demirov and Freed 
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2004; Morita and Sundquist 2004).   Matrix proteins from Ebola virus (Jasenosky, 
Neumann et al. 2001; Timmins, Scianimanico et al. 2001; Jasenosky and Kawaoka 2004), 
vesicular stomatitis virus (Li, Luo et al. 1993; Sakaguchi, Uchiyama et al. 1999; Jayakar, 
Jeetendra et al. 2004) and influenza virus (Gomez-Puertas, Albo et al. 2000), when 
expressed alone, are released as VLPs.  The human parainfluenza virus type 1 (hPIV1) 
and the Sendai virus (SV) M proteins expressed alone induced release of VLPs (Coronel, 
Murti et al. 1999; Sakaguchi, Uchiyama et al. 1999; Takimoto, Murti et al. 2001; 
Sugahara, Uchiyama et al. 2004).  Expression of M protein was also required for simian 
virus 5 (SV5) VLP formation (Schmitt, Leser et al. 2002).  However, in contrast to PIV1 
and SV, the SV5 M protein was not sufficient for VLP release.    
Matrix proteins are also often necessary for particle release.  For example, M 
protein deficient rabies virus generated through reverse genetics was severely impaired in 
virion formation (Mebatsion, Weiland et al. 1999).  Measles virus (MV) (Cathomen, 
Mrkic et al. 1998)  and Sendai virus (SV) (Inoue, Tokusumi et al. 2003) modified by 
reverse genetics to lack the M protein genes were impaired in budding and release.  
Moreover, MV containing mutant M protein derived from subacute sclerosing 
panencephalitis (SSPE) virus was also defective in release of particles (Patterson, Cornu 
et al. 2001).    
The essential role of these matrix proteins in release is due in part to short motifs, 
called late domains, in these proteins that interact with components of the host vacuolar 
protein sorting (VPS) system (Martin-Serrano, Zang et al. 2001; Strack, Calistri et al. 
2002; Jasenosky and Kawaoka 2004; Morita and Sundquist 2004; Schmitt and Lamb 
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2004; Takimoto and Portner 2004; Patton, Morris et al. 2005; Bieniasz 2006).  It is 
thought that these proteins hijack the host VPS pathway for use in virus budding (Freed 
2002; Martindale 2003; Strack, Calistri et al. 2003; Morita and Sundquist 2004).  A late 
domain sequence in the SV5 M protein has been defined (Schmitt, Leser et al. 2005).  
However, this sequence cannot be sufficient for SV5 release since the M protein of this 
virus, when expressed alone, does not direct particle release.   
While paramyxovirus M proteins are clearly pivotal in the release of assembled 
virus, the interactions between M protein and other viral proteins required for the 
assembly of complete particles are less well defined.  Indeed, available information, 
based on properties of VLPs formed after co expression of different viral proteins with M 
protein or on co-localization or co-fractionation of M protein with other viral proteins 
have often led to contradictory conclusions.  For example, some reports suggest that M 
protein binds to F protein while others suggest a specific interaction with HN protein or 
both HN and F proteins (Sanderson, Wu et al. 1994; Ali and Nayak 2000; Ghildyal, Li et 
al. 2005).  M protein is also proposed to interact with NP protein in some studies 
(Stricker, Mottet et al. 1994).   
Thus general rules for assembly and release of paramyxoviruses are not yet clear.  
Important questions include (i) the role of each viral protein in virus assembly, (ii) the 
full definition of paramyxovirus late domains in viral structural proteins, and (iii) the 
cellular factors involved in the budding process.   
Using NDV as a prototype paramyxovirus, we sought to clarify the role of each 
paramyxovirus protein in assembly and release.  We combined a definition of the viral 
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protein requirements for assembly and release of VLPs with a characterization of the 
protein-protein interactions in VLPs formed with different combinations of viral proteins.  
We also characterized the co-localization of M protein with the viral glycoproteins in 
plasma membranes.  Our results show that particle assembly involves a network of 
specific protein-protein interactions and likely correct targeting of proteins to specific 
cellular domains. 
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B.  Materials and Methods 
Cells and viruses.  A spontaneously transformed fibroblast cell line derived from the 
East Lansing strain (ELL-0) of chicken embryos (UMNSAH/DF-1) was obtained from 
the American Type Culture Collection and maintained in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with penicillin-streptomycin and 10% fetal bovine 
serum (FBS).  NDV, strains Australia-Victoria (AV) and B1 were propagated in 
embryonated chicken eggs by standard protocols (McGinnes, Pantua et al. 2006).  Strain 
AV was grown in BCL-3 containment. 
Plasmids.  NDV cDNA sequences encoding NP, M, HN, and uncleaved F (F-K115Q) 
proteins were subcloned into the expression vector pCAGGS (Miyazaki, Takaki et al. 
1989; Niwa, Yamamura et al. 1991) to generate pCAGGS-NP, pCAGGS-M, pCAGGS-
HN and pCAGGS-F-K115Q, respectively.  The F protein cDNA contained a point 
mutation in the cleavage site sequence at residue 115 (K115Q) which eliminated the furin 
recognition site (Li, Sergel et al. 1998).   
Transfection, infection and metabolic labeling.  Transfections of subconfluent ELL-0 
cells were accomplished using Lipofectamine (Invitrogen) as recommended by the 
manufacturer.  The following amounts of plasmid DNA were used per 35mm dish: 1.0 μg 
pCAGGS-NP, 1.0 μg pCAGGS-M, 0.75 μg pCAGGS-F-K115Q, and 1.0 μg pCAGGS-
HN.  These amounts were previously determined to yield levels of expression similar to 
cells infected with NDV at a multiplicity of infection of 5.  A total of 3.75 μg of plasmid 
DNA per 35mm plate was used in all transfection experiments.  When only one, two, or 
three cDNAs were used, the total amount of transfected DNA was kept constant by 
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adding vector pCAGGS DNA.  For each transfection, a mixture of DNA and 5 μl of 
Lipofectamine in OptiMEM media (Gibco/Invitrogen) was incubated at room 
temperature for 45 minutes and then added to cells previously washed with OptiMEM.  
The cells were incubated for 5 hours, the Lipofectamine-DNA complexes were removed, 
and 2 ml of supplemented DMEM was added.  After 36 hours, the medium was replaced 
with 0.7 ml DMEM without cysteine and methionine and supplemented with 100 μCi of 
[35S] methionine and [35S] cysteine mixture (NEG-772 EASYTAGTM Express Protein 
Labeling Mix, [35S], Perkin Elmer Life Sciences Inc.).  After 4 hours of pulse label, one 
set of transfected plates was lysed, while in another set the medium was replaced with 1.0 
ml of supplemented DMEM with 0.1 mM cold methionine (Nutritional Biochemicals 
Corporation).  After 8 hours of chase, the medium was collected and the cells were lysed 
in 0.5 ml lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl pH7.4) containing 
Triton-DOC (1% Triton X-100, 1% sodium deoxycholate) and 1.25 mg N-
ethylmaleimide (NEM).  Cells were harvested with a cell scraper and homogenized by 
passing through a 26 gauge needle 10 to 15 times. 
ELL-0 cells were infected at an MOI of 5 pfu for 5 hours and labeled with [35S] 
methionine and [35S] cysteine mixture for 30 min, and chased in nonradioactive medium 
for 8 hours as described above.  Cell supernatant was harvested and virions purified as 
described below.  Cells were lysed and homogenized as described above. 
Virus and VLP purification.  VLPs as well as virions were purified from cell 
supernatants in protocols previously developed for virus purification (Levinson and 
Rubin 1966). The cell supernatants were clarified by centrifugation at 5000 rpm for 5 min 
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at 4oC, overlaid on top of a step gradient consisting of 3.5 ml 20% and 0.5 ml 65% 
sucrose solutions (g/ml) in TNE buffer (25mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM 
EDTA), and centrifuged at 40,000 rpm for 12 hours at 4oC using a SW50.1 rotor 
(Beckman).  The interface (containing concentrated particles) was collected in 0.5 ml, 
mixed with 2.0 ml of 80% sucrose, and overlaid on top of 1.0 ml 80% sucrose cushion.  
Additional layers of sucrose (1.0 ml of 50 % and 0.5 ml of 10% sucrose) were layered on 
top of the sample.  The gradient was centrifuged at 38,000 rpm for 20 h at 4oC.  The 
gradient was collected from the bottom into one 1ml fraction and eight 0.5 ml fractions 
using a polystaltic pump.  Densities of each fraction were determined using a 
refractometer.  Particles derived from expression of all combinations of proteins were 
prepared in a single experiment, thus enabling direct comparison of results.  The 
experiment was repeated three times. 
Antibodies.  Antiserum used to precipitate NP (anti-NDV) was rabbit polyclonal 
antibody raised against UV inactivated NDV by standard protocols.  Anti-NDV also 
contained antibodies specific for HN, F and M proteins.  Antisera used to precipitate F 
protein were raised against glutathione S-transferase (GST) fusion  proteins that 
contained amino acid sequences 130 to 173 (anti-HR1) (McGinnes, Gravel et al. 2002), 
470 to 500 (anti-HR2) (Dolganiuc, McGinnes et al. 2003), or 96 to 117 (anti-F2-96).  
Antiserum used to precipitate HN protein was raised against HN protein sequences from 
amino acid 96 to 117 (anti-A) (McGinnes and Morrison 1998).    Antiserum used to 
precipitate M protein was a mouse monoclonal antibody raised against purified M protein 
(Faeberg and Peeples 1988).   
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Immunoprecipitation and polyacrylamide gel electrophoresis.  Immunoprecipitation 
was accomplished by combining one volume of cell lysate or sucrose gradient fraction 
with two volumes of TNE buffer with 1% Triton X-100.  Samples were incubated with 
specific antibodies for 16 hours at 4oC.  Immune complexes (ICs) were adsorbed to 
Protein A (Pansorbin Cells, CALBIOCHEM) for 2 hours at 4oC, pelleted, and then 
washed three times in immunoprecipitation (IP) wash buffer (phosphate buffer saline 
(PBS) containing 0.5% Tween-20 and 0.4% sodium dodecyl sulfate (SDS)).  ICs were 
resuspended in SDS-polyacrylamide gel electrophoresis sample buffer (125 mM Tris-
HCl [pH 6.8], 2% SDS, 10% glycerol, 0.4 % Bromphenol blue) with 1 M β 
mercaptoethanol (BME) and boiled.  Proteins were separated on 8% polyacrylamide-SDS 
gel and subjected to autoradiography.  Quantification of resulting autoradiographs was 
accomplished using a Fluor-STM MultiImager (BioRad). 
Co-immunoprecipitation.  Purified VLPs were incubated in ice cold TNE buffer (25mM 
Tris HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA) containing 1% Triton X-100, 2.5 mg/ml 
N-ethylmaleimide for 15 min.  Excess primary antibody was added and VLPs were 
incubated at 4oC overnight.  Pansorbin cells, blocked overnight in TNE buffer containing 
1% Triton X-100 and 5 mg bovine serum albumin (BSA) and then prewashed in TNE 
containing 1% Triton X-100 and 1 mg/ml BSA, were added in excess as determined in 
preliminary experiments, and incubation was continued at 4oC with constant mixing for 
at least 2 h.  Immune complexes were collected by centrifugation (10,000 rpm for 30 s in 
a microcentrifuge) and washed three times in ice-cold TNE containing 0.5% Triton X-
100.  The pelleted complexes were resuspended in gel sample buffer. 
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Protease Protection Assay.  Protease digestion of M protein from avian cell extracts and 
VLPs was accomplished by adding 0.25, 0.5, 1, 5, 10, and 20 μg of proteinase K per ml 
of sample and incubating for 30 min on ice.  In parallel, VLPs were also made 0.5 % with 
respect to Triton X-100 prior to incubation with proteinase K.  After digestion, 
phenylmethylsulfonyl fluoride (PMSF) (0.1 M) was added.  For subsequent 
immunoprecipitation, the reaction mixtures were made 1% with respect to Triton X-100 
and 0.5% with respect to sodium deoxycholate. 
Immunofluorescence Microscopy.  Avian cells, grown in 35 mm dish containing glass 
cover slips, were transfected with different combinations of NDV cDNAs as described 
above.  After 40 h, nuclei were stained with 5 μg/ml 4’,6-Diamidino-2-phenylindole 
(DAPI) for 30 min at 37oC. Cells were washed twice with ice-cold immunofluorescence 
(IF) buffer (PBS containing 1% bovine serum albumin, 0.02 % sodium azide, and 5 mM 
CaCl2), fixed with 2% paraformaldehyde, blocked with IF buffer for 2 h, and incubated 
for 1 h at 4oC in IF buffer containing polyclonal antibodies against HN and F proteins.  
Cells were washed twice with ice-cold IF buffer, permeabilized with 0.05% Triton X-
100, blocked with IF buffer for at least 2 h and incubated for 1 h at 4oC in IF buffer 
containing purified ascites fluids containing anti-M protein monoclonal antibody.  Cells 
were then washed twice with ice-cold buffer followed by incubation for 1 h at 4oC in IF 
buffer containing fluorescein conjugated goat anti-rabbit IgG (Alexa 488) and rhodamine 
conjugated goat anti-mouse IgG (Alexa 568) (Molecular Probes) secondary antibodies.  
Cells were washed with ice-cold IF buffer, mounted onto slides using Vectashield 
mounting medium (Vector Labs, Inc) for immunofluorescence microscopy.  Fluorescence 
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images were acquired using a Nikon fluorescence microscope and Openlab software and 
processed using Adobe Photoshop. 
Electron Microscopy.  Particles were purified as described above except that, after 
flotation they were concentrated by centrifugation into a pellet (40000 rpm for 4h at 4o) 
and resuspended in TNE buffer containing 2% glutaraldehyde.  Virus and particles were 
adsorbed to Formvar carbon coated nickel grids, negatively stained with 4 % uranyl 
acetate, and examined by transmission electron microscopy. 
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C.  Results 
Cells expressing NDV NP, M, F-K115Q, and HN proteins released VLPs.  To 
determine if VLPs could be released from cells co-expressing the major structural 
proteins of NDV, radioactively labeled particles released from a chicken fibroblast cell 
line co-expressing NP, M, F and HN proteins were purified by sucrose density 
ultracentrifugation.  We used an uncleaved version of F protein to eliminate any potential 
effects of cell-to-cell fusion on particle release.  Cells were co-transfected with plasmids 
at concentrations of DNA we previously determined to result in expression levels and 
ratios of proteins comparable to infected cells (data not shown).  Cells were pulse-labeled 
with [35S] methionine and [35S] cysteine and then chased for 8 hours, a time which we 
determined in preliminary experiments to result in maximal particle release (data not 
shown).   
Co-expression of NP, M, F and HN proteins resulted in the release of VLPs with a 
density of 1.18 to 1.16 g/cc (Figure 1, panel A). Virus particles purified in parallel from 
NDV, strain AV, infected cells had a density of 1.21 to 1.19 g/cc (Figure 2.1, panel B).  
The slightly lighter density of VLPs compared to authentic virus was likely due to the 
absence of the virion RNA within the VLPs.   The efficiencies of VLP and virus release 
were calculated as the percentage of M protein remaining in the cell extracts after the 
chase relative to the amount of protein in the pulse.  By this criterion, the efficiency of 
VLP release was 83.8%±1.1, while the efficiency of NDV release was 91%±1.4 (Figure 
2.1, panel C).  It is assumed that M protein lost in the chase was incorporated into VLPs.  
However, it is possible that the decrease during the chase may also be due to some  
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Figure 2.1.  Co-expression of NP, F, HN and M proteins resulted in VLP formation 
and release.  Panel A: avian cells, co-transfected with pCAGGS-NP, -M, -F-K155Q, and 
–HN, were radioactively labeled with [35S] methionine and [35S] cysteine for 4 hours (P) 
and then chased in non-radioactive medium for 8 hours (C).  Panel B: avian cells, 
infected with NDV, strain AV, at an MOI of 5 for 5 hours, were pulse-labeled for 30 
minutes and chased in non-radioactive medium for 8 hours.  Radioactively labeled 
proteins in the extracts were immunoprecipitated with a cocktail of antibodies specific for 
all viral proteins and the precipitated labeled proteins are shown on the left side of each 
panel.  Particles in cell supernatants were purified as described in Materials and Methods.  
After flotation into sucrose gradients (right side of each panel), each gradient fraction was 
mixed with TNE containing 1% Triton X-100 and immunoprecipitated with the antibody 
cocktail.  The density of each fraction (g/cc) is shown at the bottom.  Panel C shows the 
quantitation of efficiency of virion and VLP release as determined by the amount of M 
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protein in the pulse and chase extracts and is the result of averaging 3 separate 
experiments.  The standard deviation is shown.  Panel D shows non-immunoprecipitated 
radiolabeled particles released from NDV, strain B1, virus infected avian cells and cells 
expressing NP, M, F-K115Q and HN proteins. Particles were isolated by concentrating 
onto the 20% and 65% sucrose interface and then floated into a step gradient.  Particles in 
the gradient fractions were then pelleted and resuspended in TNE buffer. HN, 
hemagglutinin-neuraminidase protein; F0, uncleaved fusion protein; NP, nucleocapsid 
protein; F1, cleaved fusion protein; M, membrane or matrix protein. 
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degradation although we have not seen evidence for degradation of a mutant M protein           
that is retained within cells (Manuscript in preparation). These results demonstrate that 
NDV VLPs are efficiently assembled and released from avian cells expressing the four 
major structural proteins. 
To determine the purity of released particles, we compared, without 
immunoprecipitation, the protein content of radiolabeled particles released from cells 
expressing NP, M, F-K115Q and HN proteins with that of radiolabeled tissue culture 
grown virus. NDV B1 strain was used in this experiment for two reasons. First, this strain 
packages only a uncleaved F protein like the VLPs. Second, B1 infection results in less 
inhibition of host protein synthesis than infection with the more virulent NDV strain AV 
(unpublished observation).  Thus, any host proteins that are incorporated into virus are 
more likely detected in B1 virus. Figure 2.1, panel D, shows that the profile of proteins 
present in purified VLPs is similar to that in virions (compare virus and VLP lanes).  This 
result showed that particles released from cells expressing the four major structural 
proteins are as pure as virions released from infected cells.  The identity of the major 
band below NP in both VLPs and virions is unknown.  
M protein was sufficient for release of membranous particles.  To determine the 
minimum protein requirements for particle release, we asked if any of the NDV proteins 
was individually capable of directing particle release.  Cells expressing each of the viral 
proteins individually were radioactively labeled in a pulse-chase protocol and particles 
were isolated as described above.  Figure 2.2, panel B, shows that particles were released 
only from cells expressing the M protein.  Furthermore almost no M protein could be  
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Figure 2.2.  M protein is sufficient for particle release.  Avian cells were transfected 
with pCAGGS-NP, -M, -F-K115Q, and –HN individually.  Panel A shows radioactively 
labeled proteins in the extracts at time of pulse (left) and chase (right) .  Particles in the 
supernatants of avian cells, expressing NP, M, F, and HN individually, were concentrated 
and floated into sucrose gradients as described in legend to Figure 1.  Panel B shows the 
distribution in the gradients of radioactively labeled proteins derived from each 
supernatant.  Densities of gradient fractions are shown at bottom (g/cc).  Quantification 
of the amounts of proteins in particles present in all fractions is shown in panel C.  The 
results of three separate experiments were averaged and the standard deviation is shown. 
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detected in cell extracts after the 8 hour chase (Figure 2.2A, right panel) indicating that 
much of the pulse-labeled protein was released from cells.  By comparing the levels of M 
protein in the pulse labeled extract and the chase extract, the efficiency of release was 
calculated to be 90%±3.0. In contrast, most of the pulse labeled NP, F and HN proteins 
remained in extracts after the chase (Figure 2.2, panel A).  This result correlated with the 
lack of significant amounts of particles detected in the corresponding cell supernatant 
(Figure 2.2, panel B) although there was a trace of very light density material released 
from HN protein expressing cells. 
Figure 2.2, panel C, shows the quantification of VLPs produced from cells 
expressing each protein individually.  Interestingly, the amount of M protein-containing 
particles from cells expressing M protein alone was greater than when all four structural 
proteins were expressed.    However, the M protein-only particles had a very 
heterogeneous density, with values ranging from 1.24 to 1.12 g/cc (Figure 2.2, panel B ).  
These results show that M protein is sufficient for the release of particles.  
The observation that M protein, released from cells, floated into a sucrose 
gradient indicates that the protein was associated with membrane.  To confirm that the M 
protein-containing particles were membrane-bound particles, these particles were 
incubated with protease.  In this assay, VLPs and cell extracts were either left untreated 
(Figure 2.3, panel A, lane 1) or treated with different concentrations of Proteinase K 
(lanes 2 to 7).  As expected, the M protein in cell extracts was sensitive to low 
concentrations of protease (Figure 2.3, panel A, extract panel).  The lower band below the 
M protein is a protease digestion product indicating that M protein has a protease  
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Figure 2.3.  M proteins are encased in membranous particles. Panel A: Avian cells 
were transfected with pCAGGS-M and radioactively labeled VLPs were isolated and 
purified as described in Materials and Methods.  Extract (upper panel) and VLPs, which 
were concentrated onto 20%-65% sucrose interface (middle panel), were treated with 
different concentrations (0.25, 0.5, 1, 5, 10, and 20 μg /ml; lanes 2 to 7 respectively) of 
Proteinase K for 30 min on ice.  In parallel, particles were incubated in 1% Triton X-100 
prior to Proteinase K treatment (bottom panel).  After incubation with protease, reactions 
were stopped by adding 0.1 mM PMSF.  M proteins were immunoprecipitated as 
described in Materials and Methods. Panel B: Electron microscopy of particles released 
from NDV infected cells (B1), M protein expressing cells (M), or cells expressing NP, M, 
F-K115Q and HN proteins (VLPs).  Particles were purified as described in Materials and 
Methods. Middle and left panels show two representative particles from each preparation. 
Right panels show enlargements of the edges of typical particles. 
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resistant core.  However, M proteins in particles were largely protected from protease 
digestion (Figure 2.3, panel A, VLP panel).  In contrast, disruption of the particle 
membrane with detergent resulted in digestion of the M protein (Figure 2.3, panel A, 
VLP with Triton X-100 panel).  Taken together, these results demonstrated that the M 
protein particles are membrane-bound particles. 
Particles visualized by electron microscopy. Visualization of particles released from 
cells expressing M protein only (Figure 2.3, panel B, M panel) as well as from cells 
expressing all four proteins (Panel B, VLP panel), and purified tissue culture virions 
(Panel B, B1 panel) was accomplished using electron microscopy.  Particles formed with 
all four proteins looked very similar to authentic virus.  Both B1 virions and VLPs 
released (B1 and VLP panels) from cells expressing all four proteins have membrane 
structures that were suggestive of spike glycoproteins in the envelope (see arrows).  M 
protein particles were more variable in size and had no evidence of glycoprotein spike 
structures. 
M protein was required for VLP release.    Since the M protein is sufficient for particle 
release, we next asked whether the M protein is required for the release.  To answer this 
question, cells were transfected with all possible combinations of NP, F, and HN cDNAs 
in the absence of the M gene.  Cells expressing any combination of proteins without M 
protein did not release particles (Figure 2.4). Furthermore, in the absence of M protein, 
NP, F and HN proteins expressed in pair wise combinations were retained in cell extracts 
after the 8 hour chase (Figure 2.5, panel A, lanes 2, 4 and 5).  These results strongly 
suggest that M protein is required for particle release. 
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Figure 2.4.  M protein is required for particles release.  Avian cells were transfected 
with all possible combinations of cDNAs in pCAGGS vector encoding NP, F, and HN 
proteins in the absence of M cDNA (F-K115Q+HN, F-K115Q+NP, HN+NP, NP+F-
K115Q+HN).  Particles in cell supernatants were purified as described in legend to 
Figure 1. Panels show proteins present in each gradient fraction.  Radioactively labeled 
infected cell extract was used as marker.  Densities of fractions are shown at the bottom 
(g/cc).  The control for this experiment is shown in Figure 1, panel A. 
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Minimal amounts of glycoprotein or NP were incorporated into VLPs after pair-
wise expression with M protein.  To determine the contribution of NP, F or HN proteins 
to M protein-driven particle release, particles released from cells expressing all possible  
combinations of two proteins were isolated and characterized as described above.  Pair 
wise expression of NP, F or HN proteins with M protein resulted in the release of  
particles containing both proteins (Figure 2.5, panel B). Intriguingly, however, particles 
contained only trace amounts of NP, F or HN proteins, while M protein was the 
predominant protein (Figure 2.5, panel B).  The distribution of NP, F or HN proteins in 
the gradients was identical to that of M protein (Figure 2.5, panel B).    In addition, the 
particle densities were very heterogeneous and were much like that of M protein-only 
particles.  Surprisingly, the amounts of M protein containing particles were decreased 
upon co-expression of M protein with particularly NP but also with F or HN proteins 
(Figure 2.5, panel C).   
Efficient incorporation of other viral proteins into VLPs required the expression of 
M protein and at least two of the other proteins.  To examine the effects of co-
expression of three viral proteins on particle release, cells were transfected with all 
possible combinations of three cDNAs (Figure 2.6, panel A).  In contrast to the 
expression of a single glycoprotein with the M protein, co-expression of both F and HN 
glycoproteins with M protein resulted in significantly increased incorporation of both 
glycoproteins into particles (Figure 2.6, panels B and C).  The F and HN proteins were 
detected in the same gradient fractions as M protein. Furthermore, the densities of the 
particles were more homogenous compared to those generated from cells expressing M  
 49
 
A 
C 
B 
N
M
F
H
 
 
Figure 2.5.  Effect of expressing NP, F or HN proteins with M protein on particle 
release.  Avian cells, transfected with cDNAs encoding structural protein genes F-
K115Q+M, HN+M or NP+M, as well as all four cDNAs were labeled in a pulse-chase 
protocol as described in legend to Figure 1.  Particles present in the supernatants were 
concentrated and then floated into sucrose gradients as described in Materials and 
Methods.  Panel A shows labeled proteins in cell extracts at end of pulse (top) and chase 
(bottom).  Panel B shows the proteins present in each gradient fraction after 
immunoprecipitation of each fraction with an antibody cocktail.  Densities (g/cc) of the 
fractions are shown at the bottom.  Panel C show the quantification of each protein in 
particles in all fractions.  Autoradiographs of gradient fractions from F-K115Q+NP, F-
K115Q+HN and HN+NP expressing cells did not contain any protein and are shown with 
gels in Figure 4.  Results are the average of three experiments and the standard deviation 
is shown. 
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protein alone (compare Figure 2.6, panel B and Figure 2.2, panel B) or M protein with a 
single glycoprotein. These results indicate that expression of both F and HN proteins with 
M protein is necessary for efficient incorporation of either glycoprotein into particles.     
Expression of M protein with NP and either F or HN protein resulted in increased 
incorporation of NP as well as the glycoprotein into particles (Figure 2.6, panels B and 
C).  The distribution of NP protein-containing particles in the gradient was similar to that 
of particles released from cells expressing all four structural proteins (Figure 2.6, panel 
B).  Importantly, the densities of these particles were more homogeneous compared to 
particles released from cells expressing M protein alone, and were analogous to the 
density of the authentic virus or complete VLPs (compare Figure 2.6, panel B and Figure 
1, panel B). Overall, these results indicate that M protein is necessary and sufficient for 
particle release and that expression of M protein with at least two other proteins is 
required for efficient incorporation of other proteins into particles.  
M protein co-localized with viral glycoproteins.  To explore further the role played by 
each protein in VLP assembly, we characterized, by immunofluorescence, the plasma 
membrane localization of M, F and HN proteins after their expression individually or 
after expression of combinations of NP, M, F and HN proteins.  Transfected cells were 
incubated with anti-F protein or anti-HN protein antibodies prior to cell permeabilization 
to limit binding of antibodies to cell surface F or HN proteins.  Cells were then 
permeabilized using 0.05% Triton X-100 and then incubated with M protein specific 
antibody.  Figure 2.7, panel A, shows vector transfected control cells and as well as cells 
expressing individually M, F-K115Q or HN proteins.  The F-K115Q and HN proteins  
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Figure 2.6.  Effect of expressing all combinations of three viral proteins on particle 
release.  Avian cells, transfected with all possible combinations of three NDV structural 
protein genes including M cDNA, were labeled in a pulse-chase protocol and particles in 
the supernatant were concentrated and floated into a sucrose gradient as in Figure 1.  The 
proteins in the cell extracts were immunoprecipitated with the antibody cocktail.  Panel A 
show labeled proteins in cell extracts at end of pulse (top) and chase (bottom).  Panel B 
shows the proteins present in each gradient fraction after immunoprecipitation of each 
fraction with an antibody cocktail.  Densities (g/cc) of the fractions are shown at the 
bottom.  Panel C shows quantification of the amounts of each protein in particles in all 
fractions. Autoradiograph of particles released from NP, F, and HN protein expressing 
cells is shown in Figure 4. 
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were diffusely distributed on the surface of the cells (F-K115Q and HN panels).  M 
protein exhibited diffuse cytoplasmic staining as well as punctate structures of various 
sizes (Figure 2.7, panel A, anti-M and merged image).  Co-expression of either F or HN 
proteins with M protein (panel B) had little effect on the distribution of M protein, F 
protein, or HN protein (Figure 2.7, panel B, anti-M, anti-F and anti-HN images) and little 
to no co-localization of F or HN glycoproteins with M protein was observed (Figure 2.7, 
panel B, merged image).  This finding correlates with the very low incorporation of F or 
HN proteins into M protein containing particles after pair-wise co-expression.   
 Co-expression of M protein with at least two other proteins slightly changed the 
distribution of M protein (Figure 2.7, panel C, anti-M images) and F and HN proteins 
(Figure 2.7, panel C, anti-F and anti-HN images) and increased the co-localization of M 
protein with either F or HN proteins (Figure 2.7, panel C, merged images).  This result is 
consistent with increased incorporation of HN, F, or NP proteins when two proteins are 
co-expressed with M protein.  
  When all four proteins were co-expressed, the distribution of M protein was 
changed to more punctuate structures distributed mostly along the edges of the cells 
(Figure 2.7, panel D, anti-M images).  Importantly, most of the F or HN protein signal 
co-localized with the M protein (Figure 2.7, panel D, merged images).  This result is 
consistent with the more ordered assembly of VLPs when all four proteins are co-
expressed.   
 Altogether, these results suggest that co-localization of viral proteins is detected 
with expression of three proteins and is most dramatic when NP, M, F and HN proteins  
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Figure 2.7.  Co-localization of M protein with F and HN proteins.  The cell surface 
localization of NDV F and HN proteins and the cellular localization of M proteins were 
analyzed by immunofluorescence microscopy.  Avian cells were either transfected 
individually (A) or with F-K115Q+M or HN+M (B), with NP+M+F-K115Q, NP+M+HN 
or M+F-K115Q+HN (C)  and all 4 cDNAs (D).  Nuclei were stained with DAPI (blue) 40 
h post-transfection.  Intact transfected cells were stained with rabbit anti-F protein 
antibodies or anti-HN protein antibodies as indicated in the panels.  Cells were 
permeabilized with 0.05% Triton X-100 prior to incubation with anti-M protein antibody.  
Secondary antibodies were anti-rabbit Alexa 488 conjugate (green) and anti-mouse Alexa 
568 conjugate (red).  Images were taken at 60x magnification and were merged using 
Adobe Photoshop. Results shown are representative of all cells in the slide. 
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are co-expressed. These results also suggest that there are specific protein-protein 
interactions involved in assembling particles. 
There are specific viral protein interactions in VLPs.  To identify the specific protein 
interactions involved in VLP assembly, radioactively labeled particles formed with 
different combinations of proteins were solubilized in 1% Triton X-100 and proteins 
present were precipitated, separately, with cocktails of monospecific antibodies for M, 
HN or F proteins.  Proteins were also precipitated with a mix of antibodies with 
specificities for all proteins in order to precipitate total proteins.  First, each antibody 
cocktail precipitated all proteins from VLPs formed with M, HN, F and NP, although the 
efficiency of precipitation for each protein varied with the antibody specificity (Figure 
2.8, panel A).  These results are consistent with a network of interactions between all four 
proteins such that precipitation of one resulted in the precipitation of the other three 
proteins.   The results also suggested that proteins indirectly linked to the precipitated 
protein were less efficiently precipitated than a protein directly linked to a precipitated 
protein.  For example, anti-F protein antibody precipitated NP very efficiently (lane 3) 
but M protein very inefficiently (lane 3).  This result suggests that there may be a direct 
link between F protein and NP but not F protein and M protein.   
 The interactions in VLPs were more clearly defined by precipitation of proteins 
from particles formed with all combinations of three proteins.  When particles released 
from cells expressing M, F-K115Q and HN proteins were used in a similar co-
immunoprecipitation procedure (Figure 2.8, panel B), anti-F protein precipitated only F 
protein and traces of HN protein (Figure 2.8, panel B, lane 3).  This result indicates that  
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Figure 2.8. Co-immunoprecipitation of viral proteins in particles.  Radioactively 
labeled particles released from cells expressing NP+M+F-K115Q+HN (A), M+F-
K115Q+HN (B), NP+M+F-K115Q (C) and NP+M+HN (D) were purified into 20%-65% 
sucrose interface. Particles were solubilized in TNE buffer containing 1% Triton X -100 
at 4oC for 15 min.  Solubilized particles were then incubated with excess amounts of 
cocktail of anti-F protein antibodies (anti-HR1, anti-HR2, anti-Ftail, anti-F2-96 and 
monoclonal anti-F (G5)), anti-HN protein antibodies (mix of monoclonal antibodies), 
anti-M protein monoclonal antibody or cocktail of NDV-specific antibodies for overnight 
at 4oC.  No antibody as well as pre-immune sera were used as negative controls.  Immune 
complexes were precipitated with prewashed Pansorbin A for at least 2 h at 4oC with 
constant mixing.  Samples were washed three times in cold TNE with 0.5% Triton X-
100.  All steps of co-immunoprecipitation were accomplished at 4oC.  Proteins were 
resolved by SDS-PAGE as described in Materials and Methods.  Results show one of 
three independent experiments, all with identical results. 
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the F protein does not directly complex with the M protein.  Immunoprecipitation with 
anti-HN protein antibody precipitated M protein with HN protein (Figure 2.8, panel B, 
lane 4) and immunoprecipitation with anti-M protein antibody brought down HN protein 
with M protein (Figure 2.8, panel B, lane 5).  These results strongly suggest that the M 
protein interacts with HN protein but not with the F protein.  
 When particles containing NP, M and F-K115Q were used in a similar 
immunoprecipitation protocol, complexes formed with anti-F protein antibody contained 
NP, as well as F protein, but not M protein (Figure 2.8, panel C, lane 3).  Complexes 
formed with anti-M protein antibody contained NP as well as M protein but no F protein 
(Figure 2.8, panel C, lane 4).  These observations indicate that M protein directly 
interacts with NP and that the F protein interacts with NP and confirm the lack of F and 
M protein interactions.  Anti-M protein antibody does not indirectly precipitate detectible 
amounts of F protein.  This result may be due to inefficient precipitation of NP protein, 
decreasing the amounts of F protein precipitated to very low levels.  Alternatively, NP-
NP interactions required to precipitate F protein with anti-M protein antibody may be 
disrupted by particle lysis. 
When particles containing NP, M and HN were used, complexes formed with 
anti-HN protein antibody contained NP and M proteins as well as HN protein (Figure 2.8, 
panel D, lane 3).  In addition, anti-M protein antibody precipitated NP and HN proteins 
(Figure 2.8, panel D, lane 4).  These observations are consistent with the conclusion that 
the M protein interacts with both NP and HN proteins.  These results cannot rule out an 
interaction between HN protein and NP.  
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Overall, results of co-immunoprecipitation of proteins in particles as well as 
results of cellular co-localization studies provide a rational basis for the incorporation of 
viral proteins into VLPs and suggest that specific protein interactions are involved in the 
assembly of an NDV virus-like particle. 
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D.  Discussion 
 Paramyxoviruses spread through cell monolayers or through an organ by two 
mechanisms, successive rounds of virus infection and cell-cell fusion.  Thus infected cell 
surfaces produce virus particles as well as fuse with adjacent cells.  In order to begin to 
understand the relationships between these two processes in NDV infected cells, the 
protein requirements for assembly and release of virus-like particles were characterized.  
Avian cells, expressing the viral NP, M, HN and F proteins, released VLPs nearly as 
efficiently as virus.  These particles released had protein ratios similar to infectious virus 
and their densities were homogeneous and only slightly less than that of authentic virus.  
The efficiencies of release of VLPs produced in three other paramyxovirus systems were 
10% (SV), 34% (SV5), and 70% (SV) (Takimoto, Murti et al. 2001; Schmitt, Leser et al. 
2002; Sugahara, Uchiyama et al. 2004).  All previously described paramyxovirus systems 
have utilized human 293T cells for expression of viral proteins.  We have found that 
NDV VLP release from avian cells, the natural host cell for NDV, had an efficiency of 
nearly 84%, but the efficiency of NDV VLP release from 293T or COS-7 cells was 
approximately 50% (unpublished observations).  Therefore, differences between the 
efficiencies of VLP formation in the NDV system reported here and the efficiencies 
reported in other systems may be due to a cell type dependent effect.   Thus NDV VLP 
assembly in avian cells represents an ideal system to explore protein requirements for 
assembly and release of virus particles. 
Using avian cells, we found that the NDV M protein, and only M protein, was 
sufficient for particle release.  Expression of M protein alone resulted in release of M 
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protein containing particles with an efficiency comparable to that observed when all four 
proteins were expressed, suggesting that no other protein is required for efficient release.   
Particles released from cells expressing NDV M protein alone were, however, very 
heterogeneous with respect to density. While the reasons for this finding are unclear, it is 
possible that budding of M protein particles occurred indiscriminately from different cell 
membranes with differing densities.  Alternatively, it is possible that particles contained 
different lipid to protein ratios due to variable oligomerization of the M protein.  M 
proteins of other negative stranded RNA viruses are reported to form oligomeric 
structures (Hewitt and Nermut 1977; Garoff, Hewson et al. 1998; Panchal, Ruthel et al. 
2003).  Particles formed from monomer M protein may have a higher lipid to protein 
ratio than particles formed from M protein in an oligomeric state.   While M proteins of 
SV and hPIV1 were also shown to be sufficient for particle release (Coronel, Murti et al. 
1999; Takimoto, Murti et al. 2001; Sugahara, Uchiyama et al. 2004), the SV5 M protein 
was not sufficient (Schmitt, Leser et al. 2002). 
The NDV M protein was also necessary for particle release.  In the absence of M 
protein expression, no other viral protein or combination of proteins resulted in 
significant particle release.  By contrast, previous studies by two different groups 
reported that SV F protein exhibited an autonomous exocytosis activity demonstrated by 
the release of vesicles containing only the F protein (Takimoto, Murti et al. 2001; 
Sugahara, Uchiyama et al. 2004), although the level of release was very low.  We found 
that cells expressing the NDV F protein alone did not release F protein containing 
material, results similar to those reported by Schmitt et al. in the SV-5 system (Schmitt, 
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Leser et al. 2002).  We did observe a trace amount of very light density material that 
contained HN protein when this protein was expressed alone but no HN protein was 
released when it was co-expressed with combinations of NP and F-K115Q.   
Although all studies agreed upon the central role played by the M protein in virus 
release, specific interactions of other viral proteins with M protein required for the 
assembly of complete VLPs are still poorly understood.  To define these interactions 
required for NDV assembly, we used three approaches.  First, we determined the 
requirements for efficient incorporation of NP, F, and HN proteins into particles by 
expressing all combinations of these proteins with M protein.  Second, the protein 
interactions in particles formed with all combinations of three and four proteins were 
defined by co-immunoprecipitation.  Lastly, the co-localization of cell surface HN and F 
proteins with M protein when expressed in different combinations with M and NP 
proteins were characterized.   
Pairwise expression of NP, HN or F proteins with M protein resulted in only trace 
amounts of NP, HN or F proteins incorporated into M containing particles.   In addition, 
expression of NP, F or HN proteins with M protein did not change the heterogeneous 
density of M protein containing particles.   In contrast, co-expression of M protein with 
two other proteins significantly increased the incorporation of NP, HN, or F proteins into 
particles.  The released particles had more homogenous density similar to that of particles 
containing all four proteins, a result that suggested necessary and specific interactions 
between the three proteins resulted in both efficient incorporation of NP or glycoproteins 
as well as more ordered particles. Furthermore, co-expression of two proteins with M 
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protein also significantly increased the co-localization of M protein with either HN or F 
proteins in the plasma membrane indicating increased interactions with M protein. 
To define these protein-protein interactions, particles formed with different 
combinations of three and four proteins were solubilized with nonionic detergent and 
proteins precipitated with cocktails of monospecific antibodies for M, HN, or F proteins.  
Each antibody cocktail precipitated all proteins from VLPs formed with M, HN, F and 
NP, although the efficiency of precipitation for each protein varied with the antibody 
specificity.  These results are consistent with a network of interactions between all four 
proteins such that precipitation of one resulted in the precipitation of the other three 
proteins but with efficiencies that varied determined by how directly a protein was linked 
to the precipitated protein.   
The protein-protein interactions were more clearly defined by 
immunoprecipitation of proteins from particles formed with all combinations of three 
proteins.   These results show a specific interaction between HN and M proteins, between 
NP and M protein, and between F protein and NP (diagramed in Figure 9).   There is no 
evidence for a direct interaction between F protein and M protein.  There is likely a weak 
interaction between F and HN proteins, since anti-F protein antibodies precipitated HN 
protein from particles containing M, HN, and F proteins.  In addition, since there is no 
interaction between F and M proteins, incorporation of F protein into these particles must 
be accomplished by interactions with HN protein. Our results cannot rule out an 
interaction between HN protein and NP.    
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Figure 2.9.  Protein-protein interactions in particles.  Inset shows viral protein-protein 
interactions detected by co-immunoprecipitation of proteins in particles.  Also shown are 
interactions proposed to result in assembly of particles formed by co-expression of all 
combinations of NP, F, and HN proteins with M protein. 
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Thus, when all four proteins are co-expressed, NP and HN protein are 
incorporated into VLPs by a direct interaction with M protein (Figure 2.9).  F protein is 
likely incorporated indirectly due to interactions with NP and HN protein.  An ordered 
complex of the four proteins is supported by the dramatic co-localization of M protein 
with F protein and M protein with HN protein in the plasma membrane when all four 
proteins are co-expressed.   
However, when only F is expressed with M protein, F protein was likely not 
significantly incorporated into particles because there was no direct interaction between 
the two proteins (Figure 2.9). Supporting this conclusion is the observation that there was 
no co-localization of F and M proteins in the plasma membrane in these cells.   
In spite of direct associations of M with NP, there was little NP protein 
incorporation into particles when NP and M proteins were co-expressed in the pair-wise 
combination.  Previous reports show that the M protein of Sendai virus is recruited in the 
cytoplasm by the viral nucleocapsid (Stricker, Mottet et al. 1994).  Perhaps NP causes the 
retargeting of M protein to this compartment. Indeed, co-expression of M protein with 
NP resulted in a 2.5 fold suppression of M protein containing particle release, a result 
also consistent with retention of M protein in cells by NP protein. 
 Although precipitations of particles proteins formed with M, HN, and F protein 
indicated a direct interaction of HN protein with M protein, there were only low levels of 
incorporation of HN protein into particles when HN and M proteins were co-expressed in 
a pairwise combination.  Furthermore, there was little co-localization of the two proteins 
in the plasma membrane.  Perhaps in the absence of other proteins, HN and M proteins 
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are never localized in the same regions of the cell, preventing their association.  It is also 
possible that the conformation of the HN protein transmembrane or cytoplasmic tail may 
be different in the absence of expression of F protein or NP protein inhibiting association 
of HN protein with M protein.   The reason for the 50% reduction  of M protein particles 
upon co-expression of HN protein with M protein is unclear but has been previously 
reported in Sendai virus system (Sugahara, Uchiyama et al. 2004).  
Particles formed with NP, M and F proteins are likely due to interactions between 
M and NP and interactions between F and NP (Figure 2.9).  F protein may relocate NP to 
the plasma membrane drawing M to specific domains containing F protein.   Indeed, 
addition of NP increases the co-localization of M protein with F protein in the plasma 
membrane.  Particles formed with NP, M and HN proteins likely form due to interactions 
of both HN protein and NP with M protein (Figure 2.9).  Expression of NP with HN and 
M proteins certainly increases the co-localization of M and HN proteins in the plasma 
membrane.  Perhaps NP-M protein interactions alter the conformation of M facilitating 
its interaction with HN protein.   Indeed, surface HN protein in the presence of NP 
appears more punctuate along the cell edges.   
The network of interactions proposed here could account for the conclusions of 
Schmidt, et al that the cytoplasmic domains (CT) of the HN and F proteins have 
redundant functions (Schmitt, Leser et al. 2002).  The CT domain of the F protein may 
target NP-M complexes to the plasma membrane by interactions with NP protein while 
the HN protein CT domain targets these complexes by virtue of direct interactions with 
M protein. 
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The proposed interaction of M protein and NP is supported by studies of Stricker, 
et al, of Sendai virus (Stricker, Mottet et al. 1994).  Interaction of HN protein with M 
protein is consistent with numerous studies suggesting an interaction of M protein with 
viral glycoproteins in paramyxovirus-infected cells or in cells transfected with 
paramyxovirus cDNAs (Ali and Nayak 2000).  Indeed, it has been reported that the 
respiratory syncytial virus G protein specifically interacts with M protein (Ghildyal, Li et 
al. 2005).  However, there are no previous reports of a direct interaction between F 
protein and NP.  It is possible that interactions between viral proteins vary within 
paramyxoviruses and the requirements for formation of VLPs may depend upon the 
distribution of late domains on the viral proteins. 
The results presented here are consistent with our proposal that the NDV M 
protein buds indiscriminately from different cellular membranes in the absence of other 
viral proteins.  When both glycoproteins are present in the plasma membrane, the M 
protein association with the plasma membrane may stabilize.  NP association with F and 
M protein may also further stabilize and organize the network of interactions within the 
assembling particle.   
In summary, we have established a VLP production system for NDV.  We also 
showed that the M protein is sufficient and required for NDV particle budding.  
Moreover, there are specific protein-protein interactions in VLPs involved in the ordered 
assembly of particles.  Interactions identified between M and HN or F and NP may play 
role in targeting M and NP into assembly sites in the plasma membrane.   
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CHAPTER III 
RELEASE OF NEWCASTLE DISEASE VIRUS-LIKE PARTICLES REQUIRES  
 
THE HOST VACUOLAR PROTEIN SORTING SYSTEM 
 
 
A.  Introduction 
Paramyxoviruses, such as Newcastle disease virus (NDV), assemble in and bud 
from plasma membranes of infected cells.  Assembly involves packaging of the 
approximately 16 KB negative-stranded RNA genome with the nucleoprotein (NP), the 
phosphoprotein (P), and the polymerase (L), to form the ribonucleoprotein (RNP) core. 
The core associates with cellular membranes modified with the hemagglutinin-
neuraminidase (HN), and fusion (F) glycoproteins, and the matrix (M) protein, which 
lines the inner surfaces of the membrane (reviewed in (Lamb and Kolakofsky 2001; 
Takimoto and Portner 2004).   
 Assembly of paramyxovirus components involves specific viral protein-protein 
interactions, which are poorly defined. However, the M protein is thought to play a 
central role in these interactions, complexing with both the viral glycoproteins and the 
RNP core in the viral assembly site (Peeples 1991).  This hypothesis is supported by the 
observation that the co-localization of viral glycoproteins with nucleocapsid was 
diminished in cells infected with measles virus that lacked the M gene (Cathomen, Mrkic 
et al. 1998).  In addition, numerous studies have reported specific interactions between 
the M protein and NP (Stricker, Mottet et al. 1994; Schmitt and Lamb 2004; Takimoto 
and Portner 2004), attachment proteins (Sanderson, McQueen et al. 1993; Sanderson, Wu 
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et al. 1994; Schmitt, He et al. 1999; Ghildyal, Li et al. 2005), or F protein (Sanderson, 
Wu et al. 1994; Henderson, Murray et al. 2002). 
 Several reports have suggested that the M protein also plays a direct role in 
paramyxovirus budding and release.  Sendai virus (SV) and measles virus (MV) with 
mutations in the M gene (Yoshida, Nagai et al. 1979; Yoshida, Hamaguchi et al. 1982) or 
which lack the M gene (Cathomen, Mrkic et al. 1998; Mebatsion, Weiland et al. 1999) 
are impaired in virion release, indicating that the M protein is required for release of 
particles.  There is also direct evidence that some paramyxovirus M proteins are 
sufficient for budding (reviewed in (Schmitt and Lamb 2004; Takimoto and Portner 
2004)).  Similar to results obtained with the matrix-like proteins of retroviruses (Morita 
and Sundquist 2004), filoviruses (Jasenosky and Kawaoka 2004), rhabdoviruses (Jayakar, 
Jeetendra et al. 2004), and influenza viruses (Barman, Adhikary et al. 2004), expression 
of SV (Takimoto, Murti et al. 2001) and human parainfluenza virus type 1 (hPIV1) 
(Coronel, Murti et al. 1999) M proteins alone resulted in the release of M protein 
containing particles.  The M protein of NDV is also both necessary and sufficient for 
release of membranous particles (Pantua, McGinnes et al. 2006).  It has also been 
reported that the Nipah virus M protein is sufficient for release of particles (Ciancanelli 
and Basler 2006).  These results indicated that these M proteins contain all the functional 
elements necessary for release of particles.  In contrast, expression of the simian virus 5 
(SV5) M protein, while necessary, was not sufficient for particle release (Schmitt, Leser 
et al. 2002).    
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 It has been shown that the matrix-like proteins of many different groups of RNA 
viruses contain short sequences required for virus budding and are thus called viral late 
(L) domains (reviewed in (Freed 2002)).  A key advance in understanding the budding 
process of enveloped RNA viruses came with the demonstration that the L domains in 
matrix-like proteins interact with components of the host vacuolar protein sorting system 
(VPS), presumably hijacking this pathway to direct virus release.  
The VPS pathway has been implicated in release of simian virus 5 (SV5), since a 
dominant-negative mutant of Vps4 (Vps4-E228Q) inhibited release of SV5 virions as 
well as VLPs (Schmitt, Leser et al. 2005).  In addition, a FPIV sequence in the SV5 M 
protein was identified as the functional L domain (Schmitt, Leser et al. 2005).  However, 
since the SV5 M protein is not sufficient for VLP release (Schmitt, Leser et al. 2002), the 
FPIV sequence cannot be sufficient for SV5 VLP release.  It has been shown that AIP1, a 
component of the host VPS system,  (Strack, Calistri et al. 2003), binds to the SV 
accessory protein C.  Furthermore, increased expression of AIP1 enhanced virus budding 
(Sakaguchi, Kato et al. 2005).  However, no functional L domain sequence has been 
identified in the SV C protein. It has been reported that a mutation of the sequence 
YMYL in the Nipah virus M protein inhibits release (Ciancanelli and Basler 2006). 
  Here, we investigated the role of the host cell VPS pathway in NDV VLP 
release.  We found that three different dominant negative mutant protein components of 
the VPS pathway inhibited particle release. Furthermore, a YXXL sequence (YANL) in 
the NDV M protein has properties of an L domain.  Mutation of this sequence abolished 
particle release while substitution of this sequence with the classical late domains YPDL 
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or PTAP fully restored particle release. We also found that AIP1, which binds YXXL late 
domains (Strack, Calistri et al. 2003) is incorporated into VLPs. 
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B.  Materials and Methods 
Cells.  Human renal epithelial cells expressing the SV40 T antigen (293T) were 
propagated in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), penicillin-streptomycin, vitamins, non-essential amino acids, 
and glutamine.  
Plasmids.  The expression vector pCAGGS (Miyazaki, Takaki et al. 1989; Niwa, 
Yamamura et al. 1991) containing NDV cDNA sequences encoding NP, M, HN, or 
uncleaved F (F-K115Q) was used to transfect 293T.  The F protein cDNA contained a 
point mutation in the cleavage site sequence at residue 115 (K115Q), which eliminated 
the furin recognition site (Li, Sergel et al. 1998).  The pBJ5 expression vector containing 
the gene encoding a Flag-tagged Vps4A with the E228Q mutation (Strack, Calistri et al. 
2003), N-and C-terminally HA-tagged AIP1, wild type Vps4A or wild type CHMP 3 
were previously described (Strack, Calistri et al. 2003).  The pDsRed2-N1 vector 
(Clontech) containing the gene encoding the CHMP3- and AIP1-Red fluorescent protein 
(RFP) fusion protein were previously described (Strack, Calistri et al. 2003). 
Site-specific mutagenesis.  Mutations in the M protein PKSP and YANL sequences at 
amino acids 216 and 219 and amino acids 232 and 235 were introduced by PCR to yield 
M-A216A219 and M-A232A235, respectively.  Specific sited-directed mutagenic primers 
were designed to substitute the proline residues at positions 216 and 219 and tyrosine and 
leucine residues at positions 232 and 235, respectively, with alanine.  Additional mutant 
M genes were constructed by substituting PTAP or YPDL sequences for YANL at amino 
acid positions 232 to 235 using PCR and mutagenic primers designed to substitute these 
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sequences.  The entire genes of each M protein mutant DNA were sequenced to verify 
that no additional mutation was introduced by the mutagenesis protocol.  Mutations 
generated are illustrated in Figure 5. 
VLP production.  To produce VLPs, 293T cells were transfected with cDNAs using 
Lipofectamine (Invitrogen) and metabolically labeled with [35S] methionine and cysteine 
as described previously (Pantua, McGinnes et al. 2006).  Briefly, sub-confluent 293T 
cells growing in 35-mm dishes were transfected with either pCAGGS M or mixture of 
pCAGGS-M, pCAGGS-NP, pCAGGS-F-K115Q and pCAGGS–HN.  After 36 hours, 
media were replaced with DMEM without methionine and cysteine containing 50 μCi of 
[35S] methionine and [35S] cysteine mixture (NEG-772 EASYTAGTM Express Protein 
Labeling Mix, [35S], Perkin Elmer Life Sciences Inc.).  After 4 hours of pulse label, one 
set of transfected plates was lysed, while in another set the medium was replaced with 1.0 
ml of supplemented DMEM with 0.1 mM cold methionine (Nutritional Biochemicals 
Corporation).  After 8 hours of nonradioactive chase, the medium was collected and the 
cells were lysed in 0.5 ml lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl 
pH7.4) containing Triton-DOC (1% Triton X-100, 0.05% sodium deoxycholate) and 1.25 
mg N-ethylmaleimide (NEM).  Cells were harvested and homogenized. 
To determine if the VPS pathway is involved in VLP budding, sub confluent 
293T cells were simultaneously transfected with either pCAGGS-M or all four major 
structural NDV protein genes (HN, F, M, and NP) and cDNAs encoding for dominant-
negative mutants of AIP1, CHMP3 and Vps4A (Strack, Calistri et al. 2003).  
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Corresponding empty vectors or wild type genes were used as controls. Cells were 
incubated for 36 hours and cells were radioactively labeled as described above. 
VLP purification.  VLPs were purified from cell supernatants in protocols previously 
developed for virus purification (Levinson and Rubin 1966; McGinnes, Pantua et al. 
2006). Briefly, cell supernatants were clarified by centrifugation at 5000 rpm for 5 min at 
4oC, overlaid on top of a step gradient consisting of 3.5 ml 20% and 0.5 ml 65% sucrose 
solutions in TNE buffer (25mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA), and 
centrifuged at 24,000 rpm for 12 hours at 4oC using a SW50.1 rotor (Beckman).  The 
20%-65% sucrose interface (containing concentrated particles) was collected in 0.5 ml, 
mixed with 2.0 ml of 80% sucrose, and overlaid on top of 1.0 ml 80% sucrose 
(weight/volume) cushion.  Additional layers of sucrose (1.0 ml of 50 % and 0.5 ml of 
10% sucrose) were layered on top of the sample.  The gradient was centrifuged at 38,000 
rpm for 20 h at 4oC.  The gradient was collected from the bottom into one 1ml fraction 
and eight 0.5 ml fractions using a polystaltic pump.  Densities of each fraction were 
determined using a refractometer.  For most experiments, VLPs used were from the 
interface of 20-65% sucrose of the first gradient. 
Antibodies.  Antisera used to precipitate viral proteins were a cocktail of anti-NDV 
antibodies.  Antiserum used to precipitate NP was rabbit polyclonal antibody raised 
against UV inactivated NDV by standard protocols.  Antisera used to precipitate F 
protein were raised against glutathione S-transferase (GST) fusion proteins that contained 
amino acid sequences 130 to 173 (anti-HR1) (McGinnes, Gravel et al. 2002), 470 to 500 
(anti-HR2) (Dolganiuc, McGinnes et al. 2003), or 96 to 117 (anti-F2-96).  Antiserum used 
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to precipitate HN protein was raised against HN protein sequences from amino acid 96 to 
117 (anti-A) (McGinnes and Morrison 1998).    Antiserum used to precipitate M protein 
was a mouse monoclonal antibody raised against purified M protein (Faeberg and Peeples 
1988).  Antibody used to precipitate HA-tagged proteins was a mouse monoclonal HA 
antibody conjugated to agarose beads (Sigma).  Secondary antibody used for 
immunoblotting was a peroxidase conjugated mouse monoclonal anti-HA antibody 
(Sigma). 
Immunoprecipitation, polyacrylamide gel electrophoresis and immunoblotting. 
Immunoprecipitation was accomplished using protocols described previously (Pantua, 
McGinnes et al. 2006).  Briefly, one volume of cell lysate or sucrose gradient fraction 
were combined with two volumes of TNE buffer containing 1% Triton X-100.  Samples 
were incubated with specific antibodies for 16 hours at 4oC with constant mixing.  
Immune complexes (ICs) were adsorbed to Protein A (Pansorbin Cells, CALBIOCHEM) 
for 2 hours at 4oC, pelleted, and then washed three times in immunoprecipitation (IP) 
wash buffer (phosphate buffer saline (PBS) containing 0.5% Tween-20 and 0.4% sodium 
dodecyl sulfate (SDS)).  Anti-HA agarose beads (Sigma) were used to precipitate HA-
tagged AIP-1.  ICs were resuspended in SDS-polyacrylamide gel electrophoresis sample 
buffer (125 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol, 0.4 % Bromphenol blue) 
with 1 M β mercaptoethanol (BME) and boiled.  Proteins were separated on 8% 
polyacrylamide-SDS gels, dried and subjected to autoradiography.  Immunoblotting for 
HA-tagged AIP1 was accomplished by using anti-HA antibody conjugated to horseradish 
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peroxidase (Sigma).  Quantification of resulting autoradiographs and chemiluminescence 
gels were accomplished using a Fluor-STM MultiImager (BioRad). 
Immunofluorescence Microscopy.  Subconfluent 293T cells grown in 35 mm dish 
containing glass coverslips, were transfected with pCAGGS-Mwt, pCAGGS- M-A232A235 
or empty vector control alone.  After 24 h, nuclei were stained with 5 μg/ml 4’,6-
Diamidino-2-phenylindole (DAPI) for 30 min at 37oC. Cells were washed twice with ice-
cold immunofluorescence (IF) buffer (PBS containing 1% bovine serum albumin, 0.02 % 
sodium azide, and 5 mM CaCl2), fixed with 2% paraformaldehyde, blocked with IF 
buffer for 2 h, and incubated for 1 h at 4oC in IF buffer containing purified ascites fluids 
containing anti-M protein monoclonal antibody.  Cells were washed twice with ice-cold 
IF buffer, permeabilized with 0.05% Triton X-100, blocked with IF buffer for at least 2 h 
and incubated for 1 h at 4oC in IF buffer containing rhodamine conjugated goat anti-
mouse IgG (Alexa 568) (Molecular Probes) secondary antibody.  Cells were washed with 
ice-cold IF buffer, mounted onto slides using Vectashield mounting medium (Vector 
Labs, Inc) for immunofluorescence microscopy.  Fluorescence images were acquired 
using a Nikon fluorescence microscope and Openlab software and processed using 
Adobe Photoshop. 
 
 
 
 
 
 76
C.  Results 
VLPs were released from 293T cells.  We have previously shown that expression of M 
protein alone or co-expression of NP, M, F and HN proteins resulted in the release of 
VLPs from avian cells (Pantua, McGinnes et al. 2006).  Because we wished to evaluate 
effects on particle release of available dominant negative mutant human VPS proteins, 
we asked if human renal epithelial cells (293T) could support the release of NDV VLPs.  
Figure 1, panel A, shows particles released from 293T cells expressing M protein alone  
or 293T cells co-expressing NP, M, F-K115Q and HN proteins (Figure 3.1, panel B).  
Particles released from 293T cells expressing M protein alone were very heterogeneous 
with respect to density (Figure 3.1, panel A), very similar to particles released from avian 
cells expressing M protein alone (Pantua, McGinnes et al. 2006).  In contrast, VLPs 
released from 293T cells expressing all 4 major structural proteins were more 
homogenous in density.  These particles were slightly less dense (1.18 g/cc) than the 
authentic virus (1.2 g/cc (Lamb and Kolakofsky 2001)) due to absence of genomic RNA.  
These results are also similar to those obtained using avian cells (Pantua, McGinnes et al. 
2006).  These combined results show that M protein VLPs and complete VLPs were 
released from 293T cells.  However, the efficiency of release of particles from 293T 
cells, as measured by the percentage of pulse labeled M protein remaining in cells after a 
long nonradioactive chase, was lower than the efficiency of release from avian cells (50% 
vs. 84%  (Pantua, McGinnes et al. 2006), respectively).  
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Figure 3.1.  VLPs released from 293T cells. 293T cells transfected with pCAGGS M 
(panel A) or with mixture of pCAGGS-NP, -M, -F-K155Q, and –HN (panel B), were 
radioactively labeled with [35S] methionine and [35S] cysteine for 4 hours (P) and then 
chased in non-radioactive medium for 8 hours (C).  Proteins present in cell lysates were 
immunoprecipitated with a cocktail of antibodies specific for all viral proteins and the 
precipitated labeled proteins are shown on the left side of each panel.  Particles in cell 
supernatants were purified as described in Materials and Methods.  After flotation into 
sucrose gradients (right side of each panel), each gradient fraction was 
immunoprecipitated with the antibody cocktail.  The density of each fraction (g/cc) is 
shown at the bottom.  Panel C:  Extract (upper panel) and M containing particles that 
were purified onto a 20%-65% sucrose interface (middle panel) were treated with 
different concentrations (0.25, 0.5, 1, 5, 10, and 20 μg /ml; lanes 2 to 7 respectively) of 
Proteinase K for 30 min on ice.  In parallel, purified particles were incubated in 1% 
Triton X-100 prior to Proteinase K treatment (bottom panel).  After incubation with 
protease, reactions were stopped by adding 0.1 mM PMSF.  Proteins were 
immunoprecipitated using NDV protein-specific antibodies and resolved by SDS-PAGE.  
HN, hemagglutinin-neuraminidase protein; F0, uncleaved fusion protein; NP, 
nucleoprotein; M, matrix protein. 
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 To determine if the M protein released from these cells was enclosed in 
membranes, the sensitivity of M protein to protease was measured.  M protein particles 
were either left untreated or treated with different concentrations of proteinase K.  As a 
control, cell extracts from M protein-expressing cells were also included.  As expected, 
M protein in cell extracts was digested by the protease (Figure 3.1, panel C, top).  In 
contrast, M protein in particles was significantly protected from protease digestion 
(Figure 3.1, panel C, middle).  Disruption of particle membranes by incubation with 1% 
Triton X-100 prior to treatment with proteinase K resulted in the digestion of M protein 
(Figure 3.1, panel C, bottom).  These results demonstrate that particles released from 
293T cells were membrane-bound particles. 
Dominant negative forms of VPS molecules inhibited VLP release.  Since previous 
studies have implicated the VPS pathway in budding of other enveloped RNA viruses 
(Pornillos, Garrus et al. 2002; Demirov and Freed 2004; Morita and Sundquist 2004), we 
asked whether this pathway is involved in M protein-driven particle release.  To address 
this question, we used a dominant-negative (dn) mutant CHMP3 protein.  CHMP3 is a 
subunit of the ESCRT III complex (von Schwedler, Stuchell et al. 2003).  Fusion of 
CHMP3 with red fluorescent protein (RFP) transforms this protein into dn protein that 
has been shown to inhibit HIV-1 gag particle release (Strack, Calistri et al. 2003).  293T 
cells were transfected with pCAGGS-M with different concentrations of either empty 
vector or cDNAs encoding the dn mutant protein.  Figure 3.2, panel A, shows that co-
expression of M protein with different concentrations of dn-CHMP3 did not inhibit M 
protein expression.  However, dn-CHMP3 inhibited the release of M protein VLPs, even  
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Figure 3.2.  Titration of dominant-negative CHMP3 and Vps4-E228Q.  Panel A, left, 
shows pulse labeled extracts of 293T cells that were simultaneously transfected with 
pCAGGS-M (1.0 μg) and either pDsRed2-N1 vector (0.1, 0.5 and 1.0 μg) or pDsRed2-
N1-CHMP3-RFP (0.1, 0.5 and 1.0 μg).  Panel A, right, shows the particles (M-VLPs) 
released from these cells after an 8-hour nonradioactive chase.  Panel C, left, shows 
extracts of pulse labeled cells that were simultaneously transfected with pCAGGS-M and 
either pBJ5 vector or pBJ5-Vps4A-E228Q.  Panel C, right, shows the particles (M-VLPs) 
released from these cells after an 8-hour chase.  Transfected 293T cells in both A and C 
were labeled in a pulse-chase protocol as described in Materials and Methods.  Particles 
in cell supernatants were purified and concentrated onto a 20% and 65% sucrose interface 
as described in Materials and Methods. Proteins were immunoprecipitated using NDV 
protein-specific antibodies and resolved by SDS-PAGE. Panels B and D shows percent of 
particles released from cells transfected with pCAGGS-M and pDsRed2-N1-CHMP3 or 
pBJ5-Vps4A-E228Q, respectively, relative to those released from cells transfected with 
pCAGGS-M and vector only.  Panels B and D show the average of two separate 
experiments. 
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at low concentrations of dn-CHMP3 DNA (Figure 3.2, panels A and B).  Vps4A is 
dominant negative form of Vps4, which is an ATPase that catalyzes the disassembly of 
the ESCRT components (Babst, Sato et al. 1997; Babst, Wendland et al. 1998).  As 
shown in Figure 3.2, panels C and D, Vps4A-E228Q inhibited release of M protein 
particles but not the expression of M protein.   
 To determine if inhibition of particle release was due only to over expression of 
these proteins, 293T cells were transfected with vector control, or wild type CHMP3 or 
wild type Vps4A as well as their dominant negative counterparts. We also included the 
wild type and dn mutant forms of the protein, AIP1 (Strack, Calistri et al. 2003).  In all 
cases, the wild type form of the VPS protein had little effect on particle release.  
However, release of M protein particles was inhibited by dn-CHMP3 to about 90% 
(Figure 3.3, panels A and B).  Vps4A-E228Q inhibited M protein VLP release by about 
90% (Figure 3.3, panels C and D), and AIP-1-RFP inhibited particle release by 90% 
(Figure 3.3, panels E and F).   
 Figure 3.4 shows that the dominant negative forms of CHMP3, Vps4A, and AIP1 
but not the wild type proteins also inhibited the release of VLPs containing all four viral 
proteins. 
 These combined results show that the inhibition of VLP release observed was not 
due to over expression of the VPS protein, but rather due to specific effects of the dn 
mutant proteins. These results support the conclusion that an intact VPS pathway is 
essential for M protein particle release.   
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Figure 3.3.  Effect of wild type and dominant-negative VPS mutant proteins on M 
protein-VLP release.  Panel A shows  pulse labeled cell extracts (top), extracts from 
cells subjected to an 8 hour chase (middle), and corresponding released particles (bottom) 
from cells co-transfected with pCAGGS-M and either pDsRed2-N1 vector (lane 1), 
pBJ5-WT-CHMP3 (lane 2) or pDsRed2-N1-CHMP3-RFP (lane 3).  Panel C shows pulse-
labeled and pulse-chase cell extracts of 293T cells (top, middle, respectively) and 
corresponding released particles (bottom) from cells co-transfected with pCAGGS-M and 
either pBJ5 vector (lane 1), pBJ5-WT-Vps4A (lane 2) or pBJ5-Vps4A-E228Q (lane 3).  
Panel E shows pulse labeled and pulse-chase extracts of 293T cells (top, middle, 
respectively) and corresponding M-VLPs (bottom) from cells co-transfected with 
pCAGGS-M and either pDsRed2-N1 vector (lane 1), pBJ5-AIP1-HA (lane 2) or 
pDsRed2-N1-AIP1-HA-CHMP3-RFP (lane 3).  M-VLPs are released from pulse labeled 
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cells during an 8-hour nonradioactive chase.  Particles were purified as described in 
legend to Figure 3.2.  Proteins were immunoprecipitated using NDV protein-specific 
antibodies and resolved by SDS-PAGE. Panels B, D and F show quantification of 
particles released relative to those released from vector controls. Standard deviations are 
shown. 
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Figure 3.4.  Effect of dominant-negative mutants CHMP3, Vps4-E228Q and AIP1 
on the release of complete VLPs.  Panels A shows pulse labeled extracts of 293T cells 
(lanes 1 to 3), extracts after an 8 hour chase (lanes 4-6) and corresponding released VLPs 
(lanes 7-9) from cells co-transfected with of NDV cDNAs, encoding NP, M, HN and F 
proteins, and either pDsRed2-N1 vector (lanes 1, 4, and 7), pBJ5-WT-CHMP3 (lanes 2, 
5, and 8) or pDsRed2-N1-CHMP3-RFP (lanes 3, 6, and 9).  Panel C shows pulse labeled 
extracts of 293T cells (lanes 1 to 3), extracts of cells after an 8 hour chase (lanes 4-6) and 
corresponding released VLPs (lanes 7-9) from cells co-transfected with the mixture of 
four NDV cDNAs and either pBJ5 vector (lanes 1, 4, and 7), pBJ5-WT-Vps4A (lanes 2, 
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5, and 8) or pBJ5-Vps4A-E228Q (lanes 3, 6, and 9).  Panel E shows pulse labeled 
extracts of 293T cells (lanes 1 to 3), extracts of cells subjected to an 8 hour chase (lanes 
4-6) and corresponding VLPs (lanes 7-9) from cells co-transfected with the mixture of 
NDV cDNAs and either pDsRed2-N1 vector (lanes 1, 4 and 7), pBJ5-AIP1-HA (lanes 2, 
5, and 7) or pDsRed2-N1-AIP1-HA-CHMP3-RFP (lanes 3, 6, and 9). VLPs, released 
from pulse labeled cells during an 8-hour nonradioactive chase, were purified as 
described in legend to Figure 3.2.   Proteins were immunoprecipitated using NDV 
protein-specific antibodies and resolved by SDS-PAGE. Panels B, D and F show 
quantification of VLPs released relative to wild type VPS protein controls. Standard 
deviations are shown. 
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Mutation of the YANL sequence inhibited VLP release.  Results in Figure 1 as well as 
previous results (Pantua, McGinnes et al. 2006) suggest that NDV M protein contains a 
fully functional and necessary L domain.  NDV M protein has two possible L domain 
sequences, PKSP and YANL, which are similar to the classical L domains PTAP and 
YPXL (reviewed in (Freed 2002)), respectively.  To determine whether these sequence 
motifs play a role in M protein-driven particle budding, we substituted the proline 
residues in the PKSP sequence with alanine (M-A216A219) and tyrosine and leucine in the 
YANL sequence with alanine (M-A232A235) (Figure 3.5, panel A).  These mutant M 
proteins were expressed either individually (Figure 3.5, panel B) or in combination with 
NP, F-K115Q and HN proteins (Figure 3.5, panel D).  Figure 3.5, panels B-E, shows that 
similar amounts of particles were released from cells expressing the M-A216A219 mutant 
and cells expressing wild type M protein.   In striking contrast, there was a significant 
reduction of particles released from cells expressing the M-A232A235 mutant (Figure 5, 
panels B and C).  Similarly, co-expression M-A232A235 mutant protein with NP, F-K115Q 
and HN proteins resulted in 80% reduction in particles released (Figure 3.5, panels D and 
E).    
 To determine if the inhibition of particle release by mutation of the YANL 
sequence was due to elimination of L domain activity or defects in conformation of the M 
protein, we substituted the YANL sequence separately with two known classical L 
domain sequences, YPDL and PTAP (Strack, Calistri et al. 2003; Morita and Sundquist 
2004).  Figure 3.5, panels B and C, shows that the amounts of M-particles released from 
cells expressing the NDV M protein containing the substituted YPDL or PTAP motifs  
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Figure 3.5.  L domain in NDV M protein.  Panel A shows wild type M protein 
sequences and mutant M proteins with alanine substitutions at amino acid positions 216 
and 219 (M-A216A219), 232 and 235 (M-A232A235), and YPDL and PTAP substitutions at 
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positions 216 to 219 and 232 to 235, respectively.  Panel B shows pulse lysate (top) and 
chase (middle) lysate, and M-VLPs released (bottom) from 293T cells expressing wild 
type or mutant M proteins.  Panel D shows pulse lysate (top) and chase (middle) lysate, 
and VLPs released (bottom) from 293T cells expressing NP, F and HN proteins with 
either wild type or mutant M proteins.  Particles were purified as described in Legend to 
Figure 3.2.   Proteins were immunoprecipitated using NDV protein-specific antibodies 
and resolved by SDS-PAGE. Panels C and E shows quantification of VLPs released 
relative to wild type M protein. Standard deviations are shown. 
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Figure 3.6. Cell association of wild type M protein and M-A232A235 mutant protein.  
Wild type and mutant M protein in cells were visualized by immunofluorescence 
microscopy using anti-M protein monoclonal antibody (left panels).  293T cells were 
transfected with pCAGGS-M wt, pCAGGS-M-A232A235, or empty vector.  Cell nuclei 
were stained with DAPI (blue) 24 h post-transfection (middle panels).  Right panels show 
merged images.  Cells were fixed in 2% paraformaldehyde and permeabilized with 0.05% 
Triton X-100 prior to incubation with anti-M protein antibody.  Secondary antibodies 
were anti-mouse Alexa 568 conjugate (red).  Images were taken with a 60x objective. 
Results shown are representative of all positive cells in the slide. 
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were comparable to wild type levels.  Cells expressing these substituted M proteins along 
with NP, F-K115Q and HN proteins released wild type levels of VLPs (panels D and E).  
These results strongly indicate that the YANL sequence at position 232 to 235 in the 
NDV M protein functions as an L domain. 
Mutation in the YANL sequence resulted in retention of M protein in cells.  Since 
expression of M-A232A235 protein did not support the release of particles, we explored the 
cellular localization of the mutant M proteins, by immunofluorescence microscopy.  
Figure 3.6 shows that both the wild type and mutant M proteins were predominantly 
present at the edges of the cells and no signal in the empty vector control.  Interestingly, 
significantly greater amounts of M-A232A235 proteins were retained in the cells (compare 
top and middle panels) with a significant concentration of the signal at the cell plasma 
membrane, as would be expected for a mutation that inhibits particle release.  There was 
also some mutant protein in large vesicles.  This material did not appear to be in the same 
focal plane as the nucleus (not shown), in contrast to results reported for mutant Nipah 
virus M proteins (Ciancanelli and Basler 2006).  The large vesicles may represent the 
back up of excess M protein in intracellular membranes.   Altogether, these results further 
support our conclusion that the YANL sequence is a functional late domain in the NDV 
M protein. 
AIP-1 incorporated into VLPs.  Retrovirus particles, which have a gag protein with an 
YPXL L domain, contain AIP1 (Strack, Calistri et al. 2003).  We consistently observed a 
polypeptide with an approximate size of 100kD, the size of AIP1, in the SDS-PAGE gels 
containing NDV VLP proteins (data not shown).  To test the possibility that AIP1 is  
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Figure 3.7.  Incorporation of AIP1 in VLPs.  293T cells were transfected with 
pCAGGS M and either empty vector, or vector with HA-taggedAIP1.  Panel A shows 
radioactively labeled M protein precipitated (IP) from cell extracts and M-VLPs using M 
protein-specific monoclonal antibody.  HA-AIP1 (N-terminally tagged) and AIP1-HA 
(C-terminally tagged) were detected in extracts and M-VLPs by immunoblotting (IB) 
using HA antibody conjugated with peroxidase.  Panel B shows precipitated radiolabeled 
M protein (left) and AIP1-HA (right) from cell extracts (top) and VLPs (bottom).   
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incorporated into VLPs, we co-expressed the M protein with either N- (HA-AIP1) or C-
terminally (AIP1-HA) HA-tagged AIP1 or with vector alone.  Figure 3.7, panel A, shows 
that M protein particles released from both cells expressing M protein and AIP1-HA 
contained AIP1-HA.   HA-AIP1 was not incorporated.  Figure 3.7, panel B, shows that  
AIP1-HA can also be precipitated from purified disrupted VLPs.  These results 
demonstrated that AIP1 is incorporated into VLPs and suggest that AIP1 may interact 
directly or indirectly with the M protein in particles. 
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D.  Discussion  
 In order to explore the mechanisms involved in paramyxovirus assembly and 
release, we have characterized VLPs released from cells expressing NDV proteins.  We 
have previously shown that VLPs with properties similar to authentic virus were very 
efficiently released from avian cells expressing NP, M, F and HN proteins (Pantua, 
McGinnes et al. 2006) and that expression of M protein is both necessary and sufficient 
for particle release from these cells. Here we showed that NDV VLPs were also released 
from the human cell line, 293T, expressing the NP, F, HN, and M proteins although the 
efficiency of release from these cells was less than from avian cells.  M protein was also 
sufficient for particle release from these cells.  These results allowed us to explore the 
role of dominant-negative mutants of human VPS proteins in NDV particle release. 
 The matrix-like proteins of many enveloped RNA viruses play a pivotal role in 
virus assembly and release due in part to the presence of short motifs, or late domains.  
Late domains are sequences that interact with components of host vacuolar protein 
sorting (VPS) system.   The cellular VPS system is associated with multivesicular bodies 
(MVBs), structures created by invagination of endosomal membranes into the endosomal 
lumen, thereby resulting in vesicles inside a vesicle (reviewed in (Martindale 2003; Babst 
2005)).  Since the topology of MVB formation is similar to that of virus budding from 
plasma membranes, it has been proposed that viral proteins usurp and redirect this host 
cell machinery to mediate virus budding (reviewed in (Martindale 2003; Demirov and 
Freed 2004; Morita and Sundquist 2004)).   
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 The formation of MVBs requires three protein complexes, first characterized in 
yeast, which are collectively known as the endosomal sorting complexes required for 
transport (ESCRT I, II, and III) (Katzmann, Babst et al. 2001; Jiang, Erickson et al. 2002; 
Katzmann, Stefan et al. 2003; Raiborg, Rusten et al. 2003; Babst 2005).  In addition, the 
Vps4 protein, which is an ATPase, is required for the dissociation of the full ESCRT 
complex important for the recycling of the complex (Raiborg, Rusten et al. 2003).  
Studies on retrovirus budding have clearly shown that the VPS pathway plays an 
essential role in virus budding.  Inhibition of the VPS pathway by either dominant-
negative mutants of specific VPS proteins (Garrus, von Schwedler et al. 2001; Strack, 
Calistri et al. 2003) or by small inhibitory RNA (Garrus, von Schwedler et al. 2001; 
Martin-Serrano, Zang et al. 2003; Tanzi, Piefer et al. 2003) specific for selected VPS 
proteins inhibited virus or VLP release. 
  A dominant negative Vps4 protein blocked release of SV5 virions or VLPs 
composed of NP, HN, F, and M proteins, implicating the VPS system in SV5 release 
(Schmitt, Leser et al. 2005).  Extending these results, we found that a dominant negative 
version of Vps4, Vps4 A-E228Q (Martin-Serrano, Yarovoy et al. 2003; Strack, Calistri et 
al. 2003; von Schwedler, Stuchell et al. 2003), blocked NDV VLP release.  Furthermore, 
our results demonstrated that this dominant negative protein blocked release of particles 
containing only M protein.  We also found that a dominant negative version of CHMP3 
(Strack, Calistri et al. 2003), a subunit of the ESCRT III complex (Babst 2005), and a 
dominant negative mutant of AIP1, a protein that binds both ESCT I and III proteins 
(Strack, Calistri et al. 2003), inhibited NDV VLP release as well as release of particles 
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containing only M protein.  This inhibition was not due to over expression of the protein 
since transfection of the wild type versions of these proteins had little effect on M particle 
release.  These results show that an intact VPS pathway is essential for both complete 
VLP and M particle release. 
 Many studies have demonstrated that L domains in the matrix proteins of viruses 
mediate their interaction with specific molecules of the VPS pathway (reviewed in (Freed 
2002; Freed 2004; Morita and Sundquist 2004; Bieniasz 2006)).  Three L domain motifs, 
PTAP, YPXL, and PPXY (reviewed in (Freed 2002; Pornillos, Garrus et al. 2002)), have 
been identified in retroviruses (Puffer, Parent et al. 1997; Strack, Calistri et al. 2003), 
rhabdoviruses (Jayakar, Murti et al. 2000; Irie, Licata et al. 2004), and filoviruses (Irie 
and Harty 2005; Irie, Licata et al. 2005). An YRKL sequence has been identified as a late 
domain in orthomyxoviruses (Hui, Barman et al. 2006).   The PTAP sequence binds 
TSG101 (tumor susceptibility gene 101) protein, a component of ESCRT I (Huang, 
Orenstein et al. 1995). The YPXL sequence has been shown to interact with AP2 (adaptor 
protein 2) (Chen, Vincent et al. 2005) and AIP1 (Strack, Calistri et al. 2003).  The YRKL 
sequence in the influenza virus M1 protein binds to VSP28, an ESCRT 1 protein that 
binds tsg101, as well as Cdc42, a member of the Rho family of GTP-binding proteins.  
The PPXY motif binds to Nedd4-like (neural precursor cell expressed, developmentally 
down regulated gene 4) ubiquitin ligases (Xiang, Cameron et al. 1996; Vana, Tang et al. 
2004).   
 Paramyxovirus M proteins do not have a PTAP, an YPXL, an YRKL, or a PPXY 
motif.  Lamb and colleagues have recently reported that the sequence FPIV in the SV5 M 
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protein was a late domain (Schmitt, Leser et al. 2005).  Mutation of this sequence 
inhibited release of particles and addition of this sequence in a retrovirus gag construct 
stimulated the release of particles.  However, since the SV5 M protein is not sufficient for 
SV5 particle release (Schmitt, Leser et al. 2002), this sequence cannot function 
independently as a late domain in the context of this paramyxovirus M protein.  Thus, it 
is not clear how SV5 uses the VPS pathway or how the FPIV sequence might function as 
a late domain.  Sequence analysis of the NDV M protein shows the presence of this FPIV 
motif.  In addition, NDV M protein contains a PKSP and a YANL sequence, not found in 
the SV5 M protein.  We have shown here that the YANL motif, but not the PKSP 
sequence, has properties of an L domain. Mutation of this sequence eliminated particle 
release and resulted in significant accumulation of the mutant protein in the cell plasma 
membrane.  There was no obvious re-localization of the protein into the nucleus as 
reported for mutant Nipah virus M proteins (Ciancanelli and Basler 2006).  Most 
importantly, substitution of this sequence with known late domains, either PTAP or 
YPDL, fully restored particle release.  Thus inhibition of particle release by mutation of 
the YANL sequence is not likely due to effects on protein folding since very different 
sequences restore activity.  These results also show that the NDV M protein may access 
the VPS pathway using either type of late domain, YPDL or PTAP domain.  These 
results also indicate that the FPIV sequence, in the context of the NDV M protein, cannot 
function as a late domain independent of the YANL sequence since the YANL mutant 
protein M-A232-A235 has a wild type FPIV sequence.   
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 YPDL late domains have been shown to interact with the VPS protein AIP1 
(Strack, Calistri et al. 2003).  Indeed, we found that AIP1 protein can be found in released 
particles containing M protein further implicating the VPS pathway in NDV release.  The 
M protein of Sendai virus has also been shown to be sufficient for release of particles 
(Takimoto, Murti et al. 2001; Sugahara, Uchiyama et al. 2004).  This protein has a YLDL 
sequence, which might serve as a late domain for SV M protein.  While the SV5 M 
protein does not have a YXXL motif, the SV5 NP protein has a number of YXXL motifs 
including a YPLL sequence.  Perhaps the required SV5 late domain is present on the SV5 
NP rather than the M protein.  Indeed, Schmitt, et al (Schmitt, Leser et al. 2002)have 
reported that SV5 VLP release is significantly enhanced by the expression of the SV5 NP 
protein with M protein as well as a glycoprotein.  Differences in requirements for the 
release of particles in different paramyxovirus systems may be due in part to different 
distributions of the late domains on structural proteins.  However, mutation of the NDV 
M protein YANL sequence eliminated particle release from cells expressing not only M 
protein but also NP, HN and F proteins.  Thus there are no late domains in the NDV NP 
that can function independently as a late domain in the context of the viral glycoproteins 
and M protein.    
In summary, we have shown that the host cell VPS pathway is necessary for M 
protein budding. We have also shown that the YANL motif in the NDV M protein has the 
properties of a late domain. 
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CHAPTER IV 
CHARACTERIZATION OF AN ALTERNATE FORM OF NEWCASTLE  
 
DISEASE VIRUS FUSION PROTEIN 
 
 
A.  Introduction 
 Newcastle disease virus (NDV) is a major agricultural pathogen that causes a fatal 
respiratory and neurological disease in poultry (Nagai, Hamaguchi et al. 1989).  This 
virus, a member of the Paramyxoviridae family, initiates infection by fusion of the viral 
membrane with host cell plasma membranes (Lamb and Kolakofsky 2001).  Virus spread 
is facilitated by cell-cell membrane fusion.  NDV, as well as other paramyxoviruses, 
encodes two spike glycoproteins, the hemagglutinin-neuraminidase (HN) protein, which 
mediates attachment of the virion to sialic acid-containing receptors, and the fusion (F) 
protein, which directly mediates membrane fusion (reviewed in reference (Lamb and 
Kolakofsky 2001)).  Primary sequence and structural analyses indicate that the F protein 
is a classical type 1 glycoprotein with an amino-terminal signal sequence, a hydrophobic 
transmembrane domain near the carboxyl terminus, and a 25 to 30-amino-acid 
cytoplasmic tail domain (CT) (Lamb and Kolakofsky 2001; Morrison 2003).  The F 
protein is synthesized as a precursor, F0, which undergoes proteolytic cleavage to form 
disulfide-linked amino-terminal F2 and carboxyl-terminal F1 polypeptides, and cleavage 
is required for fusion activity (reviewed in reference (Lamb and Kolakofsky 2001)). 
 There are now several examples of both cellular (Dunlop, Jones et al. 1995; 
Hegde, Mastrianni et al. 1998; Lu, Turnbull et al. 2000) and viral glycoproteins that are 
found in different topological forms with respect to membranes.  Examples of viral 
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glycoproteins with alternate membrane topologies include the hepatitis B virus L protein 
(reference (Lambert and Prange 2001) and references therein), the transmissible 
gastroenteritis virus M protein (Escors, Camafeita et al. 2001), and the hepatitis C virus 
envelope glycoproteins (Pavio, Taylor et al. 2002; Migliaccio, Follis et al. 2004).  We 
previously reported that synthesis of the NDV F protein in a cell-free protein-
synthesizing system containing membranes resulted in at least two topological forms of 
the protein with respect to membranes (McGinnes, Reitter et al. 2003).  The properties of 
one form were entirely consistent with a type 1 fully glycosylated F protein.  The other 
was a partially translocated or polytopic form in which approximately 200 amino acids of 
the amino terminus as well as the CT domain of the protein were translocated across 
membranes (McGinnes, Reitter et al. 2003).  Importantly, we detected this second, 
polytopic form of F protein in COS-7 cells expressing the F protein (McGinnes, Reitter et 
al. 2003) and provided evidence that it was involved in cell-cell fusion, either directly or 
indirectly. 
 Extending these results, we report that the second form of the F protein is also 
found in F protein-expressing avian cells, which are the natural host cells of NDV.  We 
have detected this second form of the F protein in virions released from both infected 
COS-7 and avian cells. We report evidence that this second form of the F protein may 
have a role in virus-cell fusion. 
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B.  Materials and Methods 
Cells, virus, and plasmids.  COS-7 cells, obtained from the American Type Culture 
Collection (ATCC), were maintained in Dulbecco's modified Eagle medium (DMEM) 
supplemented with non-essential amino acids, vitamins, penicillin-streptomycin, and 10% 
fetal calf serum.  East Lansing Line (ELL-0) chicken fibroblasts (UMNSAH/DF-1), 
obtained from ATCC, were maintained in DMEM supplemented with penicillin-
streptomycin and 10% fetal calf serum. 
NDV strain AV (virulent) and strain B1 (avirulent) stocks (Nagai, Hamaguchi et 
al. 1989) were prepared by growth in eggs by standard protocols.  AV stocks formed 
plaques in COS-7 cells, while B1 did not, consistent with the expected phenotypes of the 
two strains of NDV.  The F protein gene carried by purified NDV, strain B1, virus was 
sequenced to verify the absence of a furin recognition sequence.  The NDV F and HN 
genes were expressed in COS-7 and ELL-0 cells using pCAGGS obtained from Common 
Access to Biotechnological Resources and Information (CABRI) (Niwa, Yamamura et al. 
1991). 
Infections and virus purification.  COS-7 or ELL-0 cells were plated at 6 X 105 per 35-
mm plate and grown overnight.  Cells were then infected with NDV, strain AV, or NDV, 
strain B1, at a multiplicity of infection of 10.  After adsorption, unbound virus was 
removed and cells were washed in phosphate buffered saline (PBS) and then incubated 
for 16 or 48 h.  Supernatants were clarified by centrifugation at 5,000 rpm for 5 min at 
4oC, and virions were pelleted through 20% sucrose by centrifugation at 40,000 rpm for 4 
h at 4oC using the SW50.1 rotor (Beckman).  Virus was resuspended in 100 μl of PBS.   
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Transfection.  Transfections were accomplished using Lipofectamine (Invitrogen) as 
recommended by the manufacturer.  COS-7 or ELL-0 cells were plated at 3 X 105 per 35-
mm plate.  After 20 h, a mixture of DNA (0.5μg) in 0.1 ml OptiMEM (Gibco/Invitrogen) 
and 5 μl of Lipofectamine in 0.2 ml of OptiMEM was incubated at room temperature for 
45 minutes, diluted with 0.7 ml of OptiMEM, and added to a 35-mm plate previously 
washed with OptiMEM.  The cells were incubated for 5 h, the Lipofectamine-DNA 
complexes were removed, and then 2 ml of supplemented DMEM was added. 
Antibodies.  Anti-NDV is a polyclonal antiserum raised in rabbits against UV-
inactivated virions by standard methods.  Anti-HR1 was raised against a glutathione S-
transferase (GST) fusion protein that contained sequences from amino acid 130 to 173 of 
the F protein cloned in frame with the carboxyl terminus of GST (McGinnes, Gravel et 
al. 2002)  Anti-Ftail 523-553 was raised against a synthetic peptide with the sequence of 
the cytoplasmic domain of the fusion protein (amino acids 523-553) as previously 
described (Wang, Raghu et al. 1992) and prepared by the Peptide Core Facility of the 
University of Massachusetts Medical School. Anti-F2 was raised against a GST fusion 
protein containing the sequence between amino acid 96 and 117 cloned in frame with the 
carboxyl terminus of GST.  Anti-Ftail 540-553 was raised against a GST fusion protein 
containing the sequence between amino acid 540 and 553 cloned in frame with the 
carboxyl terminus of GST.  The GST fusion polypeptides were purified by standard 
methods recommended in the Novagen Applications Guide.  Antibody was raised in 
rabbits by standard methods by Capralogics, Inc. (Hardwick, MA).  Antibodies 
recognizing GST were removed from the sample by affinity purification using 
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immobilized GST (Pierce immobilized GST).  Antibodies raised against HR1 and Ftail 
sequences were recovered using Protein A IgG purification (Pierce Immunopure Plus 
Immobilized Protein A IgG Purification Kit).  Actin was detected using phalloidin 
coupled to Alexa 568 (Invitrogen/Molecular Probes).   
Surface Immunofluorescence.  COS-7 or ELL-0 cells, grown in 35-mm plates 
containing glass cover slips, were either infected with NDV, strain AV or strain B1, for 
12 or 16 h, respectively.  COS-7 or ELL-0 cells were transfected with cDNAs as 
described above for 48 or 24 h, respectively.  Cells were washed twice with ice-cold IF 
buffer (PBS containing 1% bovine serum albumin, 0.02% sodium azide, and 5 mM 
CaCl2), blocked with IF buffer for 15 minutes and incubated for 1 hour at 4oC in IF buffer 
containing specific antibodies, washed three times with ice-cold IF buffer, and incubated 
for 1 hour on ice with IF buffer containing Alexa 488-labeled anti-rabbit immunoglobulin 
G (IgG) (Molecular Probes).  Cells were washed with ice-cold IF buffer, fixed with 2% 
paraformaldehyde, and mounted on slides using Vectashield mounting medium (Vector 
Labs, Inc.) for immunofluorescence microscopy. 
Fluorescence images were acquired using a Nikon fluorescence microscope and 
Openlab software.   
Flow cytometry.  Transfected cells were removed from plates with 0.2 ml trypsin (50 
μg/ml)  (Sigma Corp.), washed in FACS buffer (PBS containing 1% BSA and 0.02% 
sodium azide) containing soybean trypsin inhibitor (2 μg/ml), and incubated for 1 h at 
4oC with anti-Ftail (540-553) and anti-NDV antibodies diluted in FACS buffer.  After 
three washes with FACS buffer, the cells were incubated for 1 h at 4oC with goat anti-
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rabbit IgG coupled to Alexa 488 (Molecular Probes) diluted in FACS buffer.  After three 
washes with FACS buffer, the cells were resuspended in PBS containing 2% 
paraformaldehyde and subjected to flow cytometry. 
Preparation of extracts and Western analysis.  COS-7 or ELL-0 cells, infected with 
NDV for 12 and 16 h (multiplicity of infection of 10), were washed in PBS and lysed in 
RSB buffer (0.01 M Tris-HCl, pH7.4, 0.01 M NaCl2) containing 1% Triton X-100, 0.5% 
sodium deoxycholate, 2 mg/ml of N-ethylmaleimide, and 0.2 mg/ml of DNase. Freshly 
made total extracts, diluted in sample buffer (125 mM Tris-HCl, pH 6.8, 2% sodium 
dodecyl sulfate, 10% glycerol) with 0.7 M β-mercaptoethanol and incubated at room 
temperature, were loaded onto 8% or 12% polyacrylamide gels without boiling to avoid 
protein aggregation.  After electrophoresis, gels were equilibrated in transfer buffer (25 
mM Tris, pH 8.2, 192 mM glycine, 15% methanol) and transferred to Immobilon-P 
(Millipore Corp.) membranes.  The membranes were blocked overnight at 4oC in PBS 
containing 0.5 % Tween 20 and 10% non-fat milk, washed with PBS-Tween 20, and 
incubated for 1 h at room temperature with primary antibody diluted to 1:1000 in PBS-
Tween 20.  Membranes were then washed, incubated for 1 h at room temperature with 
secondary antibody, goat anti-rabbit IgG coupled to horseradish peroxidase (Amersham 
Biosciences) diluted to 1:40000 in PBS-Tween 20, and then washed extensively in PBS-
Tween 20.  Bound antibody was detected using the ECL Western blotting detection 
reagent system (Amersham Biosciences). 
Mass Spectrometry. Protein bands were digested “in gel” according to established 
methods (Lahm and Langen 2000).  Eluted peptides were separated on a LC Packings 
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Ultimate nanoflow HPLC system in the following way.  Ten microliters of the peptide 
digest solution (approximately one half of the total digest) was manually injected onto a 
micro trap column (LC Packings Precolumn cartridge 0.3mmx5mm C18PM) and the trap 
column was manually washed with 10 μl of 0.1% formic acid prior to switching in line 
with the reverse phase separating column (LC Packings 100 μm x 15 cm C18 PepMap).  
A gradient was developed from 100% solvent A (0.1% formic acid) to 60% solvent B 
(0.1% formic acid in acetonitrile: water 70:30) in 60 minutes at a flow rate of 500 
nanoliters per minute.  The outlet of the column was connected to an electrospray needle 
(New Objective Taper tip 20 μm).  Electrospray mass spectrometry was performed on a 
Thermoelectron Finnigan LCQDeca ion trap mass spectrometer.  
Data dependent acquisitions were set up according to a triple play experiment 
program where full MS scans from 400 Da to 2000 Da were on going until an MS signal 
grew above a specified threshold upon which a high resolution scan (Zoom Scan) was 
performed to determine monoisotopic mass and charge state followed by a single MS/MS 
scan.  Dynamic exclusion was applied to prevent repeat scans of the same peptide 
masses. 
The raw data files were converted into mass peak lists using the LCQ_DTA 
program and then searched against the virus taxonomy of NCBI nr protein database using 
the Mascot search engine (Matrix Science Ltd.) (www.matrixscience.com) using 1Da 
mass tolerances for both the parent and fragment masses.   
Neutralization assay.  Confluent COS-7 or ELL-0 cells in 60mm plates were used for 
plaque assays. NDV, strain AV, was pre-incubated with anti-NDV, anti-Ftail antibodies, 
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or pre-immune sera for 1 h at room temperature prior to adsorption.  The virus and 
antibody mixes were then added to cells and incubated for 45 minutes at 37oC.  After 
adsorption, the virus-antibody mixture was removed and cells were washed once in PBS.  
For plaque assays, cells were then over layered with agar diluted to 1% in DMEM and 
supplemented with non-essential amino acids, vitamins, penicillin-streptomycin, sodium 
bicarbonate and 10% fetal bovine serum.  Plaques were counted after 48 h of incubation 
at 37oC.  Cells were fixed in methanol and stained with Giemsa Stain (Sigma) diluted 
1:20 in distilled water for photography.  For immunofluorescence detection of infected 
cells, complete media was added after removal of unbound virus and antibody, and cells 
were incubated for 9 h at 37oC.  Surface immunofluorescence was accomplished as 
described above. 
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C.  Results 
Two forms of F Protein Are Expressed in Infected Avian Cells.  Because a second 
form of paramyxovirus F protein has not been previously reported in other systems, it 
seemed possible that the alternate form of the NDV F protein could be an unusual 
property of protein expression in COS-7 cells.  Thus we asked if this second form of 
NDV F protein could be detected in avian cells, cells that are the natural host cell for 
NDV.   
Unambiguous detection of the second, partially translocated form of F protein by 
Western analysis required the expression of an F protein that was not cleaved, since the 
partially translocated F protein co-migrated on polyacrylamide gels with the F0 cleavage 
product, F1 protein (McGinnes, Reitter et al. 2003).  Therefore, we utilized the B1 strain 
of NDV, a strain that encodes an F protein missing a furin recognition sequence at the 
cleavage site.  The B1 F protein, synthesized in tissue culture cells, is not proteolytically 
cleaved (Nagai, Hamaguchi et al. 1989; Lamb and Kolakofsky 2001; Morrison 2003). 
NDV, strain AV, encodes an F protein with a furin recognition site and the F protein 
present in NDV, strain AV, infected cells is proteolytically cleaved into F1 and F2  
(Nagai, Hamaguchi et al. 1989; Lamb and Kolakofsky 2001; Morrison 2003).   
Avian cells (ELL-0 cells), as well as COS-7 cells, were infected with NDV, strain 
B1, as well as NDV, strain AV, for 12 and 16h, and F proteins present in the resulting 
cell extracts were characterized by Western analysis using F protein-specific antibodies.  
As previously reported (McGinnes, Reitter et al. 2003), two forms of F protein from B1-
infected COS-7 cells were detected (Figure 4.1, panel A, lanes 3 and 6), the fully 
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Figure 4.1.  Two forms of F protein are expressed in infected avian and COS-7 cells. 
COS-7 (panel A) and avian cells (ELL-0) (panel B), infected with NDV strain AV (lanes 
2 and 5), strain B1 (lanes 3 and 6), or mock infected (UI)(lanes 1 and 4), for 16 (lanes 1 
to 3) and 24 (lanes 4 to 6) hours, were lysed and aliquots of total extract were subjected 
to Western analysis as described in Materials and Methods.  Blots were incubated with 
anti-HR1.  Molecular weight markers were included in each blot and were used to 
determine sizes of the bands detected.  Panel C shows Western analysis of 1X and 2X 
volume of extracts from COS-7 and avian cells transfected with pCAGGS NP (lanes 2, 3, 
5, and 6).  Duplicate blots were incubated with anti-NDV or anti-HR1.  Untransfected 
(UT), lane 1. 
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translocated F0 protein (68 kDa) and a 59KDa protein.  As expected, extracts from AV-
infected COS-7 cells contained two polypeptides, a 68 KDa F0 and a 59 KDa F1 (Fig 4.1 
panel A, lanes 2 and 5).  Proteins from ELL-0 cells contained a 68 KDa host band, which 
obscured the F0 polypeptide from both B1 and AV infected cells (Figure 4.1, panel B, 
lanes 1-6).  However, ELL-0 cell infection with B1 virus resulted in the synthesis of 
significant amounts of a 59 KDa polypeptide (Figure 4.1 panel B, lanes 3 and 6), a 
polypeptide the size of the partially translocated F protein. These results show that the 
second form of F protein can be detected in B1-infected avian cells.   
To eliminate the possibility that anti-F protein antibody cross-reacted with NP, 
which is also 59 kDa, avian and COS-7 cells were transfected with NP cDNA, and 
proteins present in the resulting cell extracts were detected by Western analysis using 
anti-NDV and anti-HR1 antibodies.  The results show that NP is only recognized by anti-
NDV antibody and not by anti-HR1 antibody (Figure 4.1, panel C).  Thus the 59-kDa 
protein detected with anti-F antibodies in B1 infected cells is not due to a cross reaction 
of the antibodies with NP.   
Surface Expression of Cytoplasmic Tail Sequences.  Our analysis of the cell free 
translation products directed by F protein mRNA also showed that the F protein CT 
domain was translocated across membranes (McGinnes, Reitter et al. 2003) leading to the 
proposal that the partially translocated F protein may be a polytopic protein with the 
carboxyl terminus as well as the amino terminus of the protein exposed on cell surfaces.  
In support of this idea, we found that CT sequences could be detected on surfaces of 
COS-7 cells expressing the NDV F protein using a polyclonal antibody  
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Figure 4.2. Detection of cytoplasmic tail sequences on the cell surfaces of transfected 
and infected avian cells by immunofluorescence.  Panels B-E show results with NDV-
infected avian cells.  Panels F-L show results with transfected avian cells.  Uninfected 
avian (panel A) and avian cells infected with NDV, strain AV (panels B and D), strain B1 
(panels C and E) were incubated with anti-NDV (panels A to C) or anti-Ftail540-553 
(panels A, D and E).  Infected cells incubated with anti-NDV and anti-Ftail antibodies 
were digitally exposed for 3 sec.  Avian cells transfected with vector alone (panel F), 
transfected with pCAGGS-Fwt (panels G and J), pCAGGS-Fd523-553 (panels H and K), 
or pCAGGS-Fwt and pCAGGS-HN (panels I and L), were incubated with anti-NDV 
(panels F - I) and anti-Ftail 540-553 (panels (F and J to L).  Transfected cells incubated 
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with anti-NDV and anti-Ftail antibodies were digitally exposed for 3 secs. Images were 
acquired using a 60x objective and OPEN LAB software. 
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raised against a peptide with the F protein CT sequence (amino acids 523 to 
553)(McGinnes, Reitter et al. 2003).   
We asked if F protein CT sequences could be detected on infected or transfected 
avian cell surfaces (Figure 4.2).  We also raised another polyclonal antibody specific for 
the carboxyl terminal half of the F protein CT domain (amino acids 540 to 553) to 
eliminate the possibility that our previous results were due to a non-specific effect of the 
anti-Ftail 523-553 antibody (Figures 4.2 and 4.3).   
ELL-0 and COS-7 cells were infected with NDV AV or B1 strains.  In addition, 
ELL-0 and COS-7 cells were transfected with vector alone, wild type F (Fwt) protein 
cDNA, cDNA encoding an F protein with a cytoplasmic tail deletion (Fd523-553), or a 
mixture of Fwt protein and HN protein cDNAs.   Intact cells were incubated with anti-
Ftail 540-553 antibody, and binding of antibody was assessed by cell surface 
immunofluorescence.  Both infected and transfected ELL-0 cells, as well as COS-7 cells, 
bound this anti-Ftail antibody (Figures 4.2 and 4.3, panels D, E, J, L).  In contrast, 
binding of anti-Ftail antibody to cells expressing Fd523-553 protein was negative (Figure 2 
and 3, panel K) although these cells were positive for anti-NDV antibody (Figure 4.2 and 
4.3, panel H), which further confirms specificity of the anti-Ftail antibody for the CT 
sequences.  None of the antibodies bound to uninfected or vector transfected cells (Panels 
A and F).  Binding of anti-NDV antibody was detected in parallel cultures (Figures 4.2 
and 4.3, panels B, C, G, H, and I).  
Detection of CT sequences on surfaces of infected or transfected cells was not due 
to permeabilization of  cells during antibody binding.  Using the same conditions,  
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Figure 4.3.  Detection of cytoplasmic tail sequences on the cell surfaces of infected 
and transfected COS-7 cells by immunofluorescence.  Panels B to E show results with 
NDV-infected COS-7 cells.  Panels F to P show results with transfected COS-7 cells.  
Uninfected COS-7 cells (panel A) and COS-7 cells infected with NDV, strain AV (panels 
B and D), strain B1 (panels C and E) were incubated with anti-NDV (panels A B, and C) 
or anti-Ftail540-553 (panels A, D, and E).  Infected cells incubated with anti-NDV and 
anti-Ftail antibodies were digitally exposed for 3 sec.  COS-7 cells transfected with 
vector alone (panel F), transfected with pCAGGS-Fwt (panels G and J), pCAGGS-
Fd523-553 (panels H and K), or pCAGGS-Fwt and pCAGGS-HN (panels I and L, M, N, 
O, and P), were incubated with anti-NDV (panels F to I) or anti-Ftail540-553 (panels (F 
and J to L).  Transfected cells incubated with anti-NDV and anti-Ftail antibodies were 
digitally exposed for 3 secs using OPEN LAB software.  Intact cells expressing HN and F 
proteins were incubated with anti-NDV and phalloidin-Alexa568 (panels M and N, 
respectively).   Cells expressing HN and F proteins were incubated in 0.1% Triton X-100 
and then anti-NDV and phalloidin-Alexa568 (panels O and P, respectively). 
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fluorescence labeled phalloidin, which binds to actin, did not stain intact cells (Figure 
4.3, panel N) although phalloidin readily stained actin after permeabilizing cells in 0.1% 
Triton X-100  (Figure 4.3, panel P ). 
 To confirm expression of CT sequences on avian cell surfaces, binding of the 
anti-Ftail 540-553 antibody was also analyzed by flow cytometry.  Figure 4.4 shows that 
cells expressing F protein bound anti-Ftail 540-553 antibody, while cells expressing Fd523-
553 or HN proteins were negative (Figure 4.4, panels B and D).  These results show that 
CT sequences can be detected on the surfaces of both avian and COS-7 cells expressing 
the NDV F protein using two different anti-Ftail antibodies. 
Two Forms of F Protein are in Virions.  We next asked if the polytopic form of F 
protein was present in virions.  NDV, strain B1, virions were generated from infected 
ELL-0 or COS-7 cells.  NDV, strain AV, virions were also prepared in parallel.  Figure 
4.5 shows Western analysis of B1 virion proteins, as well as AV virion proteins, using 
two different F protein specific polyclonal antibodies.  F protein specific bands detected 
were similar to those found in the infected cell extracts.  As expected, F0 and F1 
polypeptides were detected in AV virions using anti-HR1 and anti-Ftail antibodies 
(Figure 4.5, panel A).  Similarly, F0 was detected in B1 virions grown from both COS-7 
and ELL-0 cells using anti-HR1 and anti-Ftail antibodies. Interestingly, a 59 kDa 
polypeptide was also detected in B1 virions by both anti-HR1 and anti-Ftail antibodies 
(Figure 4.5, panel A).  To determine if the 59 kDa polypeptide was due to unexpected 
cleavage of F0 protein, we used anti-F2 antibody, an antibody specific to F2 polypeptide.   
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Figure 4.4.  Detection of cytoplasmic tail sequences on the surfaces of cells 
transfected with Fwt cDNA by flow cytometry. Avian cells (panels A and B) and COS-
7 cells (panels C and D) transfected with pCAGGS vector alone, pCAGGS-Fwt, 
pCAGGS-Fd523-553, or pCAGGS-HN and were incubated with anti-NDV (panels A and 
C) and anti-Ftail540-553 (panels B and D).  FL1-H, fluorescein isothiocyanate (FITC). 
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Detection of F2 polypeptide in B1 virions would suggest that the 59 kDa polypeptide was 
due to cleavage of F0 polypeptide.  Figure 4.5, panel B, shows that while the F protein 
from the AV virions was cleaved, generating an F2 polypeptide, F2 is not present in B1 
virions indicating that F protein was not cleaved in these virions. 
 To verify this conclusion, NDV, strain B1, virions were purified from 
supernatants of avian infected cells and the polypeptides that migrated with a molecular 
weight of 59 kDa were analyzed by mass spectrometry.  As expected, peptides derived 
from the viral NP and P proteins were present in the band.  In addition, F protein-specific 
peptides were present (Table 1) supporting the conclusion that a form of the F protein co-
migrated with the NP and P proteins.  Furthermore, peptides from both the F2 and F1 
regions of the protein were detected.  F1 specific peptides detected were from the CT 
domain of the F protein and from the HR1 domain.  Surprisingly, F2 peptides detected 
were from the signal sequence of the F protein.  These findings suggest that the p59 F 
polypeptide contains sequences from the uncleaved F0 and that the signal sequence was 
not cleaved from the alternate form of the F protein.  These results are consistent with the 
presence of a second form of F protein, an uncleaved protein with a molecular weight of 
59 kDa. 
Effect of Anti-Ftail Antibodies on Plaque Formation.  Since the second form of F 
protein was detected in virions generated from both infected avian and COS-7 cells, we 
asked if it has a role in plaque formation.  We asked if anti-Ftail antibodies could 
neutralize virus infectivity in a plaque assay.  Egg-grown NDV, strain AV, was incubated  
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Figure 4.5.  Two forms of F protein are present in virions. NDV, strain AV (panel A, 
lanes 2, 5, 8, and 11) (panel B, lanes 2 and 5) and strain B1 (panel A, lanes 3, 6, 9, and 
12) ( panel B, lanes 3 and 6), generated from COS-7 (panel A, lanes 2, 3, 8, 9)(panel B, 
lanes 2,3)  and avian cells (panel A, lanes 5, 6, 11, and 12) (panel B, lanes 5, 6) were 
purified as described in Materials and Methods.  Virus particles were subjected to 
Western analysis using anti-HR1 antibody (panel A, lanes 1 to 6), anti-Ftail antibody 
(panel A, lanes 7 to 12) or anti-F2 antibody (panel B, lanes 1 to 6) antibodies.  Uninfected 
(UI) supernatant, panel A, lanes 1, 4, 7, and 10, and panel B, lanes 1 and 4.  
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a Virions were purified from the supernatants of NDV strain B1-infected avian cells and 
proteins in the purified virions electrophoresed on 8% polyacrylamide gels in the 
presence of a reducing agent. The proteins in the gel were stained with Coomasie blue 
dye, and the p59-sized band was excised and subjected to analysis by mass spectrometry 
as described in Materials and Methods. 
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with pre-immune sera, anti-NDV, or anti-Ftail antibodies (both anti-Ftail 523-553 and 
anti-Ftail 540-553) and then plated on monolayers of avian or COS-7 cells.  After 
adsorption, unbound virus and antibody was removed and the cells were washed prior to 
addition of agar overlays.  Thus effects of the antibody should reflect effects on the initial 
virus cell interaction and not subsequence cell-cell fusion.  After 40 hours plaques were 
visible on control plates (Figure 4.6, panels B, C, H, and I). As expected, anti-NDV 
neutralized virus infectivity and no plaques were observed (Figure 4.6, panels D and J).  
The anti-Ftail540-553 reduced the titer approximately 2 to 18 fold in COS-7 and 20 fold 
in ELL-0 cells compared to the pre-immune sera and no antibody controls (Table 2).  
Most importantly, however, plaques formed after incubation with both anti-Ftail 
antibodies were pinpoint (Figure 4.6 panels E, F, K, and L), much smaller than those 
produced by untreated virus or virus incubated with pre-immune serum (Figure 4.6 
panels B, C, H and I).  These results suggest that the anti-Ftail antibodies slow plaque 
formation.    This result is not likely due to a nonspecific effect of antibody raised against 
a GST fusion protein.  Incubation of virus with antibody raised against HR2 sequence 
coupled to GST protein did not inhibit plaque size or number (unpublished observations). 
Effect of Anti-Ftail antisera on a single cycle of infection.  The effect of anti-Ftail 
antibodies on plaque size suggested that the anti-Ftail antibodies, bound prior to virus 
attachment, inhibited virus entry.  To test this possibility by an alternative approach, 
effects of anti-Ftail antibody on a single cycle of infection were monitored by 
immunofluorescence.  Virus incubated with anti-Ftail antibody, anti-NDV antibody, anti-
β galactosidase, or preimmune sera, as described in Figure 4.6, was then bound to cell 
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surfaces.  After adsorption, unbound virus and antibody was removed and cells were 
washed and incubated for 9 hours at 370 C.  Infected cells were detected by the presence  
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Figure 4.6.  Anti-Ftail antibodies alter plaque morphology. COS-7 (panels A to F) and 
avian cells (panels G to L) were infected with untreated NDV, strain AV, (panels B and 
H), or NDV that was pre-incubated with pre-immune sera (panels C and I), anti-NDV 
(panels D and J), anti-Ftail540-553 (panels E and K) or anti-Ftail523-553 (panels F and 
L).  Uninfected monolayers, panels A and G.  Plaques were counted and stained with 
1:20 Giemsa and distilled water after 48 hours of incubation at 37oC.   
 
.   
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a Dilutions of 10-9 for NDV strain AV were preincubated with anti-NDV and anti-Ftail 
antibodies for 1 h prior to adsorption. No Ab, without antibody; Pre, preincubated with 
preimmune sera; UI, mock infected. Antibody was 150 ug protein per ml. 
b Plaques are pinpoint. 
 
 123
A B
C D
E F
G H
I J
K L
 
 124
Figure 4.7.  Anti-Ftail antibodies block infection. COS-7 cells were infected at an MOI 
of 10 with untreated egg grown NDV, strain B1, (panels C and D), or NDV, strain B1, 
that was pre-incubated with pre-immune sera (panels E and F), anti-β galactosidase 
(panels G and H), anti-NDV (panels I and J), or anti-Ftail540-553 (panels K and L) as 
described in Materials and Methods.   Uninfected monolayers are shown in panels A and 
B. After 9 hours of infection, cells were incubated with Hoechst stain, in order to 
visualize nuclei of all cells in the monolayer, and then anti-NDV antibody.  Binding of 
anti-NDV antibody was visualized by Alexa 568 coupled to goat anti-rabbit antisera.  
Images were acquired with a 20X objective using OPEN Lab software.  Hoechst stained 
images were digitally exposed for 0.5 sec and anti-NDV images were digitally exposed 
for 2.5 sec.  Identical results were obtained in two separate experiments. 
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a  COS-7 cells were co-transfected with cDNAs encoding the HN and F (HN + F) 
proteins or with a comparable amount of vector DNA. At 40 h post-transfection, avian 
red blood cells were incubated with cells in the presence of the indicated antibodies at 
4oC for 30 min. Binding was quantified by measuring released hemoglobin after lysis of 
the attached red blood cells as previously described (24). 
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of proteins on cell surfaces that bound anti-NDV antibody.  Figure 4.7, panels C and D, 
show the presence of virus proteins on infected cell surfaces after infection with untreated 
virus while uninfected cells were negative for anti-NDV staining (panels A and B). 
Incubation of virus in pre-immune serum or non-specific antiserum had no effect on the 
infection (panels E, F, G, and H), while incubation with anti-NDV antibody inhibited 
infection as expected (panels I and J).  Incubation of virus with anti-Ftail 540-553 
inhibited infection (Figure 4.7, panels K and L) consistent with results of the plaque 
assay.   
This inhibition by anti-Ftail antibody was not likely due to an inhibition of virus 
binding. Cells co-transfected with HN and F protein cDNAs were incubated with avian 
red blood cells in the presence or absence of antibody.  As expected, anti-NDV blocked 
the binding of RBCs to these monolayers while binding of RBCs in the presence of anti-
Ftail antibodies was unaffected (Table 3).  
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D.  Discussion 
 We have previously reported that NDV F protein, synthesized in a cell-free 
protein synthesizing system, containing membranes, inserted into membranes in at least 
two ways (McGinnes, Reitter et al. 2003).  One form of the protein (p68) was typical of a 
type 1 glycoprotein anchored in membranes by a transmembrane domain located near the 
carboxyl terminus.  The second form (p59) had properties consistent with the partial 
translocation of the protein, translocation of the F2 domain and the amino terminus of the 
F1 domain.   In addition, we reported evidence for the translocation of the CT domain of 
the protein.   Based on these observations, we suggested that the second form of F protein 
was a polytopic protein that spanned membranes at least twice. We also reported the 
detection of this second form of F protein in infected and transfected COS-7 cells.  A 
polypeptide consistent with the size of this second form was detected by Western analysis 
of proteins in extracts of infected cells.  In addition, CT sequences were detected on the 
surfaces of cells expressing the NDV F protein.   
Because of the unexpected nature of our findings and because this second form of 
F protein has not been reported in other paramyxovirus systems, we were concerned that 
formation of a polytopic NDV F protein in COS-7 cells could be attributed to a 
translocation defect in primate cells of a glycoprotein normally expressed in avian cells.  
However, as described above, we detected this second form of F protein in avian cells, 
both in infected cells as well as cells transfected with F protein cDNA.  First, we 
detected, by Western analysis, a polypeptide the size of the polytopic F protein (p59) as 
well as the fully translocated F0 protein (p68) in tissue culture grown avian cells infected 
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with an avirulent strain of NDV, strain B1, as well as in purified virions derived from 
these cells.   Cells infected with this virus should express only uncleaved protein (Nagai, 
Hamaguchi et al. 1989; Nagai 1993; Lamb and Kolakofsky 2001; Morrison 2003) and, 
indeed, virus released from cells infected with this virus do not form plaques in the 
absence of trypsin.   However, it was possible that the F protein was cleaved accounting 
for the p59 form of the protein. To verify that the p59 polypeptide was F protein and that 
it included the full-length polypeptide rather than only a cleaved form of the protein, we 
analyzed, by mass spectroscopy, the p59 material from tissue culture derived, purified 
virus particles.  As expected, the material contained NP and P protein.  Significantly, F 
protein specific peptides were detected in this band indicating that detection of F protein 
sequences by Western analysis was not due to a cross reaction of anti-F protein 
antibodies to another protein.  Furthermore, peptides from the F2 region of the protein, 
the HR1 domain, and the CT domain were detected indicating that sequences from the 
entire F0 protein were present in this polypeptide.   
 Interestingly, the F2 sequences detected in the p59 material by mass spectroscopy 
were from the signal sequence of the protein, suggesting that the signal sequence was not 
cleaved from this polypeptide.  This surprising finding suggests that the second form of F 
protein is anchored in membranes not only by sequences in the HR1 domain and the 
transmembrane domain but also the signal sequence. The presence of peptides from the 
signal sequence also indicates that the material is not from contaminating fully 
translocated F0 protein (p68) since it has been reported that the signal sequence is cleaved 
from the fully translocated F protein (Gorman, Nestorowicz et al. 1988).  It should be 
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noted that the two peptides detected from the signal sequence are overlapping but have 
two amino acid differences.  Heterogeneity in the signal sequence is not unexpected since 
comparisons of signal sequences from F proteins of many different strains of NDV have 
shown that the sequence of this region of the F protein is highly variable (Toyoda, 
Sakaguchi et al. 1989).  
Another indication for the existence of the alternate form of F protein was the 
detection, on avian cell surfaces, of sequences from the CT domain of the F protein of 
both the AV and B1 strains of NDV.  To eliminate the possibility that our previous 
detection of surface expressed CT sequences in COS-7 cells (McGinnes, Reitter et al. 
2003) was due to an unusual cross reactivity of that anti-Ftail antibody preparation, we 
prepared a second polyclonal antibody by different protocols using only the carboxyl 
terminal half of the F protein CT domain as an immunogen.  This antibody also detected 
surface expressed F protein CT sequences.  Furthermore, deletion of the CT domain of F 
protein eliminated the binding of both antibodies to transfected ELL-0 and COS-7 cell 
surfaces (these results and (McGinnes, Reitter et al. 2003)) and shows that the antibodies 
were not binding to an unrelated polypeptide.  Thus the existence of an unusual form of 
the F protein is indicated by Western analysis and mass spectroscopy of proteins in cell 
extracts and virions and by detection of CT sequences on infected and transfected cell 
surfaces. 
 The functional significance of a second form of the F protein is a key question.  It 
is possible that the alternate F protein is an aberrant form that has no direct role in the 
virus infection.  Alternatively, the expression of this form of the F protein may serve to 
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down regulate the expression of the fully translocated F protein while not having a direct 
role in infection.  However, detection of the second form of the F protein in purified 
virions released from both infected avian and COS-7 cells led us to explore a role of this 
polypeptide in membrane fusion.  
Current models for type 1 fusion proteins propose that these proteins are initially 
folded into a metastable conformation (Baker, Dutch et al. 1999; Eckert and Kim 2001; 
Jardetsky and Lamb 2004).  Upon activation of fusion, it is proposed that these proteins 
undergo a series of conformational changes that involve, first, the insertion of a fusion 
peptide into the target membrane, followed by the association of heptad repeat domains 
into a very stable, coiled coil structure.  The structure of this coiled coil as well as the 
anchoring of the protein to both the target and viral membrane by the fusion peptide and 
the transmembrane domain, respectively, results in pulling the target and viral membrane 
into close proximity (Baker, Dutch et al. 1999; Eckert and Kim 2001; Jardetsky and 
Lamb 2004).  Membrane merger proceeds first by hemifusion, then pore formation and 
expansion (Earp, Delos et al. 2005).  
 We previously reported that antibody specific for CT sequences inhibited red 
blood cell fusion to cells expressing the NDV HN and F proteins (McGinnes, Reitter et 
al. 2003). The antibody inhibited hemifusion suggesting that antibody binding interfered 
with the initial stages in the onset of fusion.   Here we explored the effects of anti-Ftail 
antibodies on virus entry.  To limit effects of the antibody to virus-cell fusion and not 
cell-cell fusion, we removed unbound antibody after virus binding.  We showed that two 
different antibodies specific for CT sequences considerably slowed plaque formation 
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suggesting a role of surface exposed CT sequences in virus-cell fusion.  Furthermore, in a 
single cycle of infection, pre-incubation of anti-Ftail antibody with virions eliminated 
infection.  These combined results suggest that antibody bound to the surface exposed CT 
sequences inhibited both virus-cell fusion (Figures 6 and 7) as well as cell-cell fusion 
(McGinnes, Reitter et al. 2003).   
Since the antibody inhibited hemifusion, initial steps of fusion are affected.  It is 
possible that binding of the antibody to CT sequences sterically inhibits conformational 
changes in the fully translocated F protein required for initiation of fusion and that the CT 
domain has no direct role in the fusion process.  Alternatively, the CT domain could be 
involved in the formation of the metastable form of the fully translocated F protein or the 
activation of that form required for fusion.  The presence of the anti-Ftail antibody could 
inhibit this activation.   
Previous reports indicate that CT domains of paramyxovirus F proteins do have a 
role in fusion (Sergel and Morrison 1995; Bagai and Lamb 1996; Dutch and Lamb 2001; 
Tong, Li et al. 2002; Seth, Goodman et al. 2004; Waning, Russell et al. 2004).  Deletion 
of the CT domain of the NDV F protein interferes with complete fusion (Sergel and 
Morrison 1995).  It has been proposed that this domain affects the conformation of the 
ectodomain (Sergel and Morrison 1995; Waning, Russell et al. 2004).  Surface exposed 
CT domains may also have additional roles.  Clarification of the role of surface expressed 
CT domain in fusion as well as potential roles of the amino terminal regions of the 
alternate F protein requires further investigation. 
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CHAPTER V 
NDV VIRUS-LIKE PARTICLES AS VACCINES 
 
 
A.  Introduction 
 Viral pathogens that cause serious public health concerns and significant 
economic disruption pose a challenge for us to develop innovative, safe and effective 
vaccines.  The goal of this part of this thesis is to develop NDV VLPs as a vaccine for 
Newcastle disease or as a framework for generation of a vaccine vector for a wide variety 
of human pathogens including emerging and re-emerging pathogens.   
Commonly used vaccines are either live, attenuated virus or inactivated, virulent 
virus.  Live, attenuated vaccines provide long-lasting, protective immunity and are 
considered the most effective type of vaccine.  However, these vaccines are not without 
their drawbacks.  First, live attenuated vaccine viruses may lead to the development of 
disease in immunocompromised individuals.  Another is that vaccine viruses have the 
potential for reversion from attenuated vaccine strain to a more virulent form, which can 
lead to the development of disease in vaccinated individuals.  In addition, teratogenic 
effects in vaccinated individuals have been associated with vaccination using live 
attenuated strains.  For example, vaccination with live attenuated blue tongue virus 
(BTV) in cattle has been reported to be teratogenic (reviewed in (Murray and Eaton 
1996)). 
Inactivated vaccines are safer but only offer a short-lived immune response 
compared to live attenuated virus.  The potential for incomplete inactivation of the virus 
could also lead to the development of disease in vaccinated animals.  Inactivation may 
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also result in alteration of epitopes, which will affect the immunogenicity of the protein.  
In addition, vaccination with some inactivated viruses, notably measles virus (Kapikian, 
Bell et al. 1962; Kapikian, Bell et al. 1966) and respiratory syncytial virus (Dittman 
1981; Graham 1995; Artimos de Oliveira, Jin et al. 2000), exacerbated the disease upon 
subsequent exposure to the live virus. 
 Subunit vaccines based on recombinant proteins offer an effective alternative to 
live, attenuated vaccines.  However, vaccinations based on subunits are more costly 
because they require multiple doses of higher concentrations of immunogen.  In addition, 
recombinant proteins may be less immunogenic due to incorrect folding. 
 DNA vaccinations are based on the transfer of genetic material, encoding an 
antigen, to the cells of the vaccine recipient.  Despite their great potential as vaccines, 
their clinical utility remains unproven (Schalk, Mooi et al. 2006).  Thus, there is still a 
need to develop vaccines that do not have or at least have minimal adverse effects while 
preserving their efficacy in protecting individuals from the disease. 
Virus-like particles (VLPs) are increasingly being considered as potential 
vaccines (Grgacic and Anderson 2006).   VLPs are multiprotein structures that mimic the 
overall morphology of the authentic virus.  VLPs are non-infectious because they 
assemble without incorporating the infectious genetic material.  VLPs offer a promising 
approach to the production of vaccines against many viral diseases for several important 
reasons.  First, VLPs have a characteristic repetitive and high density display of proteins 
that is similar to the authentic virus (Noad and Roy 2003).  In addition, VLPs contain 
surface glycoproteins that are properly folded and inserted into membranes.  Moreover, 
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VLPs provide the spatial structure for display of conformational epitopes.  Thus, the 
antigenicity of the assembled viral components is likely similar to the authentic virus.  
These properties will likely make VLPs very effective in eliciting strong immune 
responses. Vaccines based on VLPs have been generated for a variety of viruses 
including human papilloma virus (HPV), hepatitis B virus (HBV), Ebola virus and 
Marburg virus demonstrate great potential for use in prevention of infectious diseases 
(reviewed in (Grgacic and Anderson 2006)).   
VLPs have also been exploited as a framework for displaying foreign epitopes by 
generating chimeric VLPs.  Chimeric VLPs are important in producing “marker” 
vaccines and vaccine vectors.  Marker vaccines are essential in diagnostics where it is 
important to differentiate antibody production due to natural infection or vaccination.  
Chimeric VLPs as vaccine vectors are important for the delivery of foreign epitopes 
specific for other important pathogens.  Generation of chimeric VLPs can be achieved by 
making modifications in the gene sequences of the viral components necessary for VLP 
formation without altering their capacity to assemble into particles.  VLPs that have an 
insertion or fusion of foreign antigenic sequences into the VLP structural components 
have been proven to be effective in inducing a strong immune response against the 
foreign protein (Huang, Liang et al. 2005; Woo, Doan et al. 2006).  For example, VP21 
from foot and mouth disease virus (FMDV) fused with the Hepatitis B core antigen 
(HBcAg) induced immune responses to both VP21 and HBcAg after intraperitoneal 
injection in mice (Huang, Liang et al. 2005).   
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The goal of experiments described in this part of the thesis was to develop NDV 
VLPs as a vaccine vector for important human diseases as well as a vaccine for 
Newcastle disease.  Specifically, we would like to accomplish the following:  
(i) To develop a protocol for a scaled-up production of VLPs; 
(ii) To apply and extend the rules for incorporation of viral components into 
VLPs to inclusion of foreign sequences and to find permissive sites for 
incorporation of foreign sequences; 
(iii) To investigate the immunogenicity of NDV VLPs or chimeric VLPs.  
The results of this thesis accomplished the first and second goals. Our results 
showed that production of VLPs from tissue culture can be scaled up, producing particles 
that are as pure as virus generated from eggs.  We also demonstrated that a functional 
property of one of the structural components of VLPs is intact.  In addition, we showed 
that fusion of a foreign peptide to the HN protein did not inhibit incorporation of HN 
protein into VLPs.  Moreover, we found that the cytoplasmic domain of the F protein is 
necessary for its incorporation into VLPs. 
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B.  Materials and Methods 
Cells and virus.  A spontaneously transformed fibroblast cell line derived from the East 
Lansing strain (ELL-0) of chicken embryos (UMNSAH/DF-1) was obtained from the 
American Type Culture Collection and maintained in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with penicillin-streptomycin and 10% fetal bovine 
serum (FBS).  NDV, strain B1, was propagated in embryonated chicken eggs by standard 
protocols (McGinnes, Pantua et al. 2006). 
Plasmids.  Expression vector, pCAGGS (Miyazaki, Takaki et al. 1989; Niwa, Yamamura 
et al. 1991), containing NDV cDNA sequences encoding NP, M, HN, and uncleaved F 
(F-K115Q) proteins were used to express NDV proteins in avian cells (Pantua, McGinnes 
et al. 2006).   
Transfection, infection and metabolic labeling.  For large scale production of VLPs, 
avian cells were grown in T150 flasks.  Cells were transfected with 8 μg each of 
pCAGGS-NP, pCAGGS-M, pCAGGS-F-K115Q and pCAGGS-HN according to 
previously described protocols (Pantua, McGinnes et al. 2006).  After 5 h of transfection, 
culture media was replaced with supplemented DMEM.  Supernatants were collected at 
24 and 48 h post-transfection. 
 Transfection of ELL-0 cells to generate VLPs containing radioactively labeled 
NP, M, F and HN proteins were done as described previously (Pantua, McGinnes et al. 
2006).  In some experiments, pCAGGS vector containing HA-tagged HN, FLAG-tagged-
F-K115Q, B1 strain F, or B1 strain HN were used in the co-transfection when indicated. 
A pulse–chase protocol using [35S] methionine and [35S] cysteine mixture (NEG-772 
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EASYTAGTM Express Protein Labeling Mix, [35S], Perkin Elmer Life Sciences Inc.) was 
accomplished as described previously (Pantua, McGinnes et al. 2006).  Cells were 
harvested and homogenized for immunoprecipitation assays. 
Virus and VLP purification.  To purify VLPs from avian cells grown in T150 flasks, 
supernatants were initially clarified by centrifugation at 5,000 rpm for 5 min.  VLPs in 
supernatants were pelleted by ultracentrifugation at 18,000 rpm for 12 h at 4oC (Type 19 
rotor).  Pelleted VLPs were concentrated into the interface of 20% and 65% sucrose 
gradient by ultracentrifugation at 24,000 rpm for 12 h at 4oC (SW 28 large buckets).  
Particles were further purified by floating into a step gradient, as described in Materials 
and Methods of Chapter II).  The upper fraction, containing a visible particle band, was 
collected.  Finally, VLPs were diluted in TNE buffer (25mM Tris-HCl pH 7.4, 150 mM 
NaCl, 5 mM EDTA) and pelleted by ultracentrifugation at 40,000 rpm for 4 h at 4oC.   
Pelleted VLPs were resuspended in an appropriate volume of TNE buffer. 
Virus particles from amniotic fluid of virus infected embryonated eggs were 
purified using the same protocol except virus was not pelleted after flotation (McGinnes, 
Pantua et al. 2006).  
Radioactively labeled VLPs were purified as described previously in Chapter II.   
Antibodies. Rabbit polyclonal antibody, raised against UV inactivated NDV (anti-NDV) 
by standard protocols, was used to precipitate NP.  Anti-NDV also contained antibodies 
specific for HN, F and M proteins.  Antisera used to precipitate F protein were raised 
against glutathione S-transferase (GST) fusion  proteins that contained amino acid 
sequences 130 to 173 (anti-HR1) (McGinnes, Gravel et al. 2002), 470 to 500 (anti-HR2) 
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(Dolganiuc, McGinnes et al. 2003), or 96 to 117 (anti-F2-96).  Antiserum used to 
precipitate HN protein was raised against HN protein sequences from amino acid 96 to 
117 (anti-A) (McGinnes and Morrison 1998).    Antibody used to precipitate M protein 
was a mouse monoclonal antibody raised against purified M protein (Faeberg and Peeples 
1988).  Antibody used to precipitate HA-tagged HN protein was  anti-HA conjugated to 
agarose beads (Sigma).  Antibody used to precipitate FLAG-tagged F protein was anti-
FLAG antibody (Sigma). 
VLP binding assay.  Radioactively labeled VLPs were separated into three different 
aliquots.  Anti-NDV antibody was added to one VLP aliquot and incubated at room 
temperature for 1 h along with the untreated VLPs.  VLPs were added to avian cells 
grown in 12 well plates and incubated at 4oC on ice for 30 min.  Cells were then washed 
twice with cold TNE buffer and lysed in 0.1 ml lysis buffer (10 mM NaCl, 1.5 mM 
MgCl2, 10 mM Tris-HCl pH7.4) containing Triton-DOC (1% Triton X-100, 1% sodium 
deoxycholate) and 1.25 mg N-ethylmaleimide (NEM).  The resulting lysates were 
homogenized and used for immunoprecipitation protocols. 
Immunoprecipitation, polyacrylamide gel electrophoresis and silver stain.  
Immunoprecipitation of radioactively labeled proteins was accomplished by combining 
one volume of cell lysate or sucrose gradient fraction with two volumes of TNE buffer 
containing 1% Triton X-100.  Samples were incubated with specific antibodies for 16 
hours at 4oC.  Immune complexes (ICs) were adsorbed to Protein A (Pansorbin Cells, 
CALBIOCHEM) for 2 hours at 4oC, pelleted, and then washed three times in 
immunoprecipitation (IP) wash buffer (phosphate buffer saline (PBS) containing 0.5% 
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Tween-20 and 0.4% sodium dodecyl sulfate (SDS)).  ICs were resuspended in SDS-
polyacrylamide gel electrophoresis sample buffer (125 mM Tris-HCl [pH 6.8], 2% SDS, 
10% glycerol, 0.4 % bromphenol blue) with 1 M β mercaptoethanol (BME) and boiled. 
Immunoprecipitated proteins were separated on 8% polyacrylamide-SDS gels and 
subjected to autoradiography.   
Proteins in purified VLPs and virus were separated on 8% polyacrylamide-SDS 
gels and detected by silver stain using SilverSNAP® Stain Kit II as recommended by the 
manufacturer (Pierce).  Briefly, the gel was washed twice in ultrapure water and fixed in 
solution containing 30% ethanol and 10% acetic acid.  The gel was washed in ultrapure 
water twice prior to addition of essential working solutions.  In order, the gel was 
incubated in Sensitizer (1 min), Stain (30 min), and Developer Working Solutions.  The 
gel was incubated in Developer Working Solution until bands appeared (about 2 to 3 
min).  The reaction was stopped by replacing the Developer with 5% acetic acid for 10 
min. 
Quantification of resulting autoradiographs and silver stained gels were 
accomplished using a Fluor-STM MultiImager (BioRad). 
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C.  Results 
VLPs generated from tissue culture were as pure as virus produced from eggs.  To 
determine the purity of VLPs produced from tissue culture, proteins in both strain B1 
virus particles and VLPs were resolved in 8% SDS-PAGE gels.  Silver staining was used 
to visualize the proteins present in both virus and VLPs.  Figure 5.1 shows that VLPs and 
virus have a similar protein profile.  This result indicates that particles released from cells 
expressing the four major structural proteins are as pure as virions propagated from 
embryonated eggs.   
 The amounts of protein in VLPs were quantified from the silver stained gel  using 
the FluorS Imager.  Known amounts of bovine serum albumin (BSA) were correlated 
with its densitometer units.  These correlations were used to determine the amounts of 
each protein in VLPs.  Quantification of the amounts of protein in VLPs produced from 
tissue culture are shown in Table 5.1.  Avian cells expressing the NDV NP, M, F-K115Q 
and HN proteins efficiently produced VLPs with a concentration of 178.43 μg total 
protein per 1.0 X 108 cells.  NDV, strain B1, virus harvested from 3.3 dozen eggs 
contained 209.54 μg total protein.  Protein ratios in VLPs and virus were slightly 
different, which may be due to over-expression of proteins in tissue culture or differences 
in assembly of NDV strains B1 and AV.  These results suggest that VLPs can be 
generated in significant quantities from tissue culture using standard transfection 
protocols.  
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Figure 5.1.  Purity of VLPs from tissue culture.  VLPs were generated from avian cells 
grown in T150 flasks and transfected with NDV NP, M, F and HN cDNAs in pCAGGS 
vector.  NDV, strain B1 virus was propagated from embryonated eggs.  Virus and VLPs 
were pelleted from the supernatant (Type 19 rotor, 18,000 rpm, 4oC, 16 h).  Particles 
were isolated by concentrating into the interface of 20% and 65% sucrose solution (SW 
28 rotor, 24,000 rpm, 4oC, 12h).  Particles from the interface were floated into a step 
gradient.  Particles were pelleted from the flotation fractions.  Proteins in egg-grown 
NDV strain B1 virus and VLPs were separated by SDS-gel electrophoresis.  Proteins in 
the gel were silver stained as described in Materials and Methods. 
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VLPs bound to host cells.  To characterize a functional property of the structural 
components of VLPs, we initially asked whether VLPs could bind to host cells.  To 
answer this question, we performed a binding assay.  Different amounts of radioactively 
labeled VLPs were allowed to bind to avian cells at 4oC.  A polyclonal anti-NDV 
antibody was used as a control to block binding.  In addition, supernatant from cells 
transfected with vector alone was used as a negative control.  Figure 5.2 shows that VLPs 
attached to cells and the binding was inhibited by the addition of anti-NDV to VLPs prior 
to incubation with cells (compare lanes 3 to 5).  No signal was observed in the vector 
supernatant incubated cells (lane 2).  Moreover, by comparing the input VLPs to the 
maximum amounts bound to cells, we found that the majority of added VLPs bound to 
the cells (compare lanes 1 and 4).  In addition, the binding of VLPs was concentration 
dependent (lanes 4, 5 and 6).  This result clearly demonstrates that the attachment 
function of the HN protein in VLPs is intact. 
HA tagged HN glycoprotein incorporated into VLPs.  One of the new strategies in 
designing a vaccine is to incorporate a foreign peptide into one of the structural 
components of the vaccine.  To determine if there are permissive sites in the two viral 
glycoproteins for foreign epitope insertion, we generated HN and F proteins with HA and 
FLAG tags fused to their carboxyl terminus, respectively (HN-HA and F-FLAG).  The 
HN-HA and F-FLAG were shown to mediate normal attachment and membrane fusion, 
respectively (McGinnes, unpublished observation). We asked if the HN-HA and F-FLAG 
could be incorporated into VLPs.  Figure 5.3 shows that VLPs were assembled and 
released from cells that expressed either HN-HA or F-FLAG proteins along with the  
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Figure 5.2.  VLPs bound to host cells.  Different amounts (3x, 2x and 1x) of 
radioactively labeled VLPs were allowed to bind to avian cells on ice at 4oC for 30 min.  
Negative controls were supernatant from vector transfected cells (lane 2) and VLPs 
treated with anti-NDV for 1 h (lane 3).  Input lane is 3x concentration.  Cells-VLPs were 
lysed and proteins were resolved by SDS-PAGE and visualized by autoradiography. 
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Figure 5.3.  HN-HA protein is incorporated into particles.  FLAG tagged F protein (F-
FLAG) or HA tagged HN protein (HN-HA) were co-expressed with NP, M and a 
glycoprotein and radioactively labeled in a pulse–chase protocol as described in Materials 
and Methods.  Panels show, pulse (left) and chase (middle) lysates and VLPs (right). 
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other three wild type proteins.  However, F-FLAG protein was not incorporated into 
VLPs, while HA-tagged HN was incorporated into VLPs.  The amounts of VLPs released 
from cells expressing the HN-HA (with NP+M+ F or F-FLAG) were lower compared to 
cells expressing NP, M, F and HN without HA tag.  This result is likely due to the 
absence of a spacer sequence between the HN sequence and the HA tag.  Nevertheless, 
this result suggests that foreign peptides can be fused to the carboxyl terminus of HN 
protein without inhibiting incorporation into VLPs.   
F protein cytoplasmic (CT) domain is necessary for its incorporation into VLPs.  
The formation and release of VLPs without incorporation of F-FLAG is consistent with 
our previous results that particles are released in the presence of M protein and at least 
two other proteins (NP and HN proteins) (Pantua, McGinnes et al. 2006). The 
observation that appending a FLAG tag on the CT of F protein inhibited its incorporation 
into particles  suggests that the CT domain is necessary for F protein incorporation into 
VLPs.  To define the specific requirements for incorporation of NDV F protein into 
particles, we asked whether the CT domain of the NDV F protein plays a role in the 
assembly of VLPs.  Using different CT truncation mutants of F protein, we asked if any 
region of the CT domain of F protein was necessary for its incorporation into particles.  
Figure 5.4, panel A, shows a linear diagram of a full length F protein and different CT 
truncation mutants.  Deletion of the carboxy-terminal 13 amino acid residues (F-Gterm) 
inhibited incorporation of the F protein into VLPs (compare lanes 16 and 18).  In 
addition, deletion of the carboxyl-terminal 6 amino acid residues (F-Mterm) slightly  
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Figure 5.4.  CT domain of F protein is necessary for incorporation into VLPs.  
A,linear diagram of full length F-K115Q and CT (cytoplasmic tail) truncation mutants.  
B,  Full length and truncation mutants were co-expressed with NP, M and HN proteins in 
a pulse – chase protocol as described in Materials and Methods.  Panels show, pulse (left) 
and chase (middle) lysates and VLPs (right). C, amount of F protein incorporated into 
particles (values were normalized to the amount of NP).  Identical results were observed 
from two separate experiments. 
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igure 5.5.  Heterologous NDV glycoproteins are incorporated into VLPs.  NDV F
strain B1 F or HN proteins were co-expressed with NP, M and a glycoprotein from NDV 
strain AV (lanes 3 and 4, 8 and 9). B1 HN and F proteins were co-expressed with AV NP 
and M proteins (lanes 5 and 10).  Cells were subjected to a pulse - chase protocol as 
described in Materials and Methods.  Panels show, pulse lysates (left) and VLPs (right). 
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decreased incorporation of the F protein into VLPs (compare lanes 16 and 19; Figure 5.4, 
panel C).  In contrast, an internal deletion (F-delK) and deletions from amino acid 
residues 550 to 553 (F-Tterm) did not affect F protein incorporation into VLPs (compare 
lanes 16 to 20 and 21).  These results demonstrate that the CT of F protein is important 
for its incorporation into VLPs.  Moreover, these results also suggest that amino acid 
residues from position 523 to 550 are necessary for F protein incorporation into VLPs. 
Heterologous NDV glycoproteins incorporated into VLPs.  We also asked if 
glycoproteins from a different strain of NDV could be incorporated into VLPs.  We co-
expressed F or HN glycoproteins from NDV, strain B1, with NP, M and HN or F 
glycoprotein, respectively, from NDV strain AV.  We also expressed both the B1 F and 
HN proteins with AV M and NP proteins.  We found that either F or HN glycoprotein or 
both from NDV strain B1 were incorporated into VLPs with strain AV viral proteins 
(Figure 5.5). However, the amounts of VLPs from cells expressing B1 HN protein were 
slightly lower compared to amounts released from cells expressing the AV HN protein 
(compare lanes 7, 8 and 10). The B1 F protein appeared to have no effect on VLP release 
and it was normally incorporated into VLPs (compare lanes 7 and 9 in the right panel).  
These results indicate that glycoproteins from a heterologous strain of NDV would 
incorporate into AV VLPs. 
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D.  Summary and Conclusion 
 To develop NDV VLPs as a vaccine for Newcastle disease or as a vaccine vector, 
we scaled up the production of VLPs, characterized the binding activity of HN protein, 
and defined the rules for incorporation of viral components into particles.  The results 
described above demonstrate that production of VLPs from tissue culture using a 
transfection protocol can be scaled up to produce microgram quantities of VLPs that are 
as pure as virus generated from eggs.  However, this production protocol is costly due to 
the large quantities of lipofectamine required for the transfection.  Thus it is still 
necessary to develop new ways of producing NDV VLPs.  One alternative is to use a 
baculovirus multigene expression vector system.  An advantage of this system is that 
proteins have been shown to be folded correctly (Possee 1997), thus producing VLPs 
with components that are still similar to the authentic virus.  Another approach is to 
establish stable cell lines that co-express NDV NP, M, F and HN proteins.  This approach 
would eliminate the need for transfection. 
 We also showed that NDV VLPs can normally bind to host cells.  The binding 
activity of VLPs strongly suggests that the HN protein is in its normal conformation, 
which allows attachment to the receptor.   
In addition, we also showed that a foreign peptide sequence could be fused to the 
HN protein without inhibiting the incorporation of HN protein into VLPs.  However, the 
amounts of VLPs released were decreased.  It is possible that the HA tag interferes or 
blocks sites for interaction with other viral proteins, which are necessary for assembly 
and release of particles.  Thus, there is a need to identify other sites in the HN protein for 
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insertion of foreign epitopes.  Nevertheless, these findings are important in identifying 
permissive sites for the design of a chimeric VLP vaccine. 
We also found that at least part of the CT domain of F protein is necessary for its 
incorporation.  This result suggests that a specific sequence in the F protein CT domain is 
essential for its incorporation into VLPs.  Altogether, these results contribute 
significantly to the establishment of NDV VLPs as a framework for a vaccine vector for 
many human viral pathogens.   
In the future we intend to define the CT sequence of the HN protein that is 
necessary for incorporation of the HN protein.  We also plan to further define the 
necessary regions in the F protein CT domain.  By identifying specific regions in the F 
protein necessary for assembly, we can generate chimeric glycoproteins that contain the 
necessary elements for assembly and the foreign sequences that are necessary for the 
induction of immune responses.  For example, we can fuse the NDV F protein or HN 
protein CT domains to the ectodomain and transmembrane domain (TM) of a type 1 
glycoprotein or type 2 glycoprotein, respectively, and ask if the CT domains of NDV F 
and HN proteins could support incorporation of the chimeric protein into VLPs. 
We also found that heterologous NDV F and HN proteins were incorporated into 
AV VLPs.  The decreased amounts of VLPs released from cells expressing the B1 HN 
protein and AV viral proteins may be due to differences in assembly of AV and B1 
particles.  Nevertheless, these results are important in developing a multivalent vaccine 
for Newcastle disease. 
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 It is also imperative to examine the immune response induced by NDV VLPs.  
We plan determine if NDV VLPs can elicit both humoral and cell-mediated immune 
responses.  These issues are currently under investigation using a murine model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 153
CHAPTER VI 
GENERAL DISCUSSION 
 
 
The mechanisms of paramyxovirus assembly and budding have been investigated 
in this dissertation with the underlying goal of determining the viral and host protein 
requirements for assembly and release of Newcastle disease virus.  We have established a 
VLP system for NDV and we have used this system in answering important questions in 
assembly and budding of this virus.  The key player in the assembly and release of 
particles was defined here in terms of the minimum viral protein requirements for the 
formation and release of NDV VLPs.  The network of interactions between viral proteins 
involved in assembly of complete VLPs was also defined.  The involvement of cellular 
VPS machinery in virus budding was explored.  In addition, the potential involvement of 
the alternate form of NDV F protein was examined.  The potential of NDV VLPs as a 
vaccine for Newcastle disease and as a vaccine vector for important human pathogens 
was investigated. 
 Taken together, the data presented in this dissertation provide a better 
understanding of the requirements and mechanisms of assembly and budding of 
Newcastle disease virus.  A better understanding of this process could contribute to the 
design of antiviral drugs that inhibit virus release.  More importantly, the data will 
contribute to the development of safe, economical and effective vaccines for Newcastle 
disease as well as human pathogens.  Since an in depth discussion has been provided in 
Chapters II, III, IV and V, this chapter provides a brief overview of the major points 
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made in this thesis and highlights the relevant questions that remain to be answered in 
future work. 
A.  Cell sites of viral protein-protein interactions 
In this dissertation, I have shown that co-expression of viral structural 
components resulted in the formation and release of particles (Figure 6.1).  One major 
point is that these viral components interact with each other in an orderly way to initiate 
the assembly and budding process.  In this thesis, we showed that M protein-HN protein, 
M protein-nucleocapsid protein, F protein-nucleocapsid protein, and F protein-HN 
protein interactions are crucial to the assembly of particles.  An important issue in the 
virus assembly process is the site or cellular location where viral protein-protein 
interactions occur to initiate particle assembly.  Some of the important questions are the 
following: do NDV viral proteins interact strictly in the assembly site in the plasma 
membrane; alternatively, do specific interactions between these proteins occur during 
transport through the secretory pathway; lastly, is there a sequential order in viral protein-
protein interactions required for assembly and release?   
It has been widely accepted that paramyxoviruses assemble at the plasma 
membrane of infected cells (Lamb and Kolakofsky 2001).  However, there is also 
evidence that suggests that viral proteins interact while being transported to the cell 
plasma membrane (reviewed in (Schmitt and Lamb 2004; Takimoto and Portner 2004)).  
It has been reported that Sendai virus M protein accumulated at the Golgi membrane 
when transport of glycoproteins was restricted by low-temperature inhibition or by the 
addition of ionophore monensin (Sanderson, McQueen et al. 1993).  This result suggests  
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Figure 6.1.  Model of NDV assembly and budding.  This figure shows the network of 
protein interactions necessary for particle formation.  The YANL sequence serves as a 
late domain in the NDV M protein.  The late domain and the VPS machinery are both 
essential for particle budding.  1 to 4 are some of the unanswered questions in NDV 
assembly and budding:  1 - Do viral proteins form a complex while in transit to the 
secretory pathway?; 2 – Does the alternate form of F protein play a role in particle 
formation?; 3 – Does actin play a role in particle assembly and release?; and 4 – Does the 
YANL sequence in NDV M protein mediate interaction with the VPS machinery? And 
which VPS molecule interacts with the M protein? 
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that the interaction between the M protein and glycoproteins occurs during their transit 
through the secretory pathway.  But if M protein transits through the MVBs, then 
monensin or low temperature incubation would directly inhibit M protein transport to the 
plasma membrane. 
It has also been shown that the Sendai virus M protein was recruited to the 
cytoplasm by the viral nucleocapsid (Stricker, Mottet et al. 1994).  This result suggests 
that M protein-nucleocapsid complexes are formed prior to assembly of the virus particle 
in the plasma membrane.  
Based on the studies presented above, we hypothesized that NDV viral proteins 
form complexes during transport to the plasma membrane (Figure 6.1).  Based on our 
results that indicate interactions between M-HN proteins and F-NP proteins, this 
hypothesis can be tested by inhibiting the transport of NDV F or HN proteins and 
determining the site of accumulation of M protein or NP.  Accumulation of NDV M or 
NP in the Golgi membranes would suggest that complexes are formed while NDV F and 
HN proteins are in transit through the secretory pathway.  The formation of M-NP 
complexes prior to assembly in the plasma membrane could be examined by performing 
co-immunoprecipitation assays using  cytosolic fraction of cells expressing M protein and 
NP.  To further determine where in the cell the NDV viral proteins interact, viral proteins 
can be visualized by electron or confocal microscopy along with markers of the secretory 
compartments and other relevant cell compartments. 
 Another issue in the assembly of virus particles is the order of assembly of 
components.  This process is poorly understood and the relevant questions that are 
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worthy of future investigation are as follows:  Is there a sequential order of viral protein 
interactions in the formation of a complete particle; Do M protein-NP complexes form 
first before interacting with HN (with M) or F (with NP) proteins to initiate assembly; 
Are complexes formed randomly to initiate assembly?  Answers to these questions would 
provide a better understanding of the mechanisms of assembly of paramyxoviruses. 
In addition to the points presented above, we have shown evidence that the F 
protein exist in two forms, the classical type 1 glycoprotein and an alternate form, in 
virus particles.  However, the role of the alternate form of F protein in virus assembly is 
not known (Figure 6.1).  We hypothesize that the alternate form of F protein may be 
involved in the assembly process.  Using the NDV VLP system, we plan to investigate if 
the alternate form of F protein is involved in any viral protein-protein interactions that are 
necessary for particle formation.  Specifically, the localization of the alternate form of F 
protein relative to the M protein could be explored by immunofluorescence microscopy 
of cells co-expressing NP, M, F and HN proteins.  Another approach is to determine 
whether the alternate form of F would co-precipitate with HN protein or NP. 
Lastly, it is also important to confirm the cellular localization of the NDV M 
protein by confocal microscopy since there is evidence that the M protein is localized in 
the nucleus (Peeples, Wang et al. 1992).  The implication of this finding on virus 
assembly and budding should be explored in the future.   
B.  Involvement of cytoskeleton in virus budding 
Cytoskeletal proteins such as actin and tubulin are implicated in the life cycle of 
paramyxoviruses.  Previous studies indicated that cellular actin was incorporated into SV, 
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mumps virus, and measles virus particles (Lamb, Mahy et al. 1976; Orvell 1978; Tyrrell 
and Norrby 1978).  It has also been shown that the M protein of NDV and SV interacts 
with actin as shown by chromatography and cosedimentation assays (Giuffre, Tovell et 
al. 1982).  In addition, it has been shown previously by McGinness et al that cytochalasin 
D, an inhibitor of actin polymerization, significantly accelerated the release of 
radioactively labeled virions (Morrison and McGinnes 1985).  We have consistently 
observed the incorporation of actin into both NDV virions and VLPs by Western analysis 
(also in Figures containing gels of VLPs and virus, and unpublished observation).  We 
have also found that M protein and NP specifically co-precipitate from VLPs with anti-
actin antibody (unpublished observation). We also observed that actin co-precipitated 
with M protein from VLPs formed from M, F and HN proteins (Figures in chapter 2) 
indicating that the M protein may bind to actin.  Immunoprecipitation with NP-specific 
antibody would show whether actin interacts with NP.  All these findings suggest a role 
for actin in the process of NDV budding (Figure 6.1).   
Our lab has shown evidence which suggest that lipid rafts serve as platform for 
assembly and budding of NDV (Laliberte, McGinnes et al. 2006).  These findings and the 
report that show evidence that actin associates with lipid rafts (Nebl, Pestonjamasp et al. 
2002)lead us to hypothesize that actin rearrangement in lipid rafts play a role in 
assembling the viral components and in the release of virus particles.  To further explore 
the involvement of cytoskeleton in NDV budding, drugs that disrupt the microfilaments 
and microtubules may be used and examine their effects on VLP release.   
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C.  Mechanisms by which viruses use the VPS system 
The second major point in this thesis is that intact VPS machinery is essential for 
budding of NDV VLPs.  Many different studies have shown that a variety of enveloped 
RNA viruses depend on the recruitment of cellular VPS machinery to assist in the late 
stages of the virus budding process (reviewed in (Pornillos, Garrus et al. 2002; Bieniasz 
2006)).  Although we showed that the VPS system is involved in NDV VLP budding, the 
fundamental role of the VPS machinery in NDV budding remains to be determined.  
Important questions relevant to this issue are the following; first, does virus infection 
affect the cellular localization of the VPS machinery; second, how does NDV use the 
VPS machinery?  The answers to these questions would help define the steps that are 
necessary for virus assembly and release.   
The first basic question is whether virus infection changes the localization of the 
VPS machinery.  In other words, is the VPS machinery recruited to the site of NDV 
assembly and budding?  It is thought that the VPS machinery is recruited by the 
retrovirus Gag protein to the sites of assembly in the plasma membrane for virus egress 
(reviewed in (Pornillos, Garrus et al. 2002; Morita and Sundquist 2004)).  In contrast, 
there is also evidence that intracellular budding of progeny Marburg virus occured in 
MVBs (Kolesnikova, Berghofer et al. 2004). 
These results suggest that viruses may use the VPS pathway in two different 
ways.  One is by recruiting the machinery to the plasma membrane where assembly and 
budding occurs and second is by using the machinery for particle budding intracellularly 
through the MVBs (Figure 6.1).  To discriminate between the two possibilities, the cell 
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site where there are interactions between the viral matrix protein and molecules of the 
VPS machinery has to be defined.  Confocal microscopy and ultrastructural analysis of 
the localization of viral proteins and MVBs could be performed to define the site of M 
protein-VPS molecule interaction.  This issue has not been explored for any 
paramyxovirus and should be a subject for future investigation. 
Another unanswered question that we plan to address in the future is the effect of 
dominant negative mutant proteins of the VPS machinery on the release of particles from 
infected cells.  Does expression of dn mutant proteins of the VPS pathway result in the 
accumulation of the M protein as well as other viral proteins in infected cells?  We 
predict that an intact VPS pathway is also necessary for release of virus particles from 
NDV-infected cells. 
Viruses that co-opt the VPS machinery have been shown to contain L domains  in 
their matrix-like proteins (reviewed in (Pornillos, Garrus et al. 2002; Bieniasz 2006)).  L 
domains are necessary to mediate interactions between matrix-like proteins and 
molecules of the VPS machinery (reviewed in (Freed 2002; Bieniasz 2006)).  We have 
shown that the YANL sequence in the NDV M protein has L domain properties.  One 
fundamental question is how the YANL sequence in the NDV M protein mediates 
interactions with the VPS machinery (Figure 6.1).  With which particular molecule of the 
VPS machinery does M protein interact?  It has been shown that YXXL motifs mediate 
interactions with the endocytic proteins, AP2 (Chen, Vincent et al. 2005) and AIP1 
(Strack, Calistri et al. 2003), respectively.  We have shown that AIP1, a protein that 
connects ESCRT I and ESCRT III, is incorporated into VLPs.  However, we did not 
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observe an interaction between AIP1 and M protein in the extracts using a co-
immunoprecipitation assay.  It is possible that a second protein mediates the interaction 
between M protein and AIP1.  Alternatively, it is possible that another cellular protein of 
the VPS machinery, and not AIP1, interacts with the M protein to facilitate virus 
budding.  Further screening for interacting proteins has to be done to identify the 
interacting partner of NDV M protein. 
D.  VLPs as a vaccine for NDV 
 There is increasing attention and effort in developing VLPs as vaccines.  VLP 
systems have been established for several different viruses (Noad and Roy 2003).  For 
example, VLPs composed of papilloma virus capsid proteins have been approved by the 
FDA as a vaccine for cervical carcinoma (FDA 2006).  It has been reported that Ebola 
VLPs produced from insect cells can stimulate neutralizing antibody production and 
induce cytokine secretion from human dendritic cells (Ye, Lin et al. 2006).  VLPs 
composed of the HIV gag and env proteins induced significant levels of both systemic 
and mucosal neutralizing antibodies, a proliferative response of T helper cells, and 
cytolytic activity of cytotoxic T cells (Buonaguro, Racioppi et al. 2002; Jaffray, Shephard 
et al. 2004; Buonaguro, Visciano et al. 2005; Buonaguro, Tornesello et al. 2006).  
Collectively, these results suggest that VLPs can induce a wide range of immune 
responses.  However, the full potential of VLPs, which mimic enveloped viruses, as 
vaccines has not been fully exploited despite their many advantages over commonly used 
vaccines.  In the future we plan to exploit the potential of NDV VLPs as a vaccine for 
Newcastle disease.   
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We plan to develop a multivalent vaccine for NDV.  Swenson, et al, have shown 
that expression of glycoprotein (GP) and VP40 from a single filovirus, either Ebola or 
Marburg virus, resulted in the formation of VLPs from mammalian cells (Swenson, 
Warfield et al. 2004). When a mixture of Ebola and Marburg VLPs was used as vaccine, 
these VLPs stimulated a strong immune response to both viruses in guinea pigs 
(Swenson, Warfield et al. 2005). Neutralizing antibodies were produced and animals 
were protected from live virus challenge (Warfield, Swenson et al. 2004; Swenson, 
Warfield et al. 2005).  These results suggest that combinations of Ebola and Marburg 
VLPs could be used as effective multivalent vaccine for filoviruses.  With our goal of 
developing a multivalent vaccine for NDV, we examined the incorporation of 
glycoproteins from a heterologous strain of NDV into VLPs. We showed that F and HN 
proteins from the B1 strain of NDV were incorporated into VLPs.  However, it is 
important to further compare and characterize the efficiency of assembly and release of 
AV and B1 VLPs.   
It is also important to determine if AV and B1 VLPs will elicit an immune 
response in a murine model.  Furthermore, it will be important to compare the immune 
responses to AV and B1 VLP vaccinations with vaccine virus vaccinations.  Currently, 
we are conducting experiments to compare the immune responses to VLPs and UV 
inactivated B1 strain virus in a murine model.    
E.  VLPs as vaccine vectors for human pathogens 
Recombinant viruses expressing foreign proteins or epitopes have been produced 
with the aim of developing multivalent vaccines that are capable of stimulating both 
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humoral and cellular immune responses against more than one pathogen (Bukreyev, 
Huang et al. 2005; Park, Steel et al. 2006). We propose to develop NDV VLPs as vaccine 
for different human pathogens.  To this end, we have started to define rules for 
incorporation of NDV glycoproteins into VLPs in order to guide the development of 
NDV VLPs as a vaccine for human pathogens.  We showed that the CT domain of the F 
protein is necessary for F protein incorporation into VLPs.  To make chimeric NDV 
VLPs as vaccine for human pathogens, we will  fuse the CT domain of F protein to a type 
1 glycoprotein ectodomain and transmembrane (TM) domain from other pathogens to 
determine if there is an active incorporation of the chimeric protein into VLPs.  
Alternatively, it may be necessary to fuse both the CT and TM domains of F protein to 
the ectodomain of the foreign protein.  Sequences necessary for NDV HN protein 
incorporation into VLPs have yet to be defined.  By doing so, we can also use regions of 
the HN protein to create a chimera of NDV HN protein and type 2 glycoproteins from 
other pathogens.   
VLPs have also been exploited as carriers for foreign epitopes (reviewed in 
(Grgacic and Anderson 2006)).  For example, VLPs derived from the small envelope 
protein (HBsAg-S) of hepatitis B virus (HBV) containing the immunodominant 
hypervariable region of the hepatitis C virus (HCV)  E2 protein have been reported to 
induce the production of antibodies to HCV E2 in a murine model.  In addition, it has 
also been reported that mice immunized with VLPs derived from HBV core antigen 
(HBVcAg) containing a VP1 epitope from foot and mouth disease virus (FMDV) were 
protected from FMDV challenge (Huang, Liang et al. 2005).  Similarly, VLPs derived 
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from HBVcAg containing T and B cell epitopes from HCV NS3 protein induced high 
levels of anti-NS3 antibodies (Mihailova, Boos et al. 2006).  Collectively, these results 
suggest chimeric VLPs have great potential as vaccines.  
We have started to define permissive sites for addition of foreign epitopes into 
VLPs with the underlying goal of maintaining the efficient incorporation of a protein into 
VLPs as well as efficient release of particles.  We demonstrated that NDV-HN protein 
fused with an HA tag was incorporated into VLPs.  However, the amount of VLPs 
released was slightly decreased.  It is possible that the HA tag interfered with interactions 
of HN protein with other viral proteins, interactions  necessary for efficient incorporation 
of HN protein into VLPs.  It is possible that the absence of a linker in between the HN 
sequence and the HA tag influenced the decreased incorporation of the HN-HA protein.  
It has been shown that insertion of a linker sequence between the measles virus 
hemagglutinin (HA) protein and a single chain antibody resulted in a chimera protein that 
was biologically active and was assembled into recombinant measles virus (Hammond, 
Plemper et al. 2001; Peng, Donovan et al. 2003).   
A key objective in developing VLPs as a vaccine is to design strategies that would 
facilitate safe and economical methods for producing large quantities of VLPs.  Although 
we have generated significant quantities of NDV VLPs, other methods should be 
explored to scale up the production of VLPs.  An alternative to our protocol is the use of 
cells stably expressing the NDV structural proteins.  Another is to generate VLPs using a 
multigene baculovirus vector system.  Although these approaches would support a scaled 
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up production of VLPs, they are not without their drawbacks.  Stable cell lines may be 
difficult to maintain.  Use of baculovirus risks contamination with baculoviruses. 
 The ability of NDV VLPs to elicit an immune response in a murine model is 
currently being characterized in our laboratory.  The potential of chimeric NDV VLPs as 
a vaccine vector will be pursued in future work. 
F. Summary 
In summary, the results described in this thesis indicate that the budding of 
paramyxoviruses, specifically NDV, involves interactions between viral proteins and 
interplay of viral and cellular proteins.  The results in this thesis further support the 
conclusion that the M protein is the central organizer of the virus budding process.  We 
also provided evidence that the VPS pathway is involved in NDV VLP budding.  
Moreover, the NDV M protein contains a sequence that has L domain properties.        
Finally, through this work, we have taken a significant stride towards a clearer 
understanding of the steps in the assembly and budding of paramyxoviruses, which 
would contribute to the design of better strategies for therapeutic intervention and to 
development of safe, economical and effective vaccines. 
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